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Abstract 
Background 
Symptoms of Obsessive–Compulsive Disorder (OCD) sometimes do not improve 
despite being competently treated with known effective pharmacological and/or 
cognitive behavioural therapy with exposure and response prevention interventions. 
OCD symptoms that are particularly difficult to treat are related to harm /aggressive, 
sexually taboo and religious/blasphemous intrusive obsessional thoughts/images. 
Factors such as the vividness of the intrusive imagery, guilt, shame, cognitive 
inflexibility and inhibitory control deficits, are known to impact on OCD. Therefore it is 
important to further improve treatment given that the quality of life of patients with 
untreated OCD symptoms can be as equally poor as that of patients diagnosed with 
schizophrenia and in some cases worse. Imagery rescripting therapy is effective in 
reducing shame, guilt and the intensity of imagery vividness in trauma-based 
disorders such as Post-Traumatic Stress Disorder (PTSD).  The ameliorative qualities 
of imagery rescripting may be of therapeutic benefit in OCD. 
  
Aim 
This study explored the therapeutic utility of one-session imagery rescripting with 
homework practice in reducing image vividness, guilt, shame, cognitive inflexibility 
and impairment in motor inhibitory control linked to OCD related to harm/aggressive, 
sexually taboo and religious/blasphemous intrusive images. 
 
Methodology 
A multiple baseline single-case experimental design was utilised with 6 adult 
participants recruited. One participant withdrew after the initial baseline phase and 
the visual graphed data analysis for 5 participants was conducted on scores on 
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measures of vividness, shame, guilt and anxiety, with the Tau-U test utilised to 
assess trends between baseline and intervention phases. Clinical significance (CS) 
and reliable change index (RCI) calculations were used to assess changes in scores 
on global measures of OCD, depression and cognitive flexibilities before and after the 
intervention and at follow-up. A favourable ethical opinion was obtained from 
appropriate research ethics committees before data collection commenced. The 
study was conducted in accord with research ethics and governance requirements. 
 
Results 
This study found that changes in intrusive imagery vividness, was only reported in 
one of the two patients whose intrusive imageries were associated with memories of 
past adverse experiences. It was also found that patients with intrusive imageries that 
did not have an association with an adverse memory also reported improvement in 
shame, guilt and OCD following imagery rescripting. The study also found that the 
OCD patients performed worse on the CANTAB – SSRT and ED tasks compared to 
the healthy normal group but similar to the OCD clinical controls, however, the 
improvements in set-shifting deficits and or in motor inhibitory impairment following 
imagery rescripting could not be established. Instead it was found that the 
impairments improved following repeated measurements at the baseline phase in the 
absence of treatment. 
 
Conclusion and Implications 
Although only one patient supplied evidence consistent with imagery rescripting 
having therapeutic potential for OCD images, however from a broader view point the 
study demonstrated replication failure of this result across the participants. 
Furthermore, there was also no conclusive evidence to suggest imagery rescripting 
had significantly changed set-shifting and motor inhibitory impairments. Further 
 22 
investigation is required, taking into account of the study limitations and implications 
before one could comment for definite how the findings contribute to the current 
knowledge. Single case experimental design might not be particularly suitable for 
investigating neurocognitive improvement in treatment trials due to the nature of 
repeated measurements. 
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Chapter. 1  Obsessive–Compulsive Disorder 
 
1.1 Introduction 
Clinical experience has shown that, in some cases, patients with Obsessive–
Compulsive Disorder (OCD) treated with effective drugs and/or psychological 
treatments do not benefit from these treatments. OCD symptoms that are particularly 
difficult to treat are intrusive thoughts/images related to harm/aggression, sexual 
taboos and religion/blasphemy. Whilst in the main, persistent intrusive 
thoughts/images give rise to problems of anxiety and fear; in some cases shame 
and/or guilt can have a profound effect in OCD (Hezel et al. 2012). Undoubtedly, 
shame and/or guilt are common occurrences in OCD, as elucidated in Rachman and 
other’s work on mental contamination, where upon one feels dirty by exposure to 
negative intrusions and that the emotional aspects of this sense of contamination 
include disgust, shame and guilt (Coughtrey, Shafran, Knibbs & Rachman 2012; 
Rachman 2006). Moreover, OCD is associated with neurocognitive impairments such 
as inhibitory response control and set-shifting (cognitive flexibility) deficits 
(Chamberlain et al. 2005; Menzies et al. 2007). Although the said impairments are 
largely endophenotype/biological characteristics of OCD, arguably, experiencing 
negative emotions potentially worsens the impairments. For instance, it is suggested 
that negative emotions utilise more attentional effort than positive emotions (Pratto & 
John 1991) and that negative imagery/stimuli also tends to activate the utilisation of 
more attentional resources (Hartikainen et al. 2000; Tipples & Sharma 2000). On the 
other hand, in order to have an efficiently and effectively executed inhibitory action, 
sufficient attention should be given to the action on demand (Logan & Cowan 1984). 
However, Verbruggen and De Houwer (2007) observed that when a negative image 
gives rise to a negative emotion, poor inhibitory control is also observed. This is 
particularly important for the current study because of the relationship between 
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intrusive images and the emotions of shame and guilt. For instance, Simonds and 
Thorpe (2003) showed in a study of university students that the experience of harm-
related intrusive thoughts was perceived as both shameful and socially unacceptable. 
Shame and guilt, among other negative emotions, frequently occur in OCD patients 
(Weingarden & Renshaw 2015), possibly because OCD patients have a tendency to 
perceive themselves as immoral when experiencing unacceptable intrusive thoughts 
and images related to harm, sex or religion (Ferrier & Brewin 2005; McDermott 
2006). Therefore when harm, sex or religion intrusive imagery gives rise to shame 
and/or guilt, arguably the impaired inhibitory ability in OCD is also worsened. In fact, 
Whitton et al. (2014) found that rigid moral reasoning in OCD might be associated 
with cognitive inflexibility. Furthermore, Shin et al. (2000) demonstrated that moral-
based emotions (e.g. shame and guilt) could exacerbate impairment of inhibitory 
processes and perseveration/set-shifting tasks in OCD. It is significant at this juncture 
pointing out that if inhibitory response control and set-shifting (cognitive flexibility) 
deficits are by and large endophenotype/biological characteristics of OCD, then when 
the severity of the deficit worsens, arguably, the observed magnitude of change 
indicates state-cognitive inflexibilities. Shame and guilt, along with cognitive 
inflexibilities, have been implicated in contributing to poor response to OCD 
treatments such as cognitive behavioural therapy (CBT) (Greisberg & McKay 2003; 
Shapiro & Stewart 2011). Current knowledge and theory suggests that imagery 
rescripting therapy can be particularly helpful not only in reducing intrusive images 
that activate shame and guilt, but also in ameliorating other clinical symptoms. For 
instance, it has been shown that following imagery rescripting, intrusive imagery 
vividness and frequency can reduce to the point where intrusions are no longer 
distressing or, in some cases, such images can completely cease (Brewin et al. 
2009; Hagenaars & Arntz 2012). In terms of the amelioration of clinical symptoms, 
imagery rescripting has been used in the treatment of anxiety disorders with good 
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effects (Arntz, Tiesema & Kindt 2007; Arntz, Sofi & Van Breukelen 2013; Grunert et 
al. 2007). It has also been used successfully in cases where shame and guilt were 
present (Grunert et al. 2003, 2007; Kindt et al. 2007). Most recently, imagery 
rescripting has been found to have a potentially therapeutic effect in treating OCD 
(Veale, Page, Woodward & Salkovskis 2015). However, it appears that the impact of 
imagery rescripting therapy on shame, guilt and neurocognitive deficits in OCD has 
not yet been investigated. Consequently, this pilot study examined the potential effect 
of imagery rescripting therapy on shame, guilt and neurocognitive deficits in adults 
diagnosed with OCD characterised by images related to harm/aggression, sexual 
conduct, or religion. 
 
1.2 Background 
Obsessive Compulsive Disorder is a common and chronic disorder with estimated 
lifetime prevalence ranging between 0.5% and 2.3% (Grabe et al. 2001; Ruscio et al. 
2010). These estimates, arguably, are considered conservative due to the avoidance 
of seeking help for the disorder (Mayerovitch et al. 2003) due to fear and 
embarrassment (Simonds & Thorpe 2003). OCD affects both men and women and 
has a significant impact on wellbeing, functioning and quality of life. OCD also places 
a significant economic burden on society (Eisen et al. 2006). This disorder is 
considered the most incapacitating of all the anxiety disorders (Murray & Lopez 
1996). OCD is characterised by obsessions and compulsions. Obsessions are 
described as persistent and recurrent intrusive thoughts, images or urges, which are 
experienced as ego-dystonic (i.e. alien to the self) and, as a result, elicit significant 
distress and negative emotions (DSM-IV-TR: American Psychiatric Association (APA) 
2000). These negative emotions include anxiety, fear, guilt and shame. The 
obsessions and/or their associated emotions often compel the person with OCD to 
engage in mental and/or behavioural acts known as compulsions. When the person 
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engages in these acts they experience relief from the distress and the unwanted 
emotions/fears. However, the relief is short-lived and consequently the person can 
find himself or herself re-engaging in the compulsions in order to maintain the relief. 
The compulsions tend to present in the form of rituals/neutralisation, and are 
distinguishable by their underlying repertoire of characteristics, which include 
repetitive actions that are difficult to inhibit, as well as being considered senseless by 
an OCD patient (DSM-IV-TR: APA 2000). Compulsions maintain the problem 
because they interfere with reality testing (e.g. avoidance of sharp objects by the 
person who fears harming others prevents disconfirmation that harm would not 
occur). Whilst the cause of OCD is not clearly understood, environmental and 
biological factors have been proposed as possible causes of OCD onset, 
notwithstanding methodological criticisms associated with the studies the findings 
rely on. The environmental debate draws on various schools of thought, for instance 
psychosocial experiences such as stressful life events, parenting rearing style, and 
emotional neglect have been implicated in the genesis of OCD (Albert, Maina, 
Bogetto & Ravizza 2000; Alonso et al. 2004; Cath et al. 2008; Grisham et al. 2008; 
Rosso et al. 2012), and exposure to certain infections such as streptococcal infection 
has also been implicated in triggering OCD, for instance during childhood (Leonard & 
Swedo 2001). Insofar as the biological argument for the genesis of OCD is 
concerned, the serotonergic and dopaminergic pathways have been implicated, for 
example insufficient levels of serotonin chemical produced in the brain (Nicolini et al. 
2010). Others have implicated abnormalities in the neuro-networks of the brain and in 
particular the fronto-striatal and dorsolateral prefrontal – anterior cingulate circuitries 
(Menzies et al. 2007; Purcell et al. 1998, Savage et al. 2000). 
 
OCD is potentially treatable when the recommended evidence-based interventions 
are competently administered (NICE 2006). For instance, it has been shown that a 
group of psychopharmacological interventions known as selective serotonin reuptake 
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inhibitors (SSRIs), for example citalopram, escitalopram, and fluoxetine, are effective 
in controlling OCD symptoms (Fineberg & Craig 2006, 2007; Hollander et al. 2000; 
Montgomery et al. 2001; Zohar & Judge 1996). Furthermore, non-drug interventions 
that have been empirically tested and shown to be effective in treating OCD include 
cognitive behavioural therapy (CBT) (Abramowitz 1998; Clark 2004; Frost & Steketee 
1999; Piggot & Seay 1999; Roth & Fonagy 2004, 2005), and a behavioural treatment 
called exposure and response prevention (ERP) (Abramowitz 1996; Barlow et al. 
2000; Dobson 2001; Foa & Kozak 1996; Marks 1997; Rachman & Hodgson 1980; 
Rigs & Foa 1993; Hawton, Salkovskis, Kirk & Clark 1989). The treatment mechanism 
for CBT/ERP is aimed at changing the way the sufferer appraises the problematic 
intrusive obsessions and teaching the person to resist the urge to engage in 
compulsions. It is often delivered on a weekly basis with 13 to 20 sessions 
considered adequate to attain treatment benefit (March et al. 1997). 
 
However, not every patient benefits from the treatments (Roth & Fonagy 2004, 2005). 
It is estimated that up to 70% of patients respond to the treatments where treatment 
response is considered to be at least 35% reduction (Moritz et al. 2004; Pallanti et al. 
2002) in scores on the Yale-Brown Obsessive Compulsive Scale (YBOCS) 
(Goodman et al. 1989a). Patients showing poor treatment response on the YBOCS 
have been estimated at around 50% when treatment dropout rates are accounted for 
(Bolton et al. 2000). Others have suggested that about a third of the patients treated 
do not adequately benefit (Fineberg & Gale 2005; March et al. 1997). The analysis of 
rates of relapse and attrition specifically in CBT treatments indicates rates of around 
50% (Bolton et al. 2000; Fairburn et al. 1995; Hollon et al. 2002; Newman et al. 2008; 
Simpson et al. 2006; Tarrier et al. 2008). The associated adverse effects of exposure 
and response prevention (ERP), that is, the anxiety and fear arising from deliberately 
exposing oneself for a prolonged and sustained period of time to very fearful 
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situations, have been linked to patients dropping out of the CBT treatment (Mancebo 
et al. 2008).  
 
1.3 Theoretical Relevance 
Vivid and disturbing intrusive images are a common occurrence in OCD (Rachman 
2007; Speckens et al. 2007). Unpleasant intrusive vivid images can trigger and 
amplify shame and guilt (Holmes & Mathews 2005; Holmes et al. 2007) and, to an 
extent, cognitive inflexibility. 
 
Obsessive vivid intrusive images (e.g. harm, sexual taboo, and religious blasphemy 
can be particularly hard to treat (Ferrao et al. 2006; Mataix-Cols et al. 2002; Rufer et 
al. 2005). The appraisal of a negative moral view of oneself in response to 
experiencing these images repeatedly (Ferrier & Brewin 2005; Wroe & Salkovskis 
2000) tends to bring forth a fear of being morally judged unfavourably. The shame 
experienced from the images and subsequent judgement may not be successfully 
ameliorated with CBT/ERP (Grey et al. 2002; Keeley et al. 2008; Steketee et al. 
2011). This is important to note, given the argument that rigid moral reasoning might 
influence cognitive inflexibility in OCD (Whitton et al. 2014). If so then regarding the 
cognitive inflexibility in OCD, although in the main it is endophenotype driven 
(biologically influenced) (Chamberlain et al. 2006), it is likely to be amplified by 
intrusive images and their associated shame or guilt, consequently making it more 
difficult for the patient to easily inhibit/override an already initiated compulsive 
behaviour. In terms of treatment benefits, cognitive inflexibility is said to make it more 
difficult for the patient to put into practice the therapeutic techniques gained during 
therapy (Moritz et al. 2005). Figure 1 is a model of the theory showing how an 
intrusive image may trigger shame and in turn how shame may impact on cognitive 
flexibility, which subsequently gives rise to the inability to inhibit compulsive 
behaviours.  
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1.4 Significance of Study 
Obsessive–compulsive disorder is a disabling condition that impacts on occupational 
functioning and opportunities for career progression (NICE 2006), resulting in 
unacceptably poor financial wellbeing for the person with OCD. For instance, it has 
been estimated that an adult patient with untreated OCD can lose, on average, a full 
three years of wages over a lifetime (Hollander & Wong 1995). Quality of life is often 
poor (Hollander et al. 1996; Lochner et al. 2003; Rapaport et al. 2005). It is not 
surprising therefore that quality of life is equally as poor as that of patients diagnosed 
with schizophrenia (Bobes et al. 2001), if not worse (Bystritsky et al. 2001; Stengler-
Wenzke et al. 2006). The poor quality of life associated with OCD patients and the 
lack of treatment improvement in one-third to half of people with OCD following 
standard interventions, motivated the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Intrusive Imagery and OCD Symptom Provocation Theory Model. 
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1.5 Rationale for Study 
Vivid and disturbing obsessional intrusive images frequently occur in OCD (Rachman 
2007; Speckens et al. 2007), and trigger and amplify shame and guilt (Holmes & 
Mathews 2005; Holmes et al. 2007) and to an extent cognitive inflexibility. It has 
recently been demonstrated that imagery rescripting may have a potentially 
therapeutic effect in treating OCD (Page et al. 2010, 2013) but the evidence base 
thus far is very limited. Therefore there is a need to examine further the therapeutic 
utility of imagery rescripting in OCD and particularly its effect on specific factors 
known to contribute to the poor treatment outcome associated with OCD. 
 
1.6 Purpose of Study 
The purpose of the study is to assess therapeutic symptom ameliorative value of a 
single session of therapist administered imagery rescripting therapy targeting the 
research’s key clinical and neurocognitive symptoms in the OCD diagnosed patients.  
 
1.7 Summary 
This Chapter provided a conceptual overview of OCD and the study rationale. In 
Chapter 2, a literature review of cognitive inflexibility in OCD is first presented, with 
particular attention given to the impact of cognitive inflexibility on the treatment of 
OCD, and studies on treatments for cognitive inflexibility. Secondly, attention is then 
given to reviewing the literature on shame and its role in the 
exacerbation/maintenance of cognitive inflexibility, its impact on OCD treatment 
response and studies on treatments for shame. Finally, the background of imagery as 
a therapeutic tool is briefly explored before paving the way for a discussion on 
imagery rescripting therapy and the associated literature on its effect on shame, OCD 
symptoms and cognitive inflexibility. Chapter 3 is concerned with the single-case 
experimental methodology employed along with a discussion of data analysis 
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procedures. Chapter 4 provides the results of the single-case analysis. Chapter 5 
presents the discussion of the study results. In Chapter 6 the conclusions, 
implications and recommendations of the study findings are considered.  
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Chapter. 2  Literature Review 
 
2.1 Literature Search 
In this chapter a literature review of cognitive inflexibility in OCD is first presented, 
with particular attention given to impact of cognitive inflexibility on treatment of OCD, 
and studies on treatments of cognitive inflexibility.  Secondly, attention is then given 
to reviewing the literature on shame and its role in the exacerbation/maintenance of 
cognitive inflexibility, its impact on OCD treatment response and studies on 
treatments for shame. The background of imagery as a therapeutic tool is briefly 
explored before focusing on imagery rescripting therapy and the associated literature 
on its effect on shame, OCD symptoms and cognitive inflexibility. Literature search 
for the subject areas reviewed below was carried accordingly. The literature search 
terms/keywords utilised were: “obsessive compulsive disorder”, “OCD”, “shame”, 
“guilt”, “endophenotype”, “motor inhibition”, “cognitive inflexibility”, “set-shifting”, and 
“imagery rescripting”. The databases searched for relevant research articles and 
literature, which were published between 1989 and 2014, included PsycINFO, 
Medline, CINHAL, and COCHRANE. Additionally, ISI Web of Knowledge, SCOPUS, 
and specialised collection of journals for specialist subject areas such as 
Neuroscience Abstracts were also considered. 
  
2.2 Cognitive Inflexibility 
Provocation of OCD symptoms tends to result in the dysfunction of the brain region 
called the prefrontal cortex (PFC) (Baxter et al. 1996; Chamberlain et al. 2006; 
Greisberg & McKay 2003; McGuire et al. 1994; Rauch 2000; Rauch et al. 1994; 
Saxena et al. 1998; Stein et al. 1999; Veale et al. 1996). The neurocircuitry activities 
in this brain region are believed to drive the executive functioning related to a 
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person’s ability to flexibly make choices in a given situation and/or related to 
response inhibition (Frith & Dolan 1996; Milner 1964; Passingham 1993). Response 
inhibition is described as “the overriding of a planned or already initiated action” (Bari 
& Robbins 2013:44). The presence of OCD can be associated with the poor 
performance of the inhibitory process and perseveration/set-shifting (Bannon, 
Gonsalvez, Croft & Boyce 2006; Kuelz et al. 2004; Miyake et al. 2000; Monsell 2003; 
Rachman & Hodgson 1980; Rosenberg et al. 1997; Roth et al. 2007). Chamberlain et 
al. (2006) showed that OCD patients often have problems delaying and suppressing 
or overriding repetitive actions or behaviours (compulsive behaviours) despite the 
behaviours being no longer relevant to the situation. It is therefore argued that, in 
turn, impaired inhibitory control maintains OCD symptoms, for example doubt 
(Linkovski et al. 2013). Perseveration/set-shifting deficit, often termed “cognitive 
inflexibility” (Schmidtke et al. 1998; Veale et al. 1996), is markedly severe in people 
with OCD (Harvey 1986) and is said to mediate both mental and behavioural 
compulsions, which characterise OCD (Chamberlain et al. 2006; Harvey 1986; 
Rosenberg et al. 1997).  
 
Others have also shown that the same brain regions associated with the neuronal 
activities linked to neurocognitive impairments are also involved in moral-based 
emotions such as shame and guilt (Greene et al. 2004; Harrison et al. 2012). In fact, 
Whitton et al. (2014) stated that these moral-based emotions maintain cognitive 
inflexibility problems. Furthermore, it has been argued that persistent impaired set-
shifting ability (cognitive inflexibility) may contribute to problems of poor treatment 
outcome in OCD (Abbruzzese, Ferri & Scarone 1995; Cavedini et al. 1998; Moritz et 
al. 2001b; Spitznagel & Suhr 2002).  
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The prognostic value of cognitive inflexibility in the treatment of OCD has been 
investigated in various studies (Kuelz et al. 2004; Kyrios et al. 1999; Moritz et al. 
1999, 2005). A number of pharmacological OCD treatment studies have 
demonstrated evidence implicating cognitive inflexibility in poor treatment outcome 
(Kahn, Westenberg & Jolles 1984; Martinot, Peron-Magnan, Huret, Mazoyer, Baron, 
Boulenger et al. 1990). Similar implications were noted in psychological and 
behavioural treatment paradigms comparing OCD symptom amelioration in relation 
to the presence of neurocognitive deficits. Kuelz et al. (2004) examined behavioural 
treatment outcome in OCD symptoms associated with the presence of neurocognitive 
dysfunction, and reported that in Sieg et al.’s (1999) study (non-English), the severity 
of the dysfunction yielded poor treatment outcome. Furthermore, there are other 
studies whose results diverge from these studies. For instance, Kyrios et al. (1999) 
showed that patients with higher executive function deficits tended to respond poorly 
to CBT, and is consistently supported by Moritz et al. (1999), notwithstanding the 
methodological limitations noted (Nedeljkovic et al. 2011). Moreover, Moritz et al. 
(2005) show in their study that the more perseveration errors are commissioned on 
the Wisconsin Card Sorting Test (a tool for assessing underlying executive function 
deficits) the greater the degree of cognitive inflexibility and the greater the likelihood 
that the compulsions fail to respond to CBT treatment for OCD. Although they did 
point out that, overall, it is too premature to assert that neurocognitive impairment is a 
reliable predictor for non-response to CBT; they conceded that the role of 
neurocognitive impairment has the propensity to interfere with the patient’s ability to 
apply psychological techniques in their day-to-day life. If so, then identifying and 
ameliorating the factors that exacerbate cognitive inflexibility with the view to 
reducing problems of cognitive inflexibility arguably increase the patient’s ability to 
transfer therapeutic techniques and apply them in their day-to-day life. 
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Two possible factors that arguably contribute to cognitive inflexibility are those related 
to self-conscious emotions, for example shame and guilt. Notwithstanding the 
possible circular relationship between shame and cognitive inflexibility, in that it is 
arguable also that cognitive inflexibility may equally drive shame, the thinking behind 
the argument that shame worsens cognitive inflexibility is drawn from various studies 
that consistently show that self-conscious emotions activate the medial prefrontal 
cortex (Morita et al. 2008; Shin et al., 2000; Takahashi et al. 2008). Notably, the 
anterior cingulate cortex (ACC), a region embedded in the medial prefrontal cortex, is 
activated during self-conscious emotional arousal (Shin et al. 2000; Morita et al. 
2008). Furthermore, the ACC is also believed to positively enhance efficiency in 
carrying out executive function-demanding tasks that rely on cognitive flexibility and 
cognitive/motor inhibition (Huster et al. 2009; Nee et al. 2011). Therefore, shame is 
considered in the current study because of its strong association with obsessional 
intrusive images in OCD, particularly those that are viewed as morally unacceptable, 
for example sexual, religious, and harm obsessions (Steketee et al. 2011; Wroe & 
Salkovskis 2000). 
 
2.3 Shame  
Shame is a self-conscious emotion, which in contrast with primary emotions, 
arises when a person is aware of how other people might evaluate them 
(Tracey, Robins & Tangney 2007). Emotions can have a negative effect on the 
functioning of the brain’s neurocircuitry. For instance, Lapiz-Bluhm et al. (2009) 
demonstrated that stress impairs reversal learning in rats. Similarly, human emotions 
in general may increase deficits in cognitive flexibility (Barlow et al. 2004; Borkovec et 
al. 2003; Lackner & Quigley 2005). In OCD, shame and guilt are often associated 
with the experience of negative intrusive thoughts/images and/or past aversive 
memories. These emotions are also believed to affect the frontal lobe circuits of the 
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brain, inhibiting basal ganglia motor/cognitive functioning (Morita et al. 2008; Shin et 
al. 2000; Takahashi et al. 2008), and thereby giving rise to the severity of deficit in 
task-shifting ability in OCD sufferers. 
 
Shame as an emotion is said to be a by-product of one’s own subjective devaluation 
of self-image (Gausel & Leach 2011; Tangney 1999), characterised by a global self-
defect appraisal (Gilbert & Andrews 1998; Lansky 1995; Lewis 1971; Tangney & 
Dearing 2002), often stemming from beliefs about one’s moral failure (Gausel & 
Leach 2011). Shame has been implicated in various psychological problems 
(Andrews, Qian & Valentine 2002; Hastings et al. 2000; Tangney & Dearing 2003; 
Tangney et al. 1992). Literature exploring anxiety disorders, for instance, suggests 
that in some cases social anxiety may be driven by shame (Gilbert & Miles 2000; 
Lutwak & Ferrari 1997). Shame has been shown to be strongly linked with the 
maintenance of post-traumatic stress disorder (PTSD) (Wilson, Drozdek & Turkovic 
2006).  
 
It has been suggested that OCD is characterised by shame (Rachman 2003; 
Valentiner & Smith 2008) particularly arising from moral-laden intrusive 
images/thoughts involving aggressive, sexual, or religious themes (Hezel et al. 2012). 
Shame proneness in OCD is similar to the concept of thought–action fusion (TAF) 
that has received significant research attention. TAF is a cognitive bias that involves 
equating having bad thoughts as the moral equivalent of acting on those thoughts 
(Rachman 1993; Shafran & Rachman 2004). When negative intrusions present in the 
form of images, the scene unfolds from a “field” perspective (Speckens et al. 2007) 
and the intrusive images generate fear and repulsion (De Silva 1986; Lee & Kwon 
2003; Rachman 1997). This seems to serve as a re-enforcer of an internalised and 
globalistic negative self-concept (e.g. that the person possesses bad and immoral 
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traits simply for having the image). It has been argued that OCD sufferers are easily 
susceptible to such cognitive attributional biases (Doron et al. 2008; Ferrier & Brewin 
2005; Lewis 2000; Weiner 1986). Consequently, a person with OCD who tends to 
over-value the importance of maintaining a good social moral standing, arguably can 
be said to be easily prone to experiencing shame in response to a morally charged 
obsessional images/thoughts (Stopa 2009; Valentiner & Smith 2008). This is 
consistent with the theoretical argument that shame acts as a warning signal with 
regard to putting oneself in unfavourable situations that could bring forth, for instance, 
anticipation of rejection (Rachman 2007). So from a functionalist viewpoint, shame 
compels the OCD individual into efforts to prevent social rejection occurring (Mills 
2005; Nathanson 1987, 1992). This may involve hiding symptoms, avoiding other 
symptoms, or neutralising images when they occur. 
 
Shame is associated with greater OCD symptom severity (Doron et al. 2008) and has 
a potential role in amplifying problems of cognitive inflexibility associated with OCD 
(Barlow et al. 2004; Borkovec et al. 2003; Lackner & Quigley 2005). Consequently, it 
would be expected that as shame improves (lessens) so too does OCD symptom 
severity. Likewise, shame might interfere with treatment unless it is resolved. CBT 
and ERP are proven effective treatments for OCD (Abramowitz 1998), but it is not 
always the case, in particular where the OCD is characterised by shame-based 
intrusive images such as sexual taboos, aggression/violence and blasphemous 
images (Keeley et al. 2008; Steketee et al. 2011). Given that shame can prove 
challenging to ameliorate with traditional CBT (Arntz & Weertman 1999; Rector et al. 
2000), it is possible that in some cases the failure of CBT to adequately improve 
OCD symptoms could possibly be explained by the presence of unresolved shame. 
Furthermore, behavioural treatment interventions, for example ERP, have been found 
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less effective in psychological disorders involving shame (Smucker & Dancu 1999, 
2005). 
 
Other authors have suggested that where shame is prominent it should be treated in 
order to ensure successful treatment for the main disorder in which shame is present 
(Arntz et al. 2007; Rusch et al. 2000). This underpins the logic for the current study. 
The cross-sectional design of the current study does not allow a conclusion about the 
causal sequence between shame and OC symptom improvement. The study can 
however indicate whether improvements in qualities of intrusive images such as their 
vividness accompany improvements in shame, guilt, OC symptom severities and 
cognitive inflexibility. 
 
Imagery has been utilised in the treatment of shame, for instance the work of Gilbert 
(2000, 2009a) and Gilbert & Irons (2005) in treating shame using compassion-
focussed therapy and compassionate mind training. The theory behind compassion-
based intervention for shame proposes that if the shame is about not being able to 
tolerate being imperfect or unideal then compassion is about learning to tolerate the 
less than ideal aspects of oneself. The approach suggests developing a 
compassionate image whose qualities, which may include warmth and non-
judgement, result in the patient feeling being cared for and cared about (Gilbert 
2010). The evidence available suggests that the compassion-focussed imagery 
approach is effective (Gilbert & Proctor 2006; Laithwaite et al. 2009; Leary et al. 
2007). 
 
In view of the usage of imagery in treating shame, and given that the current study 
involves patients experiencing intrusive shame-based images, the view was taken 
that imagery rescripting therapy should be utilised for the current study. It is worth 
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noting that imagery rescripting-based techniques are also utilised in compassion-
focussed therapy (Gilbert 2009).  
 
2.4 Imagery Rescripting Therapy 
Imagery Rescripting Therapy was developed to treat distressing intrusive mental 
images (Arntz et al. 2007; Grunert et al. 2007; Kindt et al. 2007; Rachman 2007). The 
treatment works by modifying repetitive and distressing images as well as helping the 
patient to develop a sense of control over the intrusions (Arntz 2012) Arntz & 
Weertman 1999; Arntz et al. 2007). Patients benefiting from imagery rescripting 
therapy are observed to shift from the tendency to negatively appraise the meaning 
of the intrusions to producing a positive outcome from the undesirable images 
(Germain et al. 2004). 
 
According to Edwards (2007) and Van Der Kolk and Van Der Hart (1989), the use of 
imagery work in psychological treatment was first reported as far back as 1919, 
where the technique was utilised in treating phobias in hysteria (Janet 1919 – non-
English). The treatment has evolved since then, and is tailored to alleviate the 
disturbing aspects of intrusive imagery (Hunt & Fenton 2007; Rusch et al. 2000; 
Wheatley et al. 2007; Wild et al. 2007), including ameliorating shame and guilt 
(Andrews et al. 2002; Harman & Lee 2010; Wilson et al. 2006; Wong & Cook 1992). 
It is commonly used to treat trauma patients reporting distressing intrusive images 
(Dancu, Foa & Smucker 1993; Smucker & Dancu 1999, 2005; Smucker & Niederee 
1995; Smucker et al. 1995). Not only has imagery rescripting been effective in 
trauma-based disorders such as PTSD (Arntz et al. 2007; Grunert et al. 2007), it has 
also reportedly been effective in treating intrusive images associated with social 
phobia (Wild et al. 2007, 2008), snake phobia (Hunt & Fenton 2007), depression 
(Brewin et al. 2009; Wheatley et al. 2007), and eating disorders (Tatham 2011). 
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Furthermore, imagery rescripting has been utilised in conjunction with other 
interventions in patients with BPD (Giesen-Bloo et al. 2006) in which shame can be 
particularly problematic (Rusch et al. 2005, 2007).  
 
2.5 Rationale for Imagery Rescripting 
Obsessive Compulsive Disorder is characterised by intrusive images, which in turn 
activate shame and guilt (Speckens et al. 2007). This results in the activated shame 
and guilt affecting the brain regions where the neurocognitive functions associated 
with OCD are processed, consequently exacerbating the severity of neurocognitive 
deficits, particularly set-shifting and inhibitory control. The use of imagery rescripting 
therefore appears appropriate in this case given that it primarily works on distressing 
intrusive images, bearing in mind that these are implicated in activating shame and 
guilt. Empirical evidence shows that imagery rescripting is effective in patients with 
PTSD experiencing shame and guilt (Arntz et al. 2007; Arntz & Weertman 1999; 
Grunert et al. 2003, 2007; Rusch et al. 2000; Smucker et al. 1995). It is worth noting 
that PTSD patients present similar clinical characteristics to OCD. For instance, in 
PTSD, intrusive recurring images/memories (although they are not obsessions) often 
activate negative emotions such as shame and guilt (Rusch et al. 2000). Additionally, 
cognitive inflexibility, particularly inhibition deficit, can also be a problem in PTSD 
(Leskin & White 2007). The fact that the efficacy of imagery rescripting in PTSD in 
some cases was sustained between 3 months’ and 6 months’ follow-up (Smucker et 
al. 1995) and that imagery rescripting demonstrated encouraging therapeutic utility in 
OCD (Rachman 2007; Speckens et al. 2007; Veale et al. 2015), adds further to the 
rationale for utilising imagery rescripting as the appropriate experimental intervention 
for OCD patients in this study. In most of the PTSD studies imagery rescripting was 
administered in more than one session, and similarly in the pilot study examining the 
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effects of imagery rescripting in OCD (Page et al. 2013). However, other studies have 
also demonstrated that imagery rescripting produces good effects after only a single 
session of between 60 and 90 minutes (Rusch et al. 2000; Wild et al. 2007). The 
current study therefore opted for a single session approach given that it is an 
unfunded pilot study.  
 
2.6 Study Aims and Objectives 
The first aim of the study is to establish whether changes in imagery vividness 
coincide with the intervening 90 minutes single session of therapist-administered 
Imagery Rescripting Therapy, which is combined with 7 days’ home-based patient 
self-administered imagery rescripting. Secondly whether there is an association 
between changes in imagery vividness and or the introduction of the treatment with 
changes in shame, guilt, and obsessive-compulsive symptoms (OCD). Thirdly is to 
assess whether the OCD diagnosed patients recruited for the study do demonstrate 
set-shifting deficit and motor inhibitory impairment. Fourthly, whether the treatment or 
changes in the clinical symptoms coincide with changes in set-shifting deficit, and 
motor inhibitory impairment  
 
2.7 Research Hypotheses 
This doctorate research study hypotheses that: 
1. Patients receiving one session of imagery rescripting with 7 days’ home 
practice will report reduced vividness in the intrusive imagery, between pre- 
and post-intervention. 
2. Improvements in key clinical symptoms (shame, guilt, and OCD) will coincide 
with changes in imagery vividness. 
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3. The initial baseline scores of the individual patients’ performance on the set-
shifting (Extradimensional Set-Shift) and the motor inhibitory control (Stop-
Signal Reaction Time) tasks of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) are impaired compared to the responses 
reported for the non-OCD Healthy Control Group as published in the 
Chamberlain et al (2006) study. 
4. Improvements in neurocognitive performance will be demonstrated after one 
session of imagery rescripting with 7 days’ home practice, which will align with 
the clinical changes observed. 
5. Improvements will be maintained over a period of 3 weeks, 6 weeks and 9 
weeks follow-up. 
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Chapter. 3 Methodology 
 
3.1 Introduction 
The previous chapters discussed the types of OCD that are difficult to treat despite 
using effective evidence-based interventions. Imagery rescripting was proposed as a 
promising add-on psychological intervention with its ameliorative effects targeting 
both intrusive images/thoughts (OCD obsessions) and shame/guilt, and also 
neurocognitive symptoms, particularly cognitive inflexibility and motor inhibitory 
deficits. Consequently this study seeks to answer questions about the effects of 
imagery rescripting. This chapter provides the ethical and scientific perspectives of 
the study, beginning with section 3.2, which discusses the ethical issues related to 
the study, whilst section 3.6 covers the study’s ethical approval standing. In section 
3.7 a discussion is had about the factors that influenced the researcher to adopt 
positivist philosophical assumptions about the nature or reality of the knowledge 
inquired in the study. The philosophy of science underpinning the logic/methodology 
on which the researcher based their choice of methods is also touched upon from 
section 3.8. Readers are then signposted to a discussion on the intervention 
procedure in section 3.11. The study flowchart included in this section provides a 
visual perspective of the participants’ journey from point of recruitment to the end 
point of the study. The participants’ case studies are presented in section 3.13, 
before the procedure for the multiple baseline design (MBD) is explained in 3.14. The 
experimental intervention is then discussed in section 3.17. Section 3.18 describes 
the scientific credibility of the study’s data collection methods. Data analysis methods 
are presented in the final part of the chapter, section 3.19, which explores the multi-
data analysis methods utilised, including the visual inspection of graphed data 
analysis and statistical analysis of clinically significant and reliable change. 
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3.2 Ethical Issues 
This research was conducted in accordance with the ethical principles of respect for 
autonomy, beneficence (do good), non-maleficence (do no harm) and justice 
(Beauchamp & Childress 2013). Elements of the Concordat to support research 
integrity were also adhered to, that is, honesty, rigour, transparency and open 
communication, and care and respect (Universities UK 2012). 
 
3.2.1 Respect for Autonomy, Informed Consent and Confidentiality 
The duty to respect one’s right to self-determination/autonomy is a cornerstone of 
ethical research practice and is in accordance with the Declaration of Helsinki 1964 
(as amended 2000). The researcher was trained and certified to Good Clinical 
Practice (GCP) standard (Appendix 16); consequently the preparation and conduct of 
the study was in accordance with GCP guidelines (Hutchinson 2004) and the Code of 
Practice for Research (UK Research Integrity Office 2009).  
 
The study only recruited adult participants aged 18 years and over. The interested 
participants were given full and unconditional opportunity to make their own decision 
about taking part in the research and this was done by providing clear, jargon-free 
information about the study in the form of a Participant Information Sheet (PIS) (see 
Appendix 3). The PIS provided a full disclosure of the research, which included 
information emphasising the participants’ right to withdraw at any point during the 
study. The disclosure was presented in a clearly written and easy to read typeface, 
fully and unambiguously stating the purpose of the study, the benefits and associated 
risks. Where unfamiliar terms were used, a glossary of definitions was provided. A 
draft information sheet was prepared and piloted with a patient user group, testing for 
clarity and comprehensibility of the content, before a final version of the PIS was 
approved with the overall study proposal by the Cambridgeshire Region NHS 
 45 
Research Ethics Committee and then distributed to potential participants (Appendix 
3). Beauchamp & Childress (1989; 2013) stated that the language used in preparing 
the information provided to participants should be at a level that is easy to 
understand, and free of research and medical jargon.  
 
The patients were given sufficient time, at least 24 hours, to read the PIS. They were 
encouraged to seek advice about participating, from an advocate independent to the 
study, for example the General Practitioner (GP), a member of the community mental 
health clinical team responsible for their overall mental health care, a family member 
or a trusted friend. Before interested participants signed and dated the consent form, 
the Chief Investigator further explained the contents of the PIS. 
 
To preserve participants’ confidentiality, the management and use of personal 
information was in accordance with the Data Protection Act 1998, and participants’ 
identifying data were removed and anonymity maintained throughout the study 
(Oppenheim 1998). Strengthening the security of participants’ confidentiality was 
given effect with how the investigational site was managed; the study personal log, 
subjects’ log, the collected data and subject personal information were kept secure in 
a locked cupboard (Hutchinson 2004). Access to confidential information was strictly 
controlled with a protocol in place identifying authorised persons, including 
circumstances in which access was considered. The privacy of participants was 
maintained in that the imagery rescripting was conducted on a one-to-one basis in a 
private consultation room. 
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3.2.2 Beneficence 
The research was underpinned by the ethical principle of beneficence, to establish 
additional knowledge that could possibly help ameliorate further OCD symptom 
severity. These symptoms result in often-reported unacceptably poor quality of life for 
those with this diagnosis. Having reviewed the relevant literature as published, the 
researcher proposed to administer imagery rescripting, as an experimental 
intervention, to a small group of OCD patients and examine its therapeutic effects on 
OCD symptoms. 
 
3.2.3 Non-maleficence 
One of the dependent variables the study was interested in examining, to which the 
participants gave consent, was the experience of feeling ashamed. However, it is not 
unusual for internalised shame to manifest in anger, rage, destructiveness and 
violence (Parks 2002; Scheff 1995). Consequently patients’ risk assessments were 
reviewed before the commencement of the study. Additionally, the researcher 
recruited a research therapist who was trained in violence and aggression de-
escalation techniques, in line with the local NHS Trust policy on managing violence 
and aggression in the workplace environment. Furthermore, during therapy the 
therapist sat near the exit door, for an easy escape route if the need arose. 
 
In addition to the evaluation of risks associated with the dependent study variables, 
the researcher also evaluated the adverse impact of experimental intervention. Given 
that imagery rescripting leads to elevated anxiety initially, part of its therapeutic 
intervention approach is for the patient to focus on the most distressing aspect of the 
intrusive image in contemplation of rescripting the image with a much more positive 
and empowering imagery experience. Although the associated distress is usually 
transitory and reasonably expected with this form of psychological intervention, 
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nonetheless participants were encouraged to report any distress that persisted 
despite rescripting. In addition, the research therapist evaluated the level of distress 
at the end of each treatment session. Notwithstanding the transitory distress 
associated with the treatment, it is not unusual for patients to have a diagnosis of 
anxiety and/or depression co-occurring with their primary diagnosis of OCD (APA 
2000; Black & Noyes 1990; Hollander et al. 1996; Kamath et al. 2007; Moritz et al. 
2001a). Given that depression and anxiety are also known at times to lead to suicidal 
ideation, and attempted and successful suicides (Conwell et al. 1996; Kamath et al. 
2007; Sareen et al. 2005), arguably this inferred that the study participants could 
have had a history of attempted suicide (Hung et al. 2010; Kamath et al. 2007; Khan 
et al. 2002; Rudd et al. 1993). Therefore all the participants were screened for 
suitability and the factors that resulted in exclusion from participating in the study 
included major depressive disorder, a history of deliberate self-harm, attempted 
suicide and those admitted into hospital. The PIS also informed potential participants 
that the intervention would be stopped and support offered should the participant 
experience distress. 
 
3.2.4 Ethical Review 
The Cambridgeshire Region NHS Research Ethics Committee (REC) reviewed the 
ethical standing of this study before favourable ethical opinion was granted (Appendix 
23). Following this, the University of Surrey Faculty of Health and Medical Science 
Ethics Committee reviewed the study and also granted a favourable ethical opinion 
(see Appendix 24). The study also received approval to be undertaken at the 
proposed NHS hospital site from the Research and Development (R&D) department 
of the said proposed NHS Trust (Appendix 25). 
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3.3 Research Philosophy 
3.3.1 The Researcher’s Ontological Position 
As a practicing clinician in the management of treatment resistant OCD, the 
expectation is to provide treatment improvement knowledge/advice capable of 
demonstrating objectivity so that NHS health care professionals, contemplating to 
adopt said advice in their course of clinical duties, are assured the knowledge is 
justified. The expectation for objective knowledge is consistent with the views argued 
in the philosophy of science dealing with the nature of reality emanating from 
empiricism (Creswell 2003). Empiricism constructs the debate about human 
interpretation regarding what constitutes reality/fact from either a subjective 
(interpretivist) or objective (positivist) viewpoint (Corbett 2003; Creswell 2003). It is 
worth noting that although subjectivism (interpretivism) and objectivism (positivism) 
orientations have their roots in empiricism, nonetheless they contradict one another 
ontologically and epistemologically. 
 
For instance, Bryman (2008) talked about consideration of the nature of reality/fact 
from a subjectivist ontological position as leading to the adoption of an interpretivist 
epistemological stance, which justifies knowledge as valid on the basis that the 
knowledge is influenced by the individual’s lived experience of the phenomenon, for 
example the phenomenon under study. Similarly Corbett (2003) talked about reality 
being concerned with the meanings formulated from the individual’s experience of the 
social phenomenon. 
 
Since the aim of the study was to establish an explanation of the effects of imagery 
rescripting on clinical and neurocognitive symptoms in OCD patients, the adopted 
assumptions about the nature of reality was grounded in an objectivist ontological 
position, which is said to lead to positivist epistemology (Bryman 2008) An overview 
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is provided next, of how a deductive research approach arising from positivist 
epistemology was utilised to determine the nature of reality about imagery rescripting 
having an effect on clinical and neurocognitive symptoms associated with (OCD). 
 
3.3.2 Positivism  
Six adults diagnosed with OCD were recruited and participated in a 12-week study. 
The adoption of an objectivist ontological position, which predicates on the idea that 
the existence of the social phenomenon under study and its meanings are not 
influenced by social actors (Bryman 2008), informed the choice of data collection 
methods utilised. The existence of changes in symptom severity was therefore 
measured using structured and objective measurement tools consistent with 
quantitative research methods. 
 
The analysis of the outcome data involved a combination of two processes that were 
informed by the experimental criterion and the therapeutic criterion. First, the 
experimental criterion refers to “the ways in which data are evaluated to determine 
whether the intervention has had an effect” (Kazdin 1982: 230). Visual analysis of 
graphic data whose roots are grounded in Skinnerian behavioural analysis was 
employed (Gast & Spriggs 2010).  
 
Secondly, in order to establish whether the intervention effect produced important 
changes, the therapeutic criterion was used in addition to the statistical approach. 
The therapeutic criterion refers to “whether the effects of the intervention are 
important or of clinical significance” (Kazdin 1982:230). A reliable change index and 
clinical significance analysis were also employed (Jacobson & Truax 1991) to assess 
this. Furthermore, it is worth noting that although the clinical role of the researcher 
played a part in positioning the researcher towards a positivist philosophical 
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underpinning to the study, on the whole the most influential factor was the aim of the 
research study. 
 
3.4 Research Design Rationale 
3.4.1 Quantitative Approach 
Creswell (2009), commenting on one of the positivist assumptions, stated that in 
pursuit of knowledge a competent inquiry about the knowledge must be objective and 
the objectivity should be demonstrable through control of bias that might arise in the 
methods and conclusions used to gather the knowledge. Creswell added that the 
quantitative research approach, which is a means for testing objective theories, is 
used to examine the functional relationship between an intervention and the 
problems of interest (the variables). Moreover, in the case of treatment effectiveness 
studies, in order to obtain stronger evidence for the functional relationship among the 
variables, the utilisation of an experimental research design, namely the randomised 
controlled trial (RCT) is advocated in the first instance (Bryman 2008). 
 
3.4.2 Randomised Controlled Trial Designs (RCTs) 
Using experimental designs ensure greater control of conditions likely to give rise to 
factors that could render the study results unsuitable for drawing scientifically reliable 
causal inferences of the impact of the intervention under investigation (Kazdin 1982; 
Shadish et al. 2002). However, there are various experimental designs at the 
disposal of the researchers. Smith (2012) pointed out that wisdom has it that utilising 
group designs is much preferred as they are known to have greater control of the 
majority of rival interpretations that might account for the observed treatment effect. 
Where the control of such confounds is in place then the study is said to have internal 
validity, which means that the observed changes in the dependent variables could 
arguably be attributable only to the effects of the intervention under investigation 
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(Kazdin 2011; Poling & Grossett 1986). An RCT is one such design and, as noted by 
Smith (2012), is considered superior in minimising the major internal validity threats 
by using two or more groups of research participants. RCT designs are also referred 
to as between-group designs, as the participants are randomly allocated for instance 
to receive treatment or no treatment. The group that is not receiving the experimental 
treatment acts as a control group. However, a large sample size would be required in 
order to create randomly assigned control and experimental groups that are evenly 
matched as closely as possible. According to Bryman (2008:37), randomly assigning 
participants to the experimental and control groups allows the researchers to be 
“confident that, if they did establish a difference in performance between the two 
groups, i.e. that there was an effect, it was due to the experimental manipulation 
alone”. Consequently, RCTs are regarded as gold standard experimental designs to 
use in treatment effectiveness studies (Shadish et al. 2002). 
 
This study initially considered utilising an RCT. To ensure that the design was 
adequately powered, a statistical power calculation was conducted in line with Cohen 
(1988) in order to inform the sample size required for the RCT design. The study 
established that to detect a moderate treatment effect size based on d = .50 so as to 
achieve an adequate statistical power (≥ .80), 100 participants needed to be 
recruited. However, the calculated sample size was considered too large to be easily 
manageable within the constraints of the limited resources of the study clinic. 
Likewise it has been noted previously that RCT designs require large sample sizes, 
consequently RCTs demand greater resource input, the type of resource that 
according to others is inconceivable to achieve and maintain without large-scale 
grants (Rizvi & Nock 2008). 
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The current study was unfunded and to commit to undertake an unfunded large-scale 
study, in the outpatient clinic, undoubtedly would have resulted in the time available 
for normal clinical duties being reduced to a level that impacted the clinic’s ability to 
provide safe and adequate care to the wider patient population. Such ramifications 
clearly would have given rise to ethical issues of maleficence, which was discussed 
earlier. 
 
Furthermore it is argued that, where an exploratory research study proposes to test a 
novel intervention, a smaller sample is recommended before a costly larger 
intervention trial is considered (Gedo 1999).  
 
Another point to note is that RCT designs have been heavily criticised for failing to 
take into account the uniqueness of human experiences (Henwood & Pigeon 1992). 
Since RCTs are biased towards average estimates of clinical symptom changes 
based on group-level data, this restricts the design from capturing high levels of 
variability and heterogeneity within the study sample (Molenaar 2004). That is to say 
the analysis of the results from an RCT design looks at the “group’s average change 
score”, and such analysis loses the response of the individual patient who is part of 
the group who may not have responded to the experimental intervention. Therefore 
Borckardt and colleagues (2008) expressed concerns about the obscurity of RCT 
designs on individual processes of change in the context of assessing treatment 
effectiveness in psychotherapy. In fact, the concerns go back beyond Borckardt et 
al.’s era and are found in Skinner’s (1938) study. If this is the case, it follows that the 
use of an RCT in the current study would arguably have far-reaching consequences 
by obscuring the analysis of the individual patient’s uniqueness and complexity 
related to their response to the administered treatment. 
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Having regard to the constraints discussed above, a smaller size sample (N = 6) was 
instead considered. Recruiting such a small sample size would be more in keeping 
with what the outpatient clinic could accommodate without giving rise to the 
aforementioned ethical issues. Although in the study, using a small sample size 
addressed the ethical and resource issues discussed earlier, this also meant that it 
was no longer appropriate to utilise the RCT design given that the considered sample 
size, N= 6, was not large enough for an RCT design to be adequately statistically 
powered. Given the ethical and funding concerns with recruiting a large sample size, 
the problems associated with the use of “group’s average change score” analysis and 
the argument for using a small sample in explorative studies focussing on the 
effectiveness of new interventions, an alternative design was therefore required. A 
methodological approach based on data obtained from a smaller size sample (N = 6) 
was required. Single-subject designs rely on a smaller sample (Barlow et al. 2008; 
Kazdin 2011). However, it was important that the alternative design was also 
experimental to remain in keeping with the positivist philosophical assumptions 
grounded in a quantitative design-driven inquiry. Moreover it was important that the 
alternative experimental design strategy was capable of producing data that enabled 
drawing reliable causal inferences about the impact of the experimental treatment. 
Single-case experimental designs (SCEDs) are not only capable of helping to draw a 
reliable causal inference, they also do not require large sample sizes, and are the 
focus of the forthcoming discussion. 
 
3.5 Single-Case Experimental Design (SCED) 
Single-case experimental design (SCED), which is also known as a small-N design, 
single-subject design or N of 1 design, tends to use small sample sizes, which can be 
as small as a single individual (Creswell 2009), to examine the effects of the 
intervention under study (Borckardt et al. 2008; Kazdin 2011; Kratochwill & Levin 
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2010). The design has been utilised in health care settings since it first emerged in 
the 19th century. As pointed out by Smith (2012), the single-case experimental 
design has been used by psychologists such as Watson (1925) and Skinner (1938) in 
the field of behaviourism as a methodological approach for investigating the utility 
and effects of behavioural interventions on individual participants. 
 
Since SCED is capable of providing robust experimental appraisal of treatment 
effects using one participant, on the proviso that the design structure is 
methodologically sound and facilitates replication of effects (Barlow et al. 2008; 
Kazdin 2011; Kratochwill et al. 2010), the design offers an alternative to group 
designs. It is considered ideal for evaluating the effects of an intervention 
implemented over time, and particularly where the importance of individual variations 
in participants is paramount (Morgan & Morgan 2001; Wolery et al. 2011). Smith’s 
(2012) description of SCED helpfully puts into context some of the methodological 
approaches to studying a single subject, to enhance the experimental rigour 
expected of a design professing to be grounded in the philosophy of science (the 
positivist ideology of inquiring new knowledge): 
 
“In contrast to a group design in which one group is compared with another, 
participants in a single-subject experiment research provide their own 
control data for the purpose of comparison” (Smith 2012:2). 
 
Smith (2012) notes that this approach involves the repeated collection of target 
outcome measures over a period of time during the pre-treatment phase of the study, 
which are then compared against those collected, also repeatedly, during the 
treatment phase and/or post-treatment phase. Insofar as the collection of repeated 
data is concerned, it is also worth pointing out that the data collection should rely on 
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systematic measurements as opposed to mere verbal feedback from the participant if 
credibility is to be afforded to the experimental claims SCEDs profess to offer (Barlow 
et al. 2008; Kazdin 2011; Kratochwill & Levin 2010; Smith 2012). The measurement 
instruments used in the study are discussed later in this report. 
 
Repeated data collection in the baseline phase serves as the control just as in an 
RCT. The assumption is that if the treatment is effective, then the severity symptom 
scores in the treatment phase will be much improved compared to the baseline 
phase scores (Kazdin 2011; Rizvi & Nock 2008). The pretest/baseline data path and 
post-test/intervention data path generated by the repeated measures are transformed 
into graphs for use in the visual analysis of the study results (Kazdin 2013). 
 
There are various SCED methodological structures at the disposal of investigators 
who intend to utilise single-case research in their inquiry (Wolery et al. 2011). 
However, it is beyond the scope of this paper to list and discuss all the available 
designs, but the most commonly utilised SCED structures are: the basic design (A-
B), the withdrawal/reversal designs (A-B-A) and (A-B-A-B), and the Multiple Base-line 
Design (MBD) (Kratochwill et al. 2010; Rizvi & Nock 2008; Wolery et al. 2011). In 
order to decide the most appropriate design for the current study, first, the scientific 
credibility of the designs were taken into account by evaluating the designs against 
the recently proposed Single-Case Design (SCD) Standards (Kratochwill et al. 2010, 
2013). So the standards which were utilised, as elucidated by Kratochwill et al. 
(2013:27-29), were: 
• The design must be able to facilitate the systematic manipulation of the 
treatment. 
•  The design must be capable of allowing inter-observer reliability assessment 
of the dependent variables in each phase. 
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• The design must provide at least three different opportunities at a different 
point in time where the investigator attempts to replicate an intervention effect. 
• For a phase to have the capacity to demonstrate treatment effect, the phase 
must have at the very least three data points. 
•  Where a multiple-baseline design is used the design should be flexible 
enough to accommodate a minimum of six phases with at least three data 
points per phase. 
 
Second, when selecting designs for research, the researcher is not only asked to 
give greater cognisance to potential ethical problems associated with the designs but 
must also manage the problems appropriately (Creswell 2009). Hence, the 
consideration to adopt a design for use in the current study was further driven by the 
risk/benefit ratio decision-making process, whereupon the risks and benefits of 
utilising the design were subjectively evaluated. Where the risk ratio far outweighed 
the benefits, the design was rejected for an alternative that was not only ethically 
favourable but also deemed better placed to evaluate causal relations between the 
treatment and the observed changes (Shaughnessy et al. 2004). Third and finally, the 
selection of the design was also influenced by the research objectives and the nature 
of the variables. Rizvi and Nock (2008) argued that the selection of a design in 
single-case research is as much influenced in greater part by the type of treatment 
and the target symptoms, as it is by the associated ethical issues. To help 
contextualise the “obiter dictum” of Rizvi and Nock (2008) in this regard, the 
treatment is considered in the current study in which imagery rescripting (ImRs) 
therapy was administered to give effect to a positive and empowering appraisal on an 
intrusive distressing image, through the patient learning to manipulate/rescript the 
toxic aspects of the imagery with one that was more acceptable to the patient. In 
such cases it would be difficult to utilise a design that relied on reverting post-
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treatment improved symptoms to baseline symptoms, to strengthen support for 
causal relations, on the basis that it would not in part be viable since theoretically it 
would be difficult, if not impossible, for the patient to unlearn the acquired appraisal in 
order to revert to the negative emotion-laden appraisal. Next, each of the considered 
designs is discussed in turn in the context of the three decision processes mentioned 
above. 
 
3.5.1  A-B design 
The A-B design is the most basic form of all single-case experimental designs. It 
comprises two phases which are denoted by the letters A and B, where phase A 
represents the baseline/pre-treatment condition and phase B is concerned with data 
collected when treatment has been initiated. Similarly to other SCEDs the data in the 
phases is collected repeatedly over a period of time using systematic measurement 
tools/scales (Kazdin 2011). The repeated measurement approach utilised in the A-B 
design is considered as a strategy that helps to identify and control for some of the 
threats to internal validity that might show up during the baseline phase, such as 
threats of maturation, testing, instrumentation, and statistical regression (Kratochwill 
et al. 2010). 
 
During phase A, the target symptoms are measured repeatedly whilst observing how 
the symptoms naturally present the majority of the time over a given period before 
the treatment is initiated (Barlow & Hersen 1984). Ideally treatment should not 
commence until baseline data are stable. A stable baseline helps one to argue for the 
existence of a relationship between independent and dependent variables where it is 
observed (Engel & Schutt 2014; Nock et al. 2008).  
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Data are also collected repeatedly in the treatment phase and then used to plot a 
trend line across the data points. The direction of the tread line (upwards, downwards 
or horizontal) is compared against the projected trend line in the baseline (phase A) 
to help determine whether the direction of the trend line suggest symptom 
improvement, deterioration or no change. The role of phase “A” acts as the control 
condition for the results observed in phase B (Barlow & Hersen 1984).  
 
A-B design has been criticised as not worthy as a pure-experimental design, because 
its bi-phase mode does not permit replication of the phases that are considered 
necessary for the demonstration of effect (Kratochwill et al. 2013; Shadish et al. 
2002). It is for this reason the A-B design was not used in this study. 
 
3.5.2  Withdrawal Designs  
The underlying experimental mechanism for A-B-A and A-B-A-B designs is a 
withdrawal/reversal strategy. This is where a previously introduced intervention is 
withdrawn in order to determine whether an observed symptom improvement 
deteriorates to the range observed in the previous baseline phase (Engel & Schutt 
2014). There is however an ethical dilemma associated with utilising this design. For 
instance is it ethically sound to withdraw treatment that appears to improve the 
symptoms merely to strengthen the argument for experimental credibility of the 
design. Above all, researchers are mindful that the investigative approaches and 
tools/designs they use in research are compatible with the obligation to avoid 
inflicting harm intentionally to participants, an obligation predicated on the ethical 
principle of non-maleficence (do no harm) (Beauchamp & Childress 2013). In short, 
the investigative approach (treatment withdrawal) inherent in the A-B-A and A-B-A-B 
designs is said to be tantamount to inflicting harm intentionally to patients and in 
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particular if the treatment withdrawal is clearly not in the best interest of the patient 
participant (Kazdin 2011). 
 
3.5.3 Multiple-Baseline Design 
Multiple-baseline design (MBD) studies examine hypotheses in a systematic fashion 
using a series of single-case A-B designs. Although there are three types of multiple 
baseline designs that include MBD across settings, MBD across behaviours and 
MBD across individuals (Kazdin 2011), the focus of the current study is on MBD 
across patients. Readers who wish to know more about the other designs are 
referred to the literature on SCEDs, which include, among others, Barlow et al. 
(2008), Gast and Spriggs (2010), Kazdin (2011), and Kratochwill et al. (2010). 
 
Multiple-baseline design across individuals examines the treatment effects in 
individual participants utilising much more rigorous experimental methodological 
approaches. They are described as an evolution of the basic A-B design because 
they are much improved on the A-B design experimental weaknesses, as observed 
by others (Kratochwill et al. 2013; Shadish et al. 2002). By recruiting at least three 
basic A-B designs to run concurrently, notwithstanding the baseline phase end period 
of each of the A-B designs being different, MBDs across individuals are able to 
demonstrate changes in the dependent variables through repeated measures and the 
replication of phases, which is born out of staggering the start of the treatment 
phases across the concurrently run basic A-B design (Barlow et al. 2008; Kazdin 
2011). It is always recommended to use concurrent MBD as opposed to non-
concurrent, because the concurrent strategy further strengthens the control of threats 
to internal validity (Carr 2005). The process of staggered phases starts when the 
treatment is initiated at the end of the baseline that has the shortest length. It is worth 
noting that the treatment remains until the end of the experiment. Meanwhile, the 
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baselines for the remainder of the participants continue to be collected repeatedly. 
When one of the remaining participants with a baseline slightly longer than the first 
participant’s reaches the end of their baseline length, the same treatment is 
introduced, provided all the necessary conditions that need fulfilling during the 
baseline phase are met, particularly stability of baseline measures. The benefits of 
having various baseline lengths were discussed in a psychological therapy study by 
Arntz et al. (2013), who stated that: 
 
“variation in baseline length offers the possibility to differentiate between 
time effects and experimental effects of the treatment” (2013:276). 
 
Additionally, the use of multiple subjects allows for randomisation to be factored into 
the design, of which randomisation is also used, for example in RCT designs to 
control threats to internal validity. A further benefit of using an MBD is that in addition 
to improving the control of extraneous variables, it solves the ethical issues inherent 
in the withdrawal designs. By virtue of using a series of A-B designs, the MBD does 
not need to stop an intervention midway through the treatment phase in order to 
establish the treatment as the only causal effect, a method that is relied upon when 
withdrawal/reversal designs are used (Smith et al. 2013).  
 
The argument for causal inferences in the MBD is said to be strengthened by the 
independence of observations of baseline changes occurring across all the 
participants coinciding with the onset of the intervention. For example, a recent study 
by Arntz et al. (2013) illustrates the use of a concurrent MBD to test the effectiveness 
of Imagery Rescripting (ImRs) for complicated war-related post-traumatic stress 
disorder (PTSD) in refugees. The study used ten series of A-B designs of varying 
baseline lengths to which the 10 adult participants were randomly assigned. Five 
 61 
different baseline lengths were used in which repeated measures were collected on a 
weekly basis with all the participants commencing the baseline phase at the same 
time. The treatment condition was initiated at different times. 
 
MBD across participants was adopted for the current study on the basis that it 
addressed the ethical issues and experimental weaknesses that are exclusively 
associated with the basic A-B and withdrawal designs. In the current study, 6 
participants were randomly assigned to three varying baseline lengths that were 7, 
10, and 14-day baselines. The rationale for selecting shorter baseline lengths 
between participants was in the main to avoid the ethical problems associated with 
prolonging the waiting time for one participant to receive an intervention whilst waiting 
for the participant before them to commence their treatment first. Furthermore the 14-
day treatment waiting time threshold was considered ethically sound given that the 
participants had been recruited from a treatment waiting list for which they would 
have waited much longer to receive treatment compared to the allocated baseline 
length. Despite the waiting period to receive the experimental treatment being 
relatively shorter than the time they would have waited for their treatment as usual, 
the withholding of an intervention for a prolonged period until necessary baseline 
phase conditions are met is a known ethical criticism associated with multiple 
baseline designs (Kazdin 2011). Therefore, as part of obtaining informed consent, all 
the participants were fully informed about the delay in receiving the experimental 
treatment. 
 
Since the lack of randomisation was a criticism of the basic A-B design (Shadish et 
al. 2002), in the current study randomisation was utilised to further enhance control of 
extraneous variables.  
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Although MBD appears to have experimental rigour that is superior to other single-
case designs, the design’s methodological structure is not immune to criticism. For 
instance, the rationale for repeated measurements, particularly in the baseline phase, 
is to predict what the target symptoms will be like in the future in the absence of an 
intervention (Kazdin 2011). Consequently this helps to reveal the trajectory of change 
of the target symptoms when the intervention is administered in the treatment phase 
(Smith et al. 2013). However, one of the problems of repeated measures in MBD is 
the issue of overestimating the effects of the treatment (Borckardt et al. 2004; 
DeProspero & Cohen 1979; Matyas & Greenwood 1990). This is discussed in detail 
in the analysis section below, including the approach utilised in the study to identify 
and manage the problem of overestimating the effects. 
 
One other criticism that has been raised about single-case designs is the lack of 
evidence of external validity. External validity is the extent to which the study results 
are generalisable beyond the study sample (Gay & Airasian 2000). Perdices and 
Tate (2009) acknowledged that designs using small samples, for example single-
case designs, often yield results that are poor at generalising beyond the sample 
under study. However, on the contrary, Dallery et al. (2013) argued that the: 
 
“Findings from single-case research do not inherently lack external validity 
or generality” (2013:e22). 
 
The authors supported their argument by stating that the direct replication of the 
effect provided by single-case research demonstrates generality. For example, three 
replications of treatment effects gathered across three individual participants are said 
to provide adequate evidence to claim the results are generalisable (Wolery et al. 
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2011). The current study recruited more than three participants to facilitate the 
minimum condition for the acceptable number of replications. 
 
The next section, concerned with intervention procedure, provides an in-depth 
description and discussion of the aforementioned tactics.  
 
 
3.6 Intervention Procedure 
3.6.1  Selection and Screening Protocol  
The target OCD patient population this study was interested in examining was from 
the OCD Specialist Service. However, it was not practicable to recruit all the patients 
to the study; consequently, the study relied upon a sampling frame as a 
representative of the population of interest. Two OCD CBT Group waiting lists (a 
current list and a spent/old list) were utilised as the sampling frame where the study 
recruited potential participants. The sample size was limited to 6 participants.  
 
Twenty-three patients from the combined waiting lists were identified to have a 
diagnosis of OCD with aggression/harm, sexual perversion and/or religious 
obsessions. The chief investigator initially went through all the active medical case 
files of patients on the combined waiting lists to identify those who fitted the criteria. It 
is worth noting that the chief investigator had direct access to the files because the 
investigator worked in the OCD Service/outpatient clinic as a treating clinician. 
Furthermore, the participants from the spent/old waiting list, although their group CBT 
treatment programme ended at least six months prior to study recruitment, were not 
discharged from the service but continued to receive pharmacological intervention as 
standard treatment for their OCD. Similarly, the participants on the current waiting list 
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for group CBT were also in receipt of pharmacological intervention as standard 
treatment for their OCD. 
 
Of the 23 patients identified, only 22 patients were sent invitation letters to participate 
in the research study. The 23rd patient was not invited because they were 
participating in another study. A Participant Information Sheet (PIS) (Appendix 3) was 
enclosed, clearly stating that the participant would not be disadvantaged if they 
declined to participate or left the research study at any time during the trial period. 
Subsequent to the letter, follow-up telephone calls were made by the chief 
investigator to establish if each participant had received the letter, and to offer the 
potential participants an opportunity to ask further questions about the study. A total 
of 17 individuals from the initial 23 patients were not included in the study for the 
following reasons: 
 
• Ethical Reasons: One male patient was currently involved in another study 
and was therefore excluded from being sent an invitation to participate. 
• Non-Responders: Nine individuals who did not respond to both forms of the 
invitations were female (n = 3) and male (n = 6). 
• Declined: Seven patients declined to participate, of whom 3 were female and 
4 were male. 
 
All the patients who declined to participate, including those who were not suitable to 
take part in the study, remained on the waiting list to receive CBT as had been 
previously planned. Participants from the spent/old waiting list were also offered to 
join the waiting list, together with the rest of the current waiting list group if they 
wished to do so. The remaining 6 patients, male (n = 2) and female (n = 4), 
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expressed interest in participating and were subsequently invited to the outpatient 
clinic for screening in order to determine suitability to participate in the study. 
 
3.7 Inclusion and Exclusion Criteria 
3.7.1  Visit 1: Establishing Eligibility & Pretest Data Collection 
Each of the 6 participants was invited to attend the outpatient clinic for a screening 
interview. At the 2-hour interview the participant was given another opportunity to ask 
questions about the PIS. The consent form was then discussed with the chief 
investigator and the participant signed and dated it before determining suitability 
using the inclusion and exclusion criteria set forth. Firstly, each participant was 
interviewed using the Yale-Brown Obsessive Compulsive Scale and Symptom 
Checklist (Y-BOCS-SC) (Goodman et al. 1989b) to determine presence of harm, 
sexual, and/or religious obsessions; then the Intrusive Imagery Interview Schedule to 
determine the characteristics and frequency of the intrusive imageries; and finally the 
MINI International Neuropsychiatric Interview (MINI) questionnaire (Sheehan et al. 
1998) to screen for comorbidities, for example major depressive disorder and 
psychosis. The determination for suitability was also guided by the inclusion and 
exclusion criteria as follows: 
 
1. The participants were considered for inclusion in the study if they had an OCD 
as the primary diagnosis. Additionally, a minimum OCD symptom severity 
score at the time of screening of 17 based on the Yale-Brown Obsessive 
Compulsive Scale (YBOCS) (Goodman et al. 1989a). 
2. Participants were also included if they reported distressing and repetitive 
intrusive images or thoughts related to either one or all of the following 
obsessions: sexual, aggression/harm and/or religious obsessions based on 
the YBOC-Symptoms checklist. 
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3. They also needed to report experiencing shame and/or guilt feelings that were 
as a direct result of the intrusive images and/or thoughts. 
4. Participants were also considered potentially suitable to participate in the 
study if their age at recruitment was from 18 to 65 years old and they were 
capable of making an informed decision. It was necessary to have 65 years 
as the cut-off age limit because the age group above 65 years makes it 
difficult to establish whether the cognitive deficits are an OCD trait or an old 
age phenomenon. Evidence shows that the age group above 65 years is 
susceptible to errors of perseveration as well as showing greater deficiency 
on set-shifting tasks (cognitive deficits) (Duncan et al. 1996; Kramer et al. 
1994, 1999; Kray et al. 2002; Span et al. 2002)  
5. The participants speak and read English. 
6. The inclusion to participate in the study was also dependent upon the 
volunteers agreeing not to commence any form of psychological treatment 
including CBT and ERP during the period of the study. 
 
The exclusion criteria list, which the study also relied upon, involved the following 
guidance:  
1. Participants with severe Major Depressive Disorder and scored at least 35 on 
the Montgomery and Asberg Depression Rating Scale (MADRS) 
questionnaire were excluded from participating in the study. 
2. Equally excluded were patients with suicidal ideation screened using Module 
C of the MINI questionnaire combined with a suicidal score of less than 4 
points on item 10 (suicidal question) of the MADRS. 
3. Past and present use of alcohol and substance abuse or dependence as 
elicited by Module J and K of the MINI questionnaire. 
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4. Presence or recent history of psychosis as assessed by Module L of the MINI 
questionnaire. 
5. Participants were also excluded if they had their treatment as usual for OCD, 
be it pharmacological or psychological, modified/changed in the four weeks 
before the start of the study or at any point during the study duration. 
 
Following the screening process, all 6 participants were found to be eligible to 
participate. The 6 participants were then randomly assigned to one of the three 
varying baseline length groups as follows: 7 days baseline (n = 1), 10 days baseline 
(n = 3) and 14 days baseline (n = 2). The chief investigator and the senior consultant 
psychiatrist/clinical academic jointly conducted the random assignment using a 
random assignment table (Appendix 27). Readers are also provided with a flow chart 
(Fig. 2) mapping the patients’ journey from point of recruitment to when the study 
ended. Furthermore, following randomisation, each participant’s demographic data 
and symptoms profile were gathered at the interview by the chief investigator before 
the initial baseline measures were collected. Wolery et al. (2011) suggested that 
when reporting single-case experimental methods, one of the important issues to 
consider in the manuscript is the description of the participants; that includes 
demographic information and a clinical profile. In line with the suggestions, the 
demography and clinical profile of the 5 patients who participated in the study is also 
provided below in Table 1. 
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Figure 2. Participant Study Flow Chart 
 
 
  
	 Recruitment	
Study	participants	(n	=	23)	
Excluded	(n	=	17)	
§ Not	met	inclusion	criteria	 (n	=	0)	
§ None	responders	(n	=	9)	
§ Declined	to	participate	 (n	=	7)	
§ Other	reasons	(n	=	1)	
Received	the	treatment	 (n	=	5)	
§ 7	days	baseline	group	(n	=	1)	
§ 10	days	baseline	group		(n	=	2)	
§ 14	days	baseline	group	(n	=	2)	
Randomised	(n	=	6)	
§ 7	days	baseline	(n	=	1)	
§ 10	days	baseline	(n	=	3)	
§ 14	days	baseline	(n	=	2)	
	
Follow	up	to	full-term	(n	=	3)	
§ 7	days	baseline	(n	=	1	
§ 10	days	baseline	(n	=	1)	
§ 14	days	baseline	(n	=	1)	
Total	analysed	(n	=	6)	
§ Analysed	at	baseline	(n	=	6)	
§ Analysed	at	posttest	 (n=5)	
§ Analysed	up	to	3	weeks	follow	up	(n	=	5)	
§ Analysed	up	to	9	weeks	follow	up	(n	=	3)	
Excluded	before	
treatment	 (n	=	1)	
Dropped	out	after	week	 3	
follow-up	(n	=	2)	
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3.8 Participants Case Study Details 
All the participants were diagnosed with Obsessive Compulsive Disorder (OCD) 
whose intrusive obsessions came spontaneously to mind repetitively and each 
participant described their obsessional phenomena as distressing and unwanted. The 
intrusive obsessions were associated with a memory of a past adverse event with the 
exception of two participants. Furthermore, three of the five participants had 
previously been under the care of the principle investigator of this study and treated 
with cognitive behaviour therapy (CBT) with exposure and response prevention 
(ERP). All the participants were currently on medication for OCD and the medication 
dose was maintained throughout the duration of the study.  
 
3.8.1 Participant P1 
This female participant was between 56 to 65 years of age and experienced 
aggressive/harm obsessions in a visual form occurring more than 20 times per week. 
She experienced an extremely vivid colourful image of herself in a video form. She 
believed in that moment of the experience that it was actually real and happening. 
Consequently she thought that she was bad and evil and felt guilt and shame. The 
unique characteristic about her experiences was that the obsessional intrusive 
images presented as two images fused into one picture. She reported the experience 
of seeing the images as too important to resist/ignore.  
 
3.8.2 Participant P3  
P3 was an 18 to 35 year old man who presented with both harm and sexual 
obsessions of duration of more than 10 years at the time of recruitment to the study. 
The intrusive imageries were a mixture of visual and non-visual form with the visual 
form predominating around sexual perversion of paedophilic in nature. The images 
occurred frequently, between 10 to 20 times weekly, and were reported as played in 
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black and white video and seen from a field perspective. The vividness of the image 
was not intense and P3 did not believe that the experience was really happening. 
However the non-visual images, which were experienced in the form of both intense 
vivid thoughts and tactile sensations, at times felt as if the experiences were real. The 
visual and or non-visual imageries made him feel disgusted and ashamed and these 
feelings are underlined by dreaded fear of people judging him negatively if they were 
to find out. The unique characteristics of P3 were that the obsessions did not have 
any association with memories of past adverse events and had not been previously 
treated by the principal investigator.  
 
3.8.3 Participant P4 
P4 was a female aged between 18 to 35 years with at least 10 years history of OCD 
related to harm and sexual intrusive obsessions. She also experienced the 
obsessions both in visual and non-visual form. The visual experience was more 
prominent and occurred between 5 to 10 times per week. She experienced the 
images as series of photos that were colour snap shots as well as colour videos, 
watching herself in the scene from a field perspective. The visual images, (both harm 
and sexual), were extremely vivid and she believed the experiences as actually 
happening. The experience of the intrusive sensations, which were in the form of 
sound, smell, touch and physical sensations co-occur with the visual images and 
amplified the beliefs of sexual obsessions as 100% real at that moment in time. Both 
harm and sexual obsessions evoked intense feelings of guilt and shame, and being 
embarrassed “if people find out what really I am like”. The unique characteristics of 
P4 were that although the sexual intrusive obsessions were grounded in past 
memories of an event the event was nonetheless described as non-adverse. 
Secondly the harm-based intrusive memories did not have an association with a past 
memory. 
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3.8.4  Participant P5 
P5 was a male aged between 46 to 55 years and had a diagnosis of harm-based 
OCD of duration of 8 years. The OCD symptoms were classified as severe at point of 
admission to the study. The harm obsessions came spontaneously and repetitively to 
mind at a rate of 10 to 20 times per week. The intrusive imageries were experienced 
in non-visual form as intense thoughts about acting on the aggressive obsessions. 
He rated the vividness of the thoughts as extreme. Whenever P5 experienced the 
thoughts he believed 100% that the experience was real and consequently he felt 
ashamed. The onset of the intrusive thoughts was one year following an adverse 
event although the thoughts of acting on intrusive obsessions were not similar to the 
memory of past adverse event. The unique characteristics of P5 included a history of 
slight damage to the left side of the brain and the history of a large consumption of 
alcohol. However at commencement of the study he had a 2-year period of 
abstinence from alcohol consumption. 
 
3.8.5 Participant P6  
P6 had a 10-year history of OCD of harm and religious obsessional symptoms. The 
harm obsessions occurred spontaneously in the mind in the form of snapshot 
colourful vivid images, viewed from a vantage point. The images were repetitive, 
occurring at least twenty times per week. P6 also experienced extremely vivid 
sensations of sound, smell, and touch. P6 considered the intrusive images as 
unwanted, distressing and ego dystonic. The snapshot images were: image of P6 
seeing her child falling down from the top of the stairs and breaking his neck; image 
of god snatching her child away from her and the priest drowning the child; images of 
pushing people off buildings and seeing them covered in blood and of people hit by 
cars and covered in blood and of her standing there. The intrusive obsessions were 
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associated with past memories of adverse events. P6 interpreted the images as 
failing to protect her children, and consequently felt guilty and ashamed. The unique 
characteristics for P6 included epilepsy, PTSD and being previously treated by the 
therapist who administered the study experimental intervention (imagery rescripting). 
Furthermore at the second study follow up P6 reported that she had been admitted 
into a general medical hospital for medical physical examination.  
 
Table 1 Demographic, Clinical and Neurocognitive Profiles (All participants)  
 
 
  
Participants Sex Age Range Eductional Level
OCD 
Duration OCD Type
SMERS 
Imagery 
Vividness 
(Type)
YBOCS SMERS Shame
SMERS 
Guilt
SMERS 
Anxiety MADRS EDS SSRT
P1 F 56-65 A Level 10 Yrs+ Harm 9.6 (Visual) 34 9.40 9.80 9.33 26 26 251.3
P2 F 18-35 A Level 1-4 Yrs Harm 6 (Visual & Non-Visual) 18 6 6 9 12 26 167.075
P3 M 18-35 Degree 10 Yrs+ Harm, Sexual
7 (Visual & 
Non-Visual) 22 6.00 6.00 6.25 12 2 106.5
P4 F 18-35 Degree 10 Yrs+ Harm, Sexual 9.9 (Visual) 24 9.45 9.40 9.40 15 19 216.95
P5 M 46-55 ◊ 5-9 Yrs Harm 9.2 (Non-Visual) 29 10.00 9.60 7.40 33 29 216.125
P6 F 18-35 Diploma 10 Yrs+ Harm, Religion
10.00 (Visual 
& Non-
Visual)
29 10.00 9.30 8.60 24 26 210.45
◊  Missing data,  YBOCS measures severity of OCD symptoms,  SMERS is a non-validated instrument, MADRS measures severity of depression
EDS evaluates cognitive flexibility performance, SSRT Evaluates motor inhibition performance
Participant P2 withdrew from the study after the initial baseline assessment
Clinical & Neurocognitive Characteristics
Initial Baseline
Demography
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3.9 Multiple Baseline Across Participants Procedure 
3.9.1 Baseline Phase 
The first baseline measurements for each of the participants were collected during 
visit 1 appointment. Thereafter each patient participant collected the baseline 
measurements at home for duration allocated by randomisation process. In visit 2, a 
second baseline measure was collected followed by the intervention.  
 
3.9.2 Intervention Phase 
Imagery Rescripting (ImRs) involves inviting the patient to focus on the distressing 
aspect of their intrusive image and replacing the distressing aspects of the image 
with ones that are more acceptable to the patient (Hackmann et al. 1998; Neziroglu 
et al. 1999). In the study, although the ImRs treatment protocol was principally based 
on Arntz and Weertman (1999) approach, that is, the three-phase procedure involving 
reliving, mastering and compassion, however, the approach was modified and 
incorporated approaches utilised in later studies such as Arntz et al. (2007) and 
Hagenaars and Arntz (2012). The modification also included a cognitive restructuring 
component similar to that adopted in Wild et al.’s, (2008) ImRs approach. 
 
An important aspect to note is that ImRs can be administered in a single session. For 
instance, Wild et al.’s (2008) study on socially phobic clients showed that when ImRs 
was administered in the experimental session, significant improvement was noted in 
negative images and distressing memories including a significant reduction in the 
vividness of the images/memories. Similarly, Nilsson, Lundh and Viborg (2012) 
observed immediate improvement in the distressing memories during one session of 
1-hour duration, and the improvement was maintained 1 week post-treatment. 
Drawing from these observations, the study therefore adopted a one-off ImRs 
session. However, it is also worth pointing out that where there are multiple images, it 
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could be that more than one ImRs session is required. Veale and Neziroglu 
(2010:251) suggest that, where rescripting does not have an immediate impact, this 
may be due to multiple aversive memories at play; therefore all of them may need 
addressing. In such cases one might therefore need more than one session of ImRs. 
To address this, the participants in the study were asked to utilise at home on a daily 
basis the learnt ImRs to address intrusive images still being experienced.  
 
A counselling psychologist administered the intervention (ImRs). Although they did 
not have prior experience of utilising ImRs in a clinical setting, they had at least 5 
years post-graduate experience as a therapist and regularly incorporated imagery 
work to treat intrusive images and aversive memories in trauma patients such as 
those diagnosed with PTSD. Additionally, the therapist had received half a day expert 
guidance on how to administer ImRs, approximately three weeks before 
commencement of the study. Furthermore, they were provided with a treatment 
protocol (Table 2), and regularly met with the chief investigator to ensure that 
treatment was being administered correctly. It is worth noting that other studies have 
utilised therapists with no prior experience of ImRs and only having received a day’s 
training (Arntz et al. 2013).  
 
Each participant received only one session of therapist-administered ImRs. The 
session lasted for up to 90 minutes. The intervention was administered in the same 
consultation therapy room, on a one-to-one basis. The session was conducted in 
three phases but adapted for the purpose of this study. During phase 1, up to 30 
minutes was spent discussing the nature and approach of ImRs, followed by the 
patient describing in graphic detail the content and meaning of their OCD distressing 
intrusive images and how they were related/linked to the content and meaning of 
their previously identified aversive memory. During this phase, the therapist refrained 
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from providing therapeutically active intervention other than describing the ImRs 
approach, asking/probing questions related to the intrusive imagery and to aversive 
memory (where applicable) and listening to the participant describing their lived 
experiences, thoughts and meanings held. 
 
ImRs was administered in line with the protocol. Further details are presented in 
Table 2. During the 7-day period starting from the day when ImRs was administered 
by the therapist, all the participants were asked to continue using the ImRs 
techniques at home to address any new intrusive images that arose and to record 
daily measures of imagery vividness, shame guilt and anxiety. 
 
Table 2 
 
 
One week after the therapist administered ImRs, the participants returned to the clinic 
in visit 3 with all the measures they had collected at home. The chief investigator then 
Imagery Rescripting Treatment Protocol 
Phase 1 1. Patient’s description of the images and their impact. 
2. Education about the nature and meaning of the images. 
3. Description of the treatment process. 
Phase 2 4. Imaginary exposure of image for 3 minutes, with eyes closed describing in present tense 
the experience.  
5. Imagery rescripting for 3 minutes is undertaken with eyes remaining closed. The participant 
spends the time altering the disturbing aspects of the image in a way they would like it to 
be. The therapist writes down the description. 
6. The altered image is then held in the participant’s mind for 3mins so as to achieve a more 
satisfying outcome. 
 
(Note: Phase 2 is repeated 3 times. Where a participant has several intrusive images 
they will be asked to apply imagery rescripting to each of the images) 
 
Phase 3 7. Cognitive Restructuring - In this final phase of the treatment, the therapist uses CBT 
techniques called cognitive restructuring to help enhance the alternative ways of making 
sense of the mental intrusions in more helpful and adaptive ways. 
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repeated the measurements including measurements for OCD, depression and 
neurocognitive deficits, which could only be administered in the clinic because they 
were clinicians rated. 
 
3.9.3 Post-Intervention Follow-up Phase 
The experimental treatment was considered completed when the participants 
returned to the clinic in visit 3 (V3) after their 7-day home-based ImRs phase. There 
were three post- treatment follow-up visits, V4, V5 and V6, whose intervals were 2 
weeks, 3 weeks and 3 weeks consecutively. At follow-up, the chief investigator 
gathered data on symptom severity and the other dependent variables. The 
assessments took place in the same assessment room using the same measurement 
instruments as had been used in all previous visits. 
 
3.10 Measurement Tools 
The measurement instruments used to collect data on a daily basis included the 
Subjective Measures of Emotions Rating Scales (SMERS), the State Shame and 
Guilt Scale (SSGS) and the State-Trait Anxiety Inventory (STAI-1). The data from 
these scales were then graphed and analysed visually as described in the analysis 
section. First, descriptions of the clinical symptom measurement instruments are 
provided, starting with the SMERS.  
 
3.10.1  Subjective Measures of Emotions Rating Scales (SMERS) 
This 10-point self-rating scale is concerned with negative emotions arising from the 
experience of obsessional intrusive images (Appendix 13). The variables measured 
for the study were guilt1, shame1, anxiety1, and imagery vividness1. The participant 
indicated how they felt on the day of rating by measuring the level or intensity of each 
item on a 10-point scale (Not at all intense = 1; somewhat intense = 2 - 4; moderately 
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intense = 5 - 7; very intense = 8 - 9; extremely intense = 10). The scale was a 
modified version of that used in a pilot study on ImRs in OCD (Page et al. 2010). It is 
worth pointing out that superscript “1” is used to distinguish guilt, shame, and anxiety 
data gathered using the SMERS, a non-validated measurement tool. Subsequent 
paragraphs describe psychometrically validated measurement tools also utilised to 
collect shame, guilt and anxiety data. Superscript “2” is assigned for SSGS subscale 
measures (shame and guilt) and superscript “3” for STAI-1 scale anxiety.  
 
3.10.2   State Shame and Guilt Scale (SSGS) 
The SSGS is a 15-item scale that was developed to measure the magnitude and 
frequency of shame, guilt and pride (Marschall et al. 1994). Each of the three 
subscales (shame, guilt and pride) has 5 items, which are rated on the 5-point Likert 
scale. For instance, using the shame subscale for illustration, each item, for example 
“I want to sink into the floor and disappear”, is awarded a score of 1 - 5 by the patient. 
Since there are 5 items, then the lowest possible aggregate score on the shame 
subscale is 5 and the highest is 25. The higher the score the greater the emotion is 
experienced. Since the study was examining shame and guilt, the 5 items related to 
pride were not used (Appendix 10, State Shame Guilt Scale).  
 
The SSGS is psychometrically validated. Alpha coefficients range from 0.82 to 0.89 
for each sub-scale (Tangney & Dearing 2002). Data for shame2 and guilt2 in the study 
were collected using the SSGS.  
 
  
 78 
3.10.3  State-Trait Anxiety Inventory (STAI) 
This study also examined the anxiety felt in the moment, which is called state anxiety, 
using STAI (Spielberger et al. 1983). The STAI is a widely used tool for measuring 
two different types of anxiety, using two sub-scales STAI-1 and STAI-2 of which there 
are 20 items in each sub-scale. The STAI-1 sub-scale, (Appendix 12), which was 
utilised in the study, measures state anxiety, that is, it measures feelings of anxiety 
experienced by the patient at the “present moment”. The statements are rated using 
a 4-point Likert scale (1 = almost never, to 4 = almost always); this equates to a 
severity score range of 20 - 80, where a higher score signifies greater anxiety. 
Moreover a score of 39 - 40 is considered the cut-off point to detect clinically 
significant symptoms (Knight et al. 1983). 
 
STAI-1 psychometric properties have reliability and validity established as 
satisfactory (Spielberger et al. 1983). For instance, the internal consistency 
coefficient (alpha) for the STAI-1 State scale for adult psychiatric outpatients was r = 
0.92 (Kabacoff et al. 1997). Given that STAI-1 has established psychometric 
properties, it was therefore used to collect data for the dependent variable marked 
anxiety3. The study also included dependent variables that could not be subjected to 
repeated daily data collection.  
 
3.10.4 Yale-Brown Obsessive Compulsive Scale (YBOCS) 
OCD symptom severity was measured using the clinician-rated YBOCS (Goodman et 
al. 1989a). The YBOCS is widely applied in both clinical and research settings and is 
regarded as the gold-standard assessment tool for symptom severity (Deacon & 
Abramowitz 2005; Frost et al. 1995). This validated instrument is a semi-structured 
10-item interview-based questionnaire that is comprised of two subsets: 5 questions 
relate to obsessional symptoms and the other 5 measure the severity of compulsions. 
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Each question rates the severity of the symptom over the past 7 days on a 5-point 
Likert scale ranging from 0 = (non-severe) to 4 = (extreme severity). This equates to 
a subtotal severity score ranging from 0 (none) to 20 (extreme). The subtotal scores 
are then aggregated to yield the overall YBOCS symptoms severity score that ranges 
from 0 to 40 and determines the severity of the disorder (Goodman et al. 1989a). The 
agreed standard symptom severity score ranges are: subclinical = 0 - 7; mild = 8 - 15; 
moderate = 16 - 23; severe = 24 - 31 and extreme = 32 - 40. However, for any 
observed symptom improvement to be considered clinically meaningful the widely 
accepted rule of thumb is that the reduction of the symptom severity should be at 
least 35% from the baseline (Stanford University 2015). 
   
The psychometric properties and clinical utility of the YBOCS have been empirically 
examined. For instance, Goodman et al. (1989b) evaluated its psychometric 
properties after it was administered to patients diagnosed with OCD. They 
established that it had an excellent internal consistency (r = 0.89) and also that its 
reliability, when administered by different raters on the same clinical sample, was 
excellent with an Interrater reliability score of r = 0.98. Moreover, it was reported that 
the total YBOCS score test–retest reliability assessment based on a 1-week interval 
between the tests and using a clinical sample, yielded r = 0.90 (Kim et al. 1990) and r 
= 0.97 (Kim et al. 1992). Furthermore, when the test–retest assessment was carried 
out on the YBOCS sub-scales the reliability level remained acceptable with the 
following results: obsession sub-scale r = 0.64 and compulsions sub-scale r = 0.56 
(Woody et al. 1995). A copy of the YBOCS is included in Appendix 8. 
 
3.10.5  Montgomery and Asberg Depression Rating Scale (MADRS) 
The severity and stability of the depressive symptoms were assessed and measured 
using the Montgomery and Asberg Depression Rating Scale (MADRS) (Montgomery 
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& Asberg 1979) (Appendix 11). This 10-item questionnaire is a clinician-rated scale 
for measuring the degree of severity of depressive symptoms and changes in 
symptom severity, and is widely used in pharmacological treatment studies. The 
scale was chosen because the study acknowledged that major depression could be a 
potential source of neurocognitive deficits (Gohier et al. 2009), so, selecting a tool 
that would give a reasonable indication of whether any of the patients were likely to 
be classified as having major depression was essential. Major depression is indicated 
by a score of ranging from 35 to the maximum possible score of 60 on the MADRS 
(Kearns et al. 1982). Symptom severity classifications of MADRS are: recovered (0 - 
8); mild (9 - 17); moderate (18 - 34); severe (35≥); and maximum (60) (Kearns et al. 
1982; Muller et al. 2000). If the depression severity is reduced by 25% it is 
considered an improvement (Lauge et al 1998) and if 50% or more symptom 
reduction is observed following an intervention the depression is considered to have 
responded to the intervention (Lauge et al. 1998).  
 
The MADRS is a well-validated instrument (Montgomery & Asberg 1979), which can 
be administered repeatedly at any time interval (Lam et al. 2005). A test–retest 
reliability examination carried out over 24 hours showed good reliability at 0.90 
(Mundt et al. 2006). 
 
Also utilised were measurement tests of executive functions originating from the 
Cambridge Neuropsychological Test Automated Battery (CANTAB) (Robbins et al. 
1994). One of the two measurement tests is the Intradimensional/Extradimensional 
Shift Task (ID/ED), which is used to test for two types of cognitive flexibility: 
attentional set shifting and reversal learning. For instance, the ID/ED task was utilised 
to examine the degree of cognitive flexibility in OCD patients admitted on an inpatient 
ward, and revealed that the patients made more errors at the extradimensional shift 
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(ED) stage (Veale et al. 1996). The instrument was further used in a study by 
Chamberlain et al. (2007) where impairment on performance at the ED stage was 
established not only in patients with OCD but also in their unaffected first-degree 
relatives, and was said therefore to suggest that the cognitive inflexibility as 
measured at the ED stage could be a cognitive endophenotype marker for OCD. 
Next is the description and psychometric properties of the ID/ED.  
 
3.10.6 Intradimensional/Extradimensional Shift Task (ID/ED) 
This subtest is a computerised version of the analogue 
Wisconsin Card Sorting Test. Its purpose is to assess rule 
acquisition and reversal learning tests which all require 
maintenance, shifting and attention flexibility (Robbins et al. 1998). ID/ED was used 
in the study to examine the degree of deficit in attentional set shifting (cognitive 
inflexibility). That is, the study was interested in measuring the participant’s ability to 
withhold/sustain their attention to certain rules or contingencies within a reinforced 
trigger/stimulus dimension (Intradimensional shift). Then, to assess the flexibility to 
shift their attention from the previously learnt rule (Intradimensional shift) to the new 
but previously irrelevant stimulus rule change dimension as the new contingency 
(Extradimensional shift) (Owen et al. 1993). As shown in the picture above, the test is 
comprised of two stimulus dimensions – the colour-filled shapes and the white lines. 
In the simple stimulus phase of the test the patient is presented, on a touch video 
display screen, with a pair of one of the two stimuli dimensions, for example a pair of 
simple colour-filled shapes. The patient chooses through trial and error the correct 
shape out of the pair. This is repeated several times before the rule is changed. The 
patient is expected to learn that the previously selected stimulus is no longer the 
correct one and therefore needs to shift their attention to a different shape in the new 
rule. 
 82 
 
In the second phase of the test, the patient is presented with compound stimuli, 
which involve a pair of colour-filled shapes with white lines overlying each of the 
shapes. As in the case of the simple stimulus phase, the patient also learns the 
correct stimulus by touching it, and continues to do so until the contingencies are 
reversed.  
 
There were nine blocks in the test and a new rule was introduced in each block. 
However, in order for the patient to proceed to the next stage, six consecutive correct 
answers needed to be achieved. However, OCD patients tend to persist with the 
same choice even if it is no longer relevant, and therefore more trials are needed at 
each stage before achieving the six consecutive correct answers required proceeding 
to the next stage. The more extradimensional (ED) errors commissioned the greater 
the severity of cognitive inflexibility. Conversely, fewer total ED errors indicate better 
cognitive flexibility.  
 
The test–retest reliability of neuropsychological assessments is generally poor (Lowe 
& Rabbitt 1998). For instance, the poor performance of the test–retest in ID/ED tests 
is due to the learning effect arising from the repeated practice of the test, which in 
turn affects test sensitivity (Basso et al. 1999). The EDS errors as measured by the 
ID/ED test based on healthy elderly volunteers demonstrate a low intraclass 
correlation (ICC) (R) test–retest (r = 0.70) repeated over a 2-week interval (Lowe & 
Rabbitt 1998). But the test–retest reliability for the stages completed as measured by 
the ID/ED at the 4-week interval, using healthy adult volunteers, showed a reliability 
level that was just on the cusp of an acceptable level (r = 0.75) (Lowe & Rabbitt 
1998). In the study the repeated measurement interval varied among the OCD 
patient participants ranging from 1 week to 3 weeks. 
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3.10.7  Stop Signal Task (SST) 
The stop signal task (SST) assesses motor inhibitory impairment (Logan 1994). 
There are five outcome measures in the SST; however, since the study was 
interested in patients’ reaction time to inhibit an action already initiated, the stop 
signal reaction time (SSRT) index of the SST was utilised. Stop signal reaction time 
is a computer-based tracking algorithm, which measures the degree/magnitude of 
motor response inhibitory impairment in milliseconds (Eagle et al. 2008; Lansbergen 
et al. 2007; Schachar et al. 2007). The 20-minute test is comprised of two parts. In 
the first part, the patient presses either a left or right button on a pad in response to a 
visual stimulus. The visual stimulus is an arrow flashed once at a time on a visual 
display screen. If a left-pointing arrow is flashed, the patient 
presses the left button. If a right-pointing arrow is displayed, then 
the right button should be pressed. The second part of the test 
combines visual and auditory stimuli. The subject continues to 
press the appropriate button on the press pad in response to the visual stimulus as 
before. However, upon hearing an auditory stimulus (a beep sound), the patient 
should withhold/inhibit the prepotent response. The patient’s performance is 
assessed by considering a combination of the number of trials successfully inhibited 
(SI), trials unsuccessfully inhibited (UI) and the average time of the stop signals 
(SOA). The higher/longer SSRT compared to normative data indicates greater 
inhibitory control deficit, whereas reduction of SSRT towards the direction of the 
normative data suggests improvement. According to Logan et al. (1984) the average 
reaction time (SSRT) performed by adults who do not have OCD ranges between 
200 and 250 milliseconds, and in OCD the SSRT measurement tends to be longer 
(Menzies et al. 2007).  
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The psychometric properties of SSRT recently examined using healthy adult 
volunteers found that the reliability estimates calculation yielded an average ICC 
coefficient value of 0.71 (Congdon et al. 2012). It was reported that the results were 
considered good as interpreted in line with Cicchetti’s guidelines for reliabilities 
(Cicchetti 2001). 
 
Table 3  Summary of Measurement Instruments used in the Study 
Construct Measure(s) 
Screening of Obsessive–Compulsive 
Disorder comorbidities 
MINI International Neuropsychiatric Interview (MINI) 
questionnaire 
Participants’ Personal Information Demographic Information Sheet 
Mental Images Intrusive Imagery Interview Schedule 
Obsessive–Compulsive Disorder Yale-Brown Obsessive Compulsive Scale (YBOCS) 
State Shame State Shame and Guilt Scale (SSGS) 
Cognitive Inflexibility Intradimensional/Extradimensional  (IED) – ED 
Motor Inhibitory Deficits	 Stop Signal Task (SST) – Stop signal reaction time (SSRT) 
Depressive Symptoms Montgomery-Asberg Depression Rating Scale (MADRS) 
State Anxiety The 20 State-subset items of the State-Trait Anxiety Inventory (STAI) 
Vividness, Guilt, Shame, Anxiety Subjective Measures of Emotions Rating Scales 
(SMERS) (10-point scale) 
 
3.11 Visual Analysis Procedure  
 
3.11.1  Introduction  
Following procedures recommended by other authors, data from the single-case 
experimental design (SCED) assessing the effects of ImRs were analysed in two 
ways. Firstly, visual analysis of the graphed data (Kazdin 2011) was used to evaluate 
the presence of a treatment effect, and utilising Tau-U as an estimate of effect size 
(Parker et al. 2011). The second analytic strategy assessed whether the observed 
treatment effect was statistically reliable and clinically meaningful. Clinical 
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significance and reliable change calculations were used to assess this (Jacobson & 
Truax 1991). 
 
This section describes visual analysis and how it was utilised to determine treatment 
effects. Questions about its reliability are also explored including statistical 
approaches for calculating effect sizes in visual analysis findings. Autocorrelation, a 
known problem associated with repeated measurements in SCED, is highlighted and 
presented, among other factors, as an argument against utilising conventional 
statistical approaches to calculate effect sizes. Regression-based methods and non-
overlapping data approaches as alternatives to conventional statistics are described. 
The argument for using the Tau-U statistical analysis approach (Parker et al. 2011) 
over regression-based methods and other nonoverlap-based approaches is 
presented. The discussion then focuses on the reliable change index (RCI) and 
clinical significance (CS) methods (Jacobson & Truax 1991) used in the study to 
evaluate clinical meaningfulness of the effects of all the study data. 
 
3.11.2  Visual Analysis of Graphic Data 
Visual analysis of graphed data, whose roots are grounded in behavioural analysis 
(Gast & Spriggs 2010; Kazdin 2011), was employed to evaluate the presence of a 
reduction in symptom severity following an intervention (Wolery & Harris 1982). The 
magnitude of the symptom change was assessed by visually examining the graphed 
data for pattern changes in mean and level (Kazdin 2003). Also the rate of the 
magnitude of change was evaluated by assessing the repeated measures data for 
pattern changes in trend and latency of the change (Kazdin 2003; Morgan & Morgan 
2009). However it is important to point out that if evidence of effect is observed it is 
more difficult to locate the treatment effect as a result of ImRs because the study 
design does not have a comparison sample to be able to unequivocally assess this. 
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3.11.3  Mean and Level Changes 
The way changes in means are evaluated is through examining the patterns of data 
variability (the degree of consistency in the repeated measures) across baseline and 
intervention phases. The ideal is for the data set across phases to demonstrate a low 
range of data variability/fluctuation (Morgan & Morgan 2009). In addition, where there 
is an observable difference between the levels of the baseline and intervention 
phases, a conditional claim for the presence of a treatment effect can arguably be put 
forward (Kazdin 2011). Therefore in the study, visual inspection of graphed data for 
pattern changes in level was utilised to determine whether changes occur in study 
variables following ImRs. 
 
3.11.4  Trend and Latency  
The visual inspection also examined the tendency for the graphed repeated 
measures data to demonstrate a systematic increase or downward trend over time. 
Kazdin (2013) discusses changes in trend/slope as being an important aspect in 
applying visual inspection, given that an observed decrease in the trend of the data 
across adjacent phases provides a preliminary indication that the introduction of the 
intervention coincided with changes in symptom levels, except in cases where the 
observed downward trend commenced in the baseline phase. However, the changes 
in trend per se cannot be exclusively attributed to the intervention (Morgan & Morgan 
2009). Equally important in the study was the assessment of immediacy of effect or 
latency of the change. This phenomenon is defined as the rate/speed of symptom 
change, from the last three data points in the baseline phase to the first three data 
points in the intervention phase, following the introduction of the treatment 
(Kratochwill et al. 2010). Therefore in the study the rate of symptom change was 
assessed, in addition to trend, since this arguably increases confidence by inferring 
 87 
that the observed symptom improvement provides stronger evidence that 
improvement is associated with ImRs. 
 
In summary, visual inspection of the graphed data for changes in trend, level, 
variability, etc. between baseline and treatment phases, is used to determine whether 
the ImRs intervention is likely to have made a meaningful impact/change on clinical 
symptoms. However, a number of concerns have been raised about the reliability of 
visual analysis when evaluating the magnitude of the observed treatment effects. 
 
3.11.5  Reliability of Visual Analysis 
Some authors argue that visual analysis-based evaluation is fraught with biases 
given that the interpretation of the treatment effects lacks homogeneity/consistency 
(DeProspero & Cohen 1979) and is highly subjective (Brossart et al. 2006; Morgan & 
Morgan 2009). A lack of homogeneity, according to Wolery and Harris (1982), is 
attributed to the absence of agreed guidelines for fostering an objective evaluation of 
treatment effects. Lack of objective evaluation makes visual analysis evaluation more 
vulnerable to overestimating the effect of treatment. This is due to the measurements 
of the dependent variable being collected repeatedly both under a baseline and at an 
adjacent intervention phase over time (Matyas & Greenwood 1990). Ironically, 
repeated measurement is an essential feature of SCED. Measurement during the 
intervention phase is dependent upon measurement taken during the baseline phase. 
This serial dependence of the measurements results in overestimation of the 
treatment effect. The degree of overestimation only becomes apparent when 
adjustments to the autocorrelation of the data are later taken into account (Borckardt 
et al. 2008). Autocorrelation is discussed later in this section. However, in view of the 
risk of effect size overestimation, the study validated the observed effects with an 
objective effect size calculation method (Morgan & Morgan 2009; Robey et al. 1999). 
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3.12 Effect Size Calculation 
It is imperative to calculate effect sizes in order to increase confidence in the visual 
analysis, particularly where at least moderate effects are reported (Brossart et al. 
2006; Kratochwill et al. 2010; Parker et al. 2011a). Moreover, effect size calculations 
provide, among other benefits, objectivity, enhancement in measurement precision, 
facilitating cross-case comparison, and improved interrater reliability for calculating 
SCED outcome (Parker & Hagan-Burke 2007). However, calculation of effect sizes in 
SCED comes with its own challenges. For instance, conventional statistical analysis 
is often the statistical analytic method of choice in calculating treatment effects by, for 
example, comparing the mean difference between baseline and treatment phases 
(Cohen 1988; Cohen & Cohen 1983). However, to utilise the conventional statistical 
analysis in this study would have been inappropriate because SCED relies on trend-
level changes in the data stream to estimate the treatment effect as opposed to 
comparing average differences between baseline and treatment phases (Kratochwill 
et al. 2010; Parker et al. 2011a). Furthermore, repeated measurement does not 
conform to the assumption of independent observations required of conventional 
statistical approaches (Brossart et al. 2006). Consequently, the use of conventional 
statistics would potentially lead to spurious effects – thus increasing Type I or Type II 
error rates (Ellis 1999). Type I error is when the treatment effects are said to exist 
when in fact there is no true effect (Hoffman 2015). Type II error is the rejection of the 
results as having no effect when the effect in fact exists (Hoffman 2015). The 
increase in error rates is due to autocorrelation, a phenomenon associated with 
SCED. 
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3.13 Autocorrelation  
The data in the current study was autocorrelated given that autocorrelation is a 
common phenomenon associated with SCED. This view is supported by studies that 
have examined autocorrelation in SCED. Published reviews of SCED studies have 
found that not only was autocorrelation present, but most notably that at least 33% of 
the SCED-based studies showed autocorrelated data to an unacceptable level (>.20 
to .25) (Matyas & Greenwood 1996; Parker et al. 2011a). The significance of 
autocorrelated data in the current study is that it can confound interpretation of the 
effect sizes (Matyas & Greenwood 1990), unless appropriate statistical effect size 
calculations are used that are also capable of controlling autocorrelation.  
 
3.14 Statistical Analysis 
Given the aforementioned discussion, two approaches for statistical analysis were 
carefully chosen to ensure that they were best placed to make robust conclusions 
about the treatment effect. Subsequent sections described the two approaches used 
and the rationale for their use. Measures that were taken repeatedly (SMERS, SSGS 
and STAI-1) were analysed using Tau-U given its suitability for repeated 
measurement in SCED. Measures that were only taken at pre-, post- and follow-up 
(YBOCS, MADRS, EDS total errors and SSRT) were assessed using the Reliable 
Change Index and Clinical Significance tests in view of their suitability to detect 
statistically reliable and meaningful change in standardised measures given at 
intervals before and after intervention. First in the discussion are two effect-size 
calculation methods that have been proposed as alternatives to using conventional 
statistical methods because of their suitability for handling SCED-generated data: 
regression-based methods and data non-overlap methods (Brossart et al. 2006). 
 
3.14.1 Regression-based Methods 
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There are several methods that have been used to control autocorrelation for 
instance regression-based methods (Parker & Brossart 2003). However it is beyond 
the scope of this study to discuss regression-based methods, other than providing 
examples, which included GORSUCH, CENTER-MT and ALLISON-MT. Readers 
interested in regression-based methods in single case designs are sign posted to a 
publication by Parker and Brossart (2003) who compared the performance seven 
statistical methods for calculating effect sizes, in single case research.  However one 
statistical method that has been considered for the current study is the Tau-U 
method, which is said to complement visual analysis of graphed data and that it does 
“not require parametric assumptions about data distribution or scale type” (Parker et 
al. 2011a: 304). 
 
3.15 Tau-U Statistical Analysis 
Tau-U is a time-series data analysis method that takes into account both trend and 
level, similar to the other methods discussed above. The Tau-U calculator is a web-
based tool that can be accessed free of charge on the Internet at 
http://www.singlecaseresearch.org/calculators/tau-u. A screen shot of the calculator 
is provided in Appendix 28. Tau-U was chosen because it is argued that it performs 
well in the presence of autocorrelation (i.e. is least affected by autocorrelation) 
(Parker et al. 2011a). However Tau-U analysis was not used for measures of OCD 
(YBOCS), depression (MADRS), cognitive inflexibility (ID/ED) and motor/cognitive 
inhibitory deficits (SSRT). These measures were excluded for visual analysis 
because the repeated measurements did not have sufficient data points to be 
suitable for visual analysis (Kratochwill et al. 2013).  The study encountered a 
practical problem with collecting daily measures because the ID/ED, SSRT, YBOCS 
and MADRS are clinician-administered measures and needed to be administered at 
 91 
the clinic. Moreover it would have been practically impossible as well as unethical to 
have the participants travel daily to the clinic for the measurements, since ordinarily 
in the course of treatment they would not have been expected to do so. The ID/ED 
task for assessing cognitive flexibility could not be subjected to daily repeated 
measurement because of concerns of practice effect, which undoubtedly would have 
confounded the data. However, there are clinical norms for these measures that both 
clinicians and researchers use to assess treatment effectiveness. Norms allow the 
calculation of clinically significant and reliable change. 
 
3.16 Reliable Change and Clinical Significance Analysis 
3.16.1 Reliable Change Index (RCI) 
Reliable change index determines whether the observed change in symptom severity 
could potentially be due to the experimental intervention or it is due to measurement 
error (Jacobson & Truax 1991). To assess whether the observed change is reliable it 
is necessary to calculate a Reliable Change Index (RCI). The calculation involves two 
key indices: (a) the test–retest reliability coefficient for the symptom measure of 
interest; and (b) the Standard Deviation (SD) based on the sample population the 
test–retest reliability coefficient originated from (Jacobson & Truax 1991). It is worth 
noting that guidance differs on whether one should use internal or test-retest 
reliability. So the latter method was chosen because it estimates error when a 
measure is administered on separate occasions, as is the case in the current study. 
However, test-retest estimates tend to be lower than the internal reliability estimates; 
therefore, it might be seen to be a more conservative estimate of reliable change. 
The calculated RCI for reliable change is normally set at a cut-off score of 1.96 set at 
95% confidence interval (CI) (Jacobson & Truax 1991). However, in the current study 
the cut-off score was set at the confidence interval of 90% with the RCI yielding a cut-
off set of -1.65. The reason for the negative RCI (-1.65) to classify an improvement 
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change is because a higher measure score indicates greater symptom severity, 
whilst a lower score is a function of reduced/improved symptoms (Hageman & 
Arrindell 1999). Therefore the interpretation of RCI in the study is as follows: 
• RCI > +1.65 classifies the symptoms as deteriorated 
• RCI < -1.65 classifies the symptoms as improved. 
 
The formula for calculating RCI referred to in Jacobson & Truax (1991:14) is as 
follows: 
RC = (X2-X1)/Sdiff: where X1 = either the mean score of YBOCS, MADRS, ID/ED or 
SSRT before the patient received ImRs therapy, X2 = the mean score of the same 
individual measures but after the patient received the ImRs therapy, and Sdiff = the 
standard error of the difference between the two test scores. Jacobson and Truax 
(1991:14) described the standard error of the difference (Sdiff) as “the spread of the 
distribution of change scores that would be expected if no actual change had 
occurred” and that the Sdiff in the denominator of the RCI equation above could be 
calculated directly from the standard error of measurement (SE) as follows: 
Sdiff = √2 (SE)2 
 
It is worth noting that RCI is more robust when assessing change in measures 
related to psychological constructs such as OCD and depression. However, it is not 
ideal for assessing reliable change in neurocognitive tests due to practice effects 
(Duff 2012). Thus, observed improvements may be a result of repeated exposure to 
the testing materials as opposed to the treatment (Duff 2012). Temkin et al. (1999) 
found in their review study that RCI analyses that did not account for practice effects 
yielded high error rates compared to the practice effects adjusted RCI analyses. 
Therefore in the current study, EDS data were considered for practice effect 
adjustment where the initial RCI calculation confirmed the change as reliable. Where 
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this was necessary, the RCI adjusted for practice effects (RCIPE) calculation 
suggested by Chelune et al. (1993) was utilised: 
RCIPE = ((X2 – X1) – (M2 – M1)) 
   SD 
 
X2 is the observed post-treatment (following ImRs) score, X1 the recorded score 
before treatment initiation, M2 represents the group mean post-test score, M1 the 
group mean pretest score and SD is the standard deviation of the group test–retest 
difference. Parsons et al. (2009:499) suggest that:  
 
“practice effects [are] apparent in those situations in which group mean post-
test score greater than group mean pretest score represents mean gain, and 
group mean post-test score less than group mean pretest score represents 
mean decline”.  
 
This suggestion was followed in the study so as to determine that practice effects 
were apparent. With the predicted score set at 90% CI, the adjusted RCI estimate of 
±1.65 was used as a cut-off point for the study. Reliable improvement was therefore 
evident where the RCI or RCIPE fell below the cut-off score of -1.65. If the scores are 
greater than 1.65 then a reliable decline is observed. If the values are -1.65 to 1.65, 
the interpretation is that there is no change. 
 
3.16.2 Clinical Significance change (CSC) 
Clinical significance analysis is used to establish the degree or magnitude of change 
an intervention (i.e. ImRs in the case of this study) had on the clinical symptoms and 
whether the reliable change observed had a real and meaningful impact on the 
patients’ functioning (Jacobson & Truax 1991; Jacobson et al. 1984). Crucially, the 
determination of the degree of symptom changes is based on some form of agreed 
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standards of usefulness in terms of the level of the measures (clinical norms of the 
measures) relevant to the specific clinical symptom of interest (Jacobson & Truax 
1991). In a nutshell, the assumption underlying clinical significance is “returning to 
normal functioning” (Jacobson et al. 1999:300). Jacobson and Truax (1991) provided 
three conditions for consideration to base the calculation on for determining 
participants who attained clinically significant change (CSC) following the 
intervention: 
(a) The level of functioning resultant of the intervention should be outside the 
range of the dysfunctional population, where range is expressed as a spread 
of 2 standard deviations (SD) from (in the direction of functionality) the mean ! for that population. 
 
(b) The level of functioning resultant of the intervention should be within the 
range of the normal population, where range is expressed as within 2 SD of 
the ! of that population. 
 
(c) The level of functioning resultant of the intervention places that client closer to 
the ! of the functional population than it does to the ! of the dysfunctional 
population.  
 
Table 4 provides the statistical algorithms to choose from, for instance if a cut-off 
score approach is to be utilised to determine clinical significance then the equation 
specified in “c” is chosen provided data from the functional and dysfunctional 
populations relevant to the variable of interest are available (Jacobson & Truax 
1991). However where data is not readily available in order to use criteria “c”, 
Jacobson and Truax (1991) further suggested that the equation “a” or “b” stipulated in 
Table 4 below can be utilised where an estimated cut-off point is based on 2 standard 
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deviations of either the dysfunctional or functional population Criteria. In terms of this 
study, equation “a” or “b” will be used to calculate depression (MADRS) significant 
improvement based on at least 2 standard deviations from the original mean in the 
therapeutic direction, where MADRS severe cut-off point for improvement is 35 
(Kearns et al. 1982; Muller et al. 2000). Similarly the meaningful improvement for the 
obsessive compulsive symptoms will be based on either the “a” or “b” criterion given 
that for OC symptoms the “gold” threshold considered as a meaningful improvement 
is a 35% symptom reduction from the baseline (Stanford University 2015), whilst the 
conservative threshold is 25% (Foa et al. 2005; Seibell & Hollander 2014; Stanford 
University 2015). Likewise both the neurocognitive outcome results will rely on the “b” 
criteria, where the mean for the functional population for the EDS measures and for 
the SSRT measures are based on the Chamberlain et al (2006) normative data. 
 
Table 4.  
 
Jacobson & Truax (1991) Statistical Approach to Clinical Significance. 
 ! =	 
 
 ! of dysfunct pop – 2SD of dysfunct pop	 
 
 ! =	 
 
 ! of funct pop – 2SD of funct pop	 
 
 
 ! =  (!" !" !"#$ !"! ! ! !" !"#$%&'( !"!)  +  (!" !" !"#$%&'( !"! ! ! !" !"#$ !"!)!" !" !"#$% + !" !" !"#$%&'( !"!  !: mean, SD: standard deviation, funct: functional, dysfunct: dysfunctional, pop: population 
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Chapter. 4 Results 
 
4.1 Hypothesis Testing 
Data for 5 participants were considered for analysis. The sixth participant could not 
be included in the analysis because they dropped out before commencement of the 
treatment phase. Each participant rated the SMERS, SSGS and STAI-1 5 times a 
day and the calculated median score of these 5 ratings was used in the analysis. The 
raw data for SMERS, SSGS, and STAI-1 are provided in Appendices 29 to 33 
(Tables 6-7, 10-11, 14-15, 18-19, 22-23,) consistent with the suggestions for 
reporting SCED (Kratochwill et al. 2010, 2013; Wolery et al. 2011). Data on the 
SMERS, SSGS and STAI-1 were graphed using Microsoft® Excel® for Mac 2011. 
Visual analysis was augmented with Tau-U statistical method to test the hypothesis 
(1) that: Imagery vividness, shame1, guilt1, and anxiety1 (as measured by SMERS), 
shame2 and guilt2 (SSGS) and anxiety3 (STAI-1) will reduce following ImRs. Analysis 
focused on: level (the horizontal average within phase), trend (increase or decrease), 
variability (stability/fluctuation), immediacy of effect between baseline conditions 
(Phase A) and treatment condition (Phase B), and overlap of data between the 
phases (using Tau-U). 
 
Changes in YBOCS, MADRS, EDS and SSRT scores were analysed using the 
Reliable Change Index (RCI) and Clinical Significance Change (CSC) calculations. 
The study benchmarked the clinically meaningful improvement at the accepted lower 
criterion of at least 25% reduction (Foa et al. 2005; Seibell & Hollander 2014; 
Stanford University 2015). The lower YBOCS threshold criterion was chosen 
because, if improvement is achieved at 25%, this will be used as part of the 
justification to carry out the study with a much larger sample. The MADRS significant 
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improvement was determined by at least 2 standard deviations from the original 
mean in the therapeutic direction. The MADRS severe cut-off point for improvement 
is 35 where symptom severity range classifications are: recovered (0 - 8); mild (9 - 
17); moderate (18 - 34); severe (35 ≥) and maximum (60) (Kearns et al. 1982; Muller 
et al. 2000). 
 
Additionally, where changes in scores of the YBOCS, MADRS, EDS and SSRT are 
confirmed as clinically significant improvements, then maintenance of the 
improvements is then examined at follow-up. 
 
4.2 Participant P1 Results 
Table 5 provides the pre and post ImRs median scores for the SMERS, SSGS and 
STAI-1. The results show that there is little change in median scores pre and post 
ImRs for most indices with exception of SSGS Shame. Notably, SMERS anxiety 
showed a decrease whereas STAI-1 showed an increase. The average SMERS 
index is close to the maximum intensity score of 10 before and after the intervention. 
The visual graphed data for participant P1 are provided in Figures 4 and 5. No 
analysis was carried out for the follow up phase, because participant P1 withdrew 
from the study after first follow-up, providing the phase with only one data point. At 
least 3 data points are required in order to carry out visual analysis within a phase 
and between adjacent phases. 
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Table 5 
 
 
4.2.1 Imagery Vividness1 Visual Analysis (P1) 
The graphed data analysis for the vividness1 baseline phase, (Figure 4), shows an 
average level of intensity of 8.7 across the 17 data collection points. The intensity per 
the data collection point ranged from 4.6 to 10. However, across the 8-data collection 
points intervention-phase the average level of vividness intensity was 9.5 and the 
range was 9 to 10. Only one data point was available in the follow-up phase (7). A 
decreasing trend is observed across both the baseline and intervention phases, with 
the last three data points averaging 8.7 in respect of the baseline and 9.1 for the 
intervention phase.  
 
4.2.2 Shame1 Visual Analysis (P1) 
The average level of shame1 intensity across the 17 data points at the baseline 
phase is 8.5 (ranging from 4.8 to 10) and lacks stability. As for vividness, the 
intervention phase variability was more limited (7 to 9.3) compared to the baseline 
Median Median Median Median Median Median
Vividness¹ 9.60 9.54 -0.06 9.54 7.00 -2.54
Shame¹ 9.40 9.00 -0.40 9.00 10.00 1.00
Guilt¹ 9.80 9.00 -0.80 9.00 10.00 1.00
Anxiety¹ 9.33 8.88 -0.45 8.88 7.00 -1.88
Shame² 16.80 14.30 -2.50 14.30 25.00 10.70
Guilt² 22.90 21.63 -1.27 21.63 25.00 3.37
Anxiety³ 69.87 72.00 2.13 72.00 67.00 -5.00
¹Rated using Subjective Measure Emotions Rating Scale (SMERS)
²Rated using State Shame Guilt Scale (SSGS)
³Rated using State Trait Anxiety Inventory (state subscale) (STAI) 
Time-series pretest, intervention and follow-up phases median scores (Participant P1)
Variable
diff of Score of the ...
Baseline 
Phase-A
Intervention 
Phase-B
Intervention 
Phase-B
Follow-up 
Phase-C
diff of Score of 
the ...
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phase. The average intensity is the same as the baseline phase at 8.5. The follow-up 
phase lacks a minimum of three data points to allow a meaningful visual analysis of 
the data. The baseline and the intervention phases both have a downward trend 
pattern towards therapeutic direction (Figure 4). There is no change observed 
between baseline and intervention. 
 
4.2.3 Guilt1 Visual Analysis (P1) 
The average level of guilt1 intensity across the 17 sessions at baseline phase was 9, 
(ranging from 6.4 to 10). Average intensity in the intervention phase was 8.7 (ranging 
from 7 to 10; Figure 4). The follow-up phase has one data point (10). The guilt1 
baseline has a downward trend pattern towards improvement, with the last three data 
points averaging 8.6. The intensity level averaged across the last three intervention-
phase data points is 7.6 and the performance of the trend pattern is also reducing 
downwardly.  
 
4.2.4 Anxiety1 Visual Analysis (P1) 
Figure 4, shows that the anxiety1 baseline phase had an average level of intensity of 
8.7 across the 17 sessions (ranging from 4.4 to 10). Average intensity in the 
intervention phase was 8.5 (ranging from 7 to 9.3). The follow-up phase has one data 
point (7). The baseline showed a downward trend pattern with the last three data 
points averaging 7.9. However, the intervention has an upward trend pattern, of 
which the intensity level averaged across the last 3 data points is 8.8.  
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Fig 4. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
4.2.5 Shame2 Visual Analysis (P1) 
The average level of shame2 intensity across the 16 sessions at the baseline phase 
is 15.6 of which the range of levels is 6.8 to 20.8 (Figure 5). The intervention phase 
average intensity is 14.3 and the intensity range 9.8 to 17.4. The follow-up phase has 
one data point (25). The baseline has a downward trend pattern towards 
improvement, with the last three data points averaging 15.3. Similarly, the 
intervention phase has a downward trend pattern and the intensity level averaged 
across the last three data points is 14.4 immediacy of effect is not confirmed between 
the two phases. 
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4.2.6 Guilt2 Visual Analysis (P1) 
The average level of intensity of the guilt2 baseline phase reveals a score of 21.54 
across the 16 sessions. The range of levels is 12.6 to 25 (Figure 5), whereas the 
intervention phase average intensity is 21.1 with an intensity range of 15 to 24.8. The 
follow-up phase has one data point (25). The baseline has a downward trend pattern 
with the last three data points averaging 21.5. Furthermore, the intervention has a 
downward trend pattern, of which the intensity level averaged across the last  
 
4.2.7 Anxiety3 Visual Analysis (P1) 
The average level of anxiety3 intensity across the 16 sessions at baseline phase is 
69.9 of which range of the levels is 59.2 to 79.4, whereas the average intensity and 
range, for the intervention phase, are 72.6 and 67.4 to 79.8 respectively. There is one 
data point (67) only in the follow-up phase. There is no trend pattern in both the 
baseline and intervention phases. However the baseline last three data points 
average is 71.9 and that of the intervention is 74.2. Furthermore the immediacy of 
effect is not observed between the baseline and intervention phases. 
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Fig 5. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
4.2.8 Tau-U Effect Size (P1) 
Tau-U results for P1 are shown in Table 8. The results show that the baseline trend 
did not need correcting. The Tau-U effect size data supports conclusions from the 
visual analysis that there is no evidence of a difference between baseline and 
intervention phases across all the measures for Participant P1. 
 
Table. 8    Tau-U Results Summary for Participant P1 
Measures Baseline Tau-U 
Intervention vs 
Baseline Tau-U z SDtau p value + 85%CI 
Vividness1 -0.0735 0.0392 0.1617 0.2425 p=0.8715(-0.31<>0.388) 
Shame1 -0.3824 -0.1412 -0.6025 0.2343 p=0.5468(-0.479<>0.196) 
Guilt1 -0.3603 -0.1882 -0.8034 0.2343 p=0.4218(-0.526<>0.149) 
Anxiety1 -0.2500 -0.3471 -1.4812 0.2343 p=0.1386(-0.684<>-0.01) 
Shame2 -0.3167 -0.1806 -0.7360 0.2453 p=0.4617(-0.534<>0.173) 
Guilt2 -0.1833 -0.0903 -0.3680 0.2453 p=0.7129(-0.444<>0.263) 
Anxiety3 0.0917 0.1597 0.6511 0.2453 p=0.5150(-0.194<>0.513) 
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1 = Subjective Measures Emotions Rating Scales (SMERS), 2 = State Shame Guilt Scale (SSGS), 
3 = State Trait Anxiety Inventory (STAI-1) 
 
4.3 Participant P3 Results 
Table 9 provides median scores for P3 baseline and intervention phases. The visual 
graphed data for participant P3 are provided in Figures 6 and 7. No analysis was 
carried out for the follow up phase, because participant P3 withdrew from the study 
after the first follow-up. 
 
Table 9 
 
 
4.3.1 Imagery Vividness1 Visual Analysis (P3)  
The graphed data analysis for the vividness baseline phase, (Figures 6), shows an 
average level of intensity of 6.2 across the 11 sessions. The intensity per session 
ranges from 4 to 8. However, across the 6-session intervention-phase the average 
level of vividness intensity is 6.3 and the range is 5.5 to 7. Only one data point is 
available in the follow-up phase (5). The baseline phase has no trend pattern and its 
Median Median Median Median Median Median
Vividness¹ 7.00 6.25 -0.75 6.25 5.00 -1.25
Shame¹ 6.00 4.67 -1.33 4.67 5.00 0.33
Guilt¹ 6.00 5.17 -0.83 5.17 7.00 1.83
Anxiety¹ 6.25 5.63 -0.62 5.63 6.00 0.37
Shame² 9.33 7.50 -1.83 7.50 7.00 -0.50
Guilt² 12.34 10.00 -2.34 10.00 10.00 0.00
Anxiety³ 51.17 48.00 -3.17 48.00 42.00 -6.00
¹Rated using Subjective Measure Emotions Rating Scale (SMERS)
²Rated using State Shame Guilt Scale (SSGS)
³Rated using State Trait Anxiety Inventory (state subscale) (STAI) 
Variable
Time-series pretest, intervention and follow-up phases median scores (Participant P3)
diff of Score of the 
...
diff of Score of 
the ...
Intervention 
Phase-B
Baseline 
Phase-A
Intervention 
Phase-B
Follow-up 
Phase-C
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last three data points are averaging at 6.2. However the intervention has a downward 
trend pattern with the last three data points averaging 6.2. The change in level 
between the average of the last three data points in the baseline phase (6.2) and the 
first three data points in the intervention phase (6.5), demonstrate no change.  
 
4.3.2 Shame1 Visual Analysis (P3) 
In Figure 6, the average level of shame1 intensity across the 11 data points in the 
baseline phase is 5.6 of which the range of levels is 4 to 7, whereas the 6 sessions of 
the intervention phase have an average intensity of 4.1 with a range of 1 to 5. The 
follow-up phase has one data point (5). The baseline has an upward trend pattern, 
with the last three data points averaging 6. In the intervention phase the intensity 
level averaged across the last three data points is 4.8 and the performance of the 
trend pattern is increasing. The change in level between the average of the last three 
data points in the baseline phase (6) and the first three data points in the intervention 
phase (3.3) demonstrates presence of the immediacy of effect. 
 
4.3.3 Guilt1 Visual Analysis (P3) 
The average level of guilt1 intensity across the 11 sessions at baseline phase is 6.1 of 
which the range of levels is 4 to 8. In the intervention phase the average intensity 
across the 6 sessions is 4.8 with a range of 1 to 7. There is one data point (5) only in 
the follow-up phase. The baseline has no trend pattern, with the last three data points 
averaging 6.6 (Figure 6). In the intervention phase the intensity level averaged across 
the last three phase data points is 5.78 and the performance of the trend pattern is 
increasing. Furthermore, the change in level between the average of the last three 
data points in the baseline phase (6.56) and the first three data points in intervention 
phase (3.83) shows the immediacy of effect. 
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4.3.4 Anxiety1 Visual Analysis (P3) 
The average level of intensity across the 11 sessions of anxiety1 baseline phase is 
6.1 of which the range of levels is 4 to 8. In the intervention phase the average 
intensity across the 6 sessions is 4.9 with a range of 1 to 7. There is one data point 
(6) only in the follow-up phase. The baseline has no trend pattern, with the last three 
data points averaging 5.6. In the intervention phase the intensity level averaged 
across the last three phase data points is 6.25 and the performance of the trend 
pattern is increasing. Additionally the change in level between the average of the last 
three data points in the baseline phase (5.6) and the first three data points in the 
intervention phase (3.5) also demonstrates the immediacy of effect. 
 
 
Fig 6. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
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4.3.5 Shame2 Visual Analysis (P3) 
The average level of shame2 intensity across the 10 sessions at the baseline phase 
is 9.5 of which the range of levels is 6 to 12. In the intervention phase the average 
intensity across the 5 sessions is 7.7 and the range is 7 to 9. There is one data point 
(7) only in the follow-up phase (Figure 7). The baseline has an upward trend pattern, 
with the last three data points averaging 9.9. In the intervention the intensity level 
averaged across the last three data points is 7.3 and the performance of the trend 
pattern is decreasing. The change in level between the average of the last three data 
points in the baseline phase (7.3) and the first three data points in the intervention 
phase (8.1) do not demonstrate an obvious immediacy of effect. 
 
4.3.6 Guilt2 Visual Analysis (P3) 
Figure 7 also shows the average level of intensity of the guilt2 baseline phase with a 
score of 12.3 across the 10 sessions. The intensity per session ranges from 7.7 to 
15, whereas the intervention phase average intensity across the 5 sessions is 10.2 
with intensity per session ranging 9.5 to 12. The follow-up phase has one data point 
(10). The baseline has an upward trend pattern with the last three data points 
averaging 13.2. The intervention has an upward trend pattern, of which the intensity 
level averaged across the last three data points is 10.5. The level change between 
the average of the last three baseline data points (13.2) and the first three in the 
intervention (9.7) demonstrates the immediacy of effect. 
 
4.3.7 Anxiety3 Visual Analysis (P3) 
The average level of anxiety3 intensity across the 10 sessions at baseline is 50.4. 
The intensity per session ranges from 37 to 59 (Figure 7) whereas the intervention 
phase average intensity across the 5 sessions is 47.5 with intensity per session 
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ranging from 42.5 to 53. The follow-up phase has one data point (42). The baseline 
phase has an upward trend pattern with the last three data points averaging 52.8. 
The intervention has an upward trend pattern, of which the intensity level averaged 
across the last three data points is 50. The level change between the average of the 
last three baseline data points (52.8) and the first three in the intervention (45.2) 
demonstrates the immediacy of effect. 
 
 
Fig 7. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
 
4.3.8 Tau-U Effect Size (P3) 
Tau-U results for P3 are shown in Table 12 and the data across all the measures 
show no need to control for baseline trend. The Tau-U effect size showed that 
shame1 indicated evidence of an intervention effect (p= .051). Also of note, shame2 
(p= .073) and guilt2 (p= .092) showed some evidence of an intervention effect.  
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Table 12 
   Tau-U Results Summary for Participant P3 
Measures Baseline Tau-U 
Intervention vs 
Baseline Tau-U z SDtau p value + 85%CI 
Vividness1 0.0909 -0.1169 -0.4076 0.287 p=0.6836(-0.53<>0.296) 
Shame1 0.1273 -0.5584 -1.9472 0.287 p=0.0515(-0.971<>-0.145) 
Guilt1 0.0182 -0.2857 -0.9962 0.287 p=0.3191(-0.699<>0.127) 
Anxiety1 -0.2909 -0.3506 -1.2227 0.287 p=0.2215(-0.764<>0.062) 
Shame2 0.2889 -0.5500 -1.7897 0.307 p=0.0735(-0.993<>-0.107) 
Guilt2 0.3778 -0.5167 -1.6812 0.307 p=0.0927(-0.959<>-0.074) 
Anxiety3 0.4000 -0.4000 -1.3016 0.307 p=0.1931(-0.843<>0.043) 
1 = Subjective Measures Emotions Rating Scales (SMERS), 2 = State Shame Guilt Scale (SSGS),  
3 = State Trait Anxiety Inventory (STAI-1) 
 
4.4 Participant P4 Results 
Table 13 provides median scores for P4 baseline and intervention phases. The visual 
graphed data for participant P4 are provided in Figures 8 and 9. 
 
Table 13 
Time-series, baseline, intervention and follow-up phases medians (Participant P4) 
 1Denotes Measurements based on the Subjective Measure Emotions Rating Scale (SMERS) 
2Denotes Measurements based on the State Shame Guilt Scale (SSGS) 
3Denotes Measurements based on the State Trait Anxiety Inventory (state subscale) (STAI)  
 
 
Median Median Median Median Median Median
Vividness¹ 9.90 8.20 -1.70 8.20 8.00 -0.20
Shame¹ 9.45 9.00 -0.45 9.00 9.00 0.00
Guilt¹ 9.40 9.40 0.00 9.40 9.00 -0.40
Anxiety¹ 9.40 8.00 -1.40 8.00 9.00 1.00
Shame² 21.80 23.00 1.20 23.00 20.00 -3.00
Guilt² 24.80 25.00 0.20 25.00 25.00 0.00
Anxiety³ 71.00 73.80 2.80 73.80 71.00 -2.80
¹Rated using Subjective Measure Emotions Rating Scale (SMERS)
²Rated using Stat  Shame Guilt Scale (SSGS)
³Rated using State Trait Anxiety Inventory (state subscale) (STAI) 
Intervention 
Phase-B
Follow-up 
Phase-C
diff of Score of the 
...
Time-series prete t, i tervention and follow-up phases m dian scores (Participant P4)
Variable
Baseline 
Phase-A
Intervention 
Phase-B
diff of Score 
of the ...
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4.4.1 Imagery Vividness1 Visual Analysis (P4) 
The vividness baseline (Figures 8) shows an average intensity of 8.7 across the 14 
sessions. The vividness intensity per session ranges from 5 to 10. However, across 
the 9-session intervention-phase the average vividness is 8.3 and the range is 5 to 
10. In the follow-up phase, the average across the 3 sessions is 8.3 and the range is 
8 to 9. An upward trend pattern is observed across the baseline and intervention 
phases. The average of the last three baseline data points is 10 whilst the 
intervention-phase shows 8.3. Additionally, the change in level between the average 
of the last three data points in the baseline phase (10) and the first three data points 
in the intervention phase (8.3), shows there is no immediacy of effect. The follow-up 
phase has no trend pattern and its last three data points average 8.3. Furthermore, 
no overlapping data exist between the worst performing data points of the 
intervention and of the follow-up. Instead, a change in the level between the average 
of the last three intervention data points (8.3) and the first three of the follow-up (8.3) 
shows no difference in symptom performance.  
 
4.4.2 Shame1 Visual Analysis (P4) 
In Figure 8, the average level of shame1 intensity across the 14 sessions at the 
baseline phase is 9. The intensity per session ranges from 5.8 to 10.0 whereas the 
intervention phase average intensity across the 9 sessions is 8.7 with intensity per 
session ranging from 4 to 10. In the follow-up phase, the average across the 3 
sessions is 9.3 and the range is 9 to 10. An upward trend pattern is observed in both 
the baseline and intervention phases. The average of the last three baseline data 
points is 10 whilst the intervention-phase shows 9.3. Despite the initial dramatic 
symptom reduction in session 15, the level change between the average of the last 
three baseline data points (10) and the first three in the intervention phase (8) 
demonstrates no immediacy of effect. Furthermore, the level change between the 
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average of the last three intervention data points (9.3) and the first three of the follow 
up (9.3) show no difference. 
 
4.4.3 Guilt1 Visual Analysis (P4) 
The average guilt1 intensity across the 14 sessions at the baseline phase is 9.1. The 
intensity per session ranges from 6 to 10 (see Figure 8), whereas the intervention 
phase average intensity across the 9 sessions is 8.9 with intensity per session 
ranging from 4 to 10. In the follow-up phase, the average across the 3 sessions is 9.3 
and the range is 9 to 10. An upward trend pattern is observed both in baseline and 
intervention phases. No trend pattern is observed in the follow-up phase. The 
average of the last three baseline data points is 10 whilst the last three of the 
intervention-phase is 9.3. There is an initial dramatic symptom reduction in session 
15; however, the level change between the average of the last three baseline data 
points (10) and the first three of the intervention (8) fail to demonstrate the immediacy 
of effect. In respect of the level change between the average of the last three 
intervention data points (9.3) and the first three of the follow-up (9.3) shows no 
difference. 
 
4.4.4 Anxiety1 Visual Analysis (P4) 
Figure 8 presents the average anxiety1 intensity across the 14 sessions at the 
baseline phase as 9.1 and the intensity per session ranges from 6.2 to 10. The 
intervention average intensity across the 9 sessions is 8 with intensity per session 
ranging from 4 to 9.8. In the follow-up phase, the average across the 3 sessions is 9 
and the range is 8 to 10. An upward trend pattern is observed both in baseline and 
intervention phases, whilst a downward trend pattern is observed in the follow-up 
phase. The average of the last three baseline data points is 9.7 whilst the last three 
of the intervention-phase is 8.5. A dramatic initial symptom reduction is observed in 
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session 15 (intervention phase). However, the level change between the average of 
the last three baseline data points (9.7) and the first three of the intervention (7.6) fail 
to demonstrate clear immediacy of effect. The level change between the average of 
the last three intervention data points (8.5) and the first three of the follow-up (7.6) 
shows no difference. 
 
 
Fig 8. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
 
4.4.5 Shame2 Visual Analysis (P4) 
The shame2 graph (Figure 9) shows that the baseline average across the 13 
sessions is 21.5. The intensity per session ranges from 16 to 25 whereas the 
intervention phase average intensity across the 8 sessions is 22.10 with intensity per 
session ranging from 17 to 24.2. In the follow-up phase, the average across the 3 
sessions is 20.3 and the range is 18 to 23. An upward trend pattern is observed in 
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baseline, intervention and follow-up phases. The average of the last three baseline 
data points is 23.7 and for the intervention-phase it is 22.5. There is an initial 
dramatic symptom reduction in session 16, moreover the level change between the 
averages of the last three baseline data points (23.7) and the first three of the 
intervention phase (21.4) demonstrate a symptom reduction. Nonetheless there is a 
reduced change between the average of the last three intervention data points (22.5) 
and the first three of the follow up phase (20.3). 
 
4.4.6 Guilt2 Visual Analysis (P4) 
When utilising the subscale SSGS measure to assess guilt2, (Figure 9), the results 
show that the average baseline across the 11 sessions is 23.6. The intensity per 
session ranges from 18.8 to 25, whereas the intervention phase averages 24.9 
across the 8 sessions, with intensity per session ranging from 24.4 to 25. In the 
follow-up phase, the average across the 3 sessions is 24.7 and the range is 24 to 25. 
An upward trend pattern is observed in the baseline. The intervention phase has a 
constant trend whilst the follow-up phase has a downward trend. The average of the 
last three baseline data points is 24.7. The average of the last three intervention data 
points is also 24.7. There is negligible change in the level between the average of the 
last three baseline data points (24.7) and the first three of the intervention phase (25). 
There is no immediacy of effect between the baseline and intervention phases. Also, 
comparison between the average of the last three intervention data points (24.7) and 
the first three of the follow-up (24.7) shows no difference. 
 
4.4.7 Anxiety3 Visual Analysis (P4) 
Visual analysis of the STAI-1anxiety (anxiety3) graph in Figure 9 shows that the 
baseline average of anxiety3 across the 13 sessions in the baseline phase is 81.6. 
The intensity per session ranges from 48 to 79.4, whereas the intervention phase 
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average intensity across the 8 sessions is 72.5 with intensity per session ranging 
from 64 to 76.8. In the follow-up phase, the average across the 3 sessions is 70.7 
and the range is 68 to 73. An upward trend pattern is observed in all three phases. 
The average of the last three baseline data points is 76.3 whilst the last three of the 
intervention-phase is 72.5. There is an initial symptom reduction in session 15; 
however, the level change between the average of the last three baseline data points 
(76.3) and the first three of the intervention phase (72.6) fails to demonstrate the 
immediacy of the effect.  
 
 
Fig 9. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
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4.4.8 Tau-U Effect Size (P4) 
The Tau-U results for P4 are shown in Table 16 below. The results show there was 
no need to control for the baseline trend. The Tau-U effect size analysis show, with 
the exception of anxiety 1 (p= .076) there is little evidence of an intervention effect. 
 
Table 16 
Tau-U Results Summary for Participant P4 
1 = Subjective Measures Emotions Rating Scales (SMERS), 2 = State Shame Guilt Scale (SSGS), 
3 = State Trait Anxiety Inventory (STAI-1) 
 
4.5 Participant P5 - Results 
Table 17 provides median scores for P5 baseline and intervention phases.  
Table 17 
 
Median Median Median Median Median Median
Vividness¹ 9.20 9.20 0.00 9.20 9.00 -0.20
Shame¹ 10.00 9.20 -0.80 9.20 9.00 -0.20
Guilt¹ 9.60 9.00 -0.60 9.00 8.00 -1.00
Anxiety¹ 7.40 8.00 0.60 8.00 8.00 0.00
Shame² 18.67 19.30 0.64 19.30 18.00 -1.30
Guilt² 21.30 21.70 0.40 21.70 20.00 -1.70
Anxiety³ 70.00 69.90 -0.10 69.90 71.00 1.10
¹Rated using Subjective Measure Emotions Rating Scale (SMERS)
²Rated using State Shame Guilt Scale (SSGS)
³Rated using State Trait Anxiety Inventory (state subscale) (STAI) 
Variable
Time-series pretest, intervention and follow-up phases median scores (Participant P5)
diff of Score 
of the ...
Intervention 
Phase-B
Follow-up 
Phase-C
diff of Score of the 
...
Baseline 
Phase-A
Intervention 
Phase-B
Measures Baseline Tau-U 
Intervention vs 
Baseline Tau-U Z SDtau p value + 85%CI 
Vividness1 0.1758 -0.1964 -0.8487 0.2315 p=0.3961(-0.53<>0.137) 
Shame1 0.1648 -0.0417 -0.1800 0.2315 p=0.8571(-0.375<>0.292) 
Guilt1 0.2088 0.0536 0.2315 0.2315 p=0.8170(-0.28<>0.387) 
Anxiety1 0.0220 -0.4107 -1.7745 0.2315 p=0.0760(-0.744<>-0.077) 
Shame2 0.3636 -0.0331 -0.1313 0.2517 p=0.8955(-0.396<>0.329) 
Guilt2 0.1273 0.3140 1.2476 0.2517 p=0.2120(-0.048<>0.677) 
Anxiety3 0.4231 0.0979 0.4056 0.2414 p=0.6851(-0.25<>0.446) 
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4.5.1 Imagery Vividness1 Visual Analysis (P5) 
The graphed data analysis for the vividness baseline phase, (Figures 10), shows an 
average level of intensity of 9.1 across the 17 sessions. The level of the intensity per 
session ranges from 7.8 to 10. The intervention phase is similar; across the 9-
sessions the average level of vividness intensity is 9.1 and the range is 8 to 10. This 
suggests little change within and between baseline and intervention phases. In the 
follow-up phase, the average level across the 3 sessions is 8.67 and the range is 
from 8 to 9. An increasing trend across the baseline phase has the last three data 
points averaging 9.3 compared to a decreasing trend pattern in the intervention-
phase showing the average of the last 3 data points of 8.9. There is no change in 
level between the average of the last three data points in the baseline phase (9.3) 
and the first three data points in the intervention, hence no immediacy of effect. The 
follow-up phase has a decreasing trend in the direction of improvement with the last 3 
data points averaging 8.7. A comparison of the average of the last 3 data points of 
the intervention phase (8.9) and the first 3 data points of the follow-up phase (8.7) 
show that there is no immediacy of effect on leaving the intervention phase. 
 
4.5.2 Shame1 Visual Analysis (P5) 
The average level of shame1 intensity across the 17 sessions of the baseline phase 
is 9.7 with a range of 7 to10. The intervention phase average level of the intensity is 
9.2 and the range 8 to 9.8. The follow-up phase averages 8.7 with a range of 8 to 9.  
The baseline has an upward trend pattern with a 9.7 intensity level averaged across 
the last 3 phase data points. Whereas in the intervention, the intensity level averaged 
across the last 3 phase data points is reduced to 9.47, the performance of the trend 
pattern also increasing away from therapeutic direction. In contrast there is a 
downward trend towards therapeutic direction in the follow-up phase, which averages 
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8.7 over its three data points. Whilst change is observed between baseline and 
intervention, the immediacy of effect is not dramatic. When the average of the last 3 
data points in the intervention phase (9.5) is compared to the first three data points of 
the follow-up (8.7), there is no immediacy of effect. 
 
4.5.3 Guilt1 Visual Analysis (P5) 
The baseline average level of guilt1 intensity across the 17 sessions is 9.4 and the 
range is 7.4 to 10. Whereas the intervention-phase average intensity is reduced to 
8.4, the range of the level of intensity is also reduced to 6 to 9.2. The follow-up phase 
shows the average level of guilt1 across the 3 data points is reduced to 8.3 with a 
range of intensity from level 8 to 9. The baseline has an increasing trend pattern with 
a 9.3 intensity level averaged across the last 3 phase data points. The intervention 
phase also has an increasing trend pattern with an 8.8 intensity level averaged 
across the last 3 data points. In addition, the average level of the follow-up guilt1 
intensity is reduced to 8.3 across the 3 sessions with a horizontal trend. The 
comparison of the average of the last 3 data points of the baseline (9.33) with the 
average of the first 3 points of the intervention (7.4) showed a rapid reduction hence 
a strong immediacy of effect.  The comparison of the average of the last 3 points of 
the intervention phase (8.8) with the first 3 points of the follow-up phase (8.3) show a 
slight reduction hence no immediacy of effect.  
 
4.5.4 Anxiety1 Visual Analysis (P5) 
The average level of anxiety1 intensity across the 17 sessions at baseline phase is 
7.5 of which the range of the levels is 5.4 to10 (see Figure 10).  The intervention has 
an increased average intensity level of 7.7 and ranges from 6 to 8.4. The follow-up 
phase shows an average level of 6.3 and ranges from 8 to 10. The baseline phase 
shows an increasing trend pattern, whereas the intervention and follow-up phases 
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show no trends. The average of the last 3 points of the baseline is 8.7. The average 
of the last 3 points of the intervention is 7.6 and the average of the last 3 points of the 
follow-up is 6 respectively. Furthermore, the comparison of the last 3 data points of 
the baseline phase (8.7) with the adjacent first 3 points of the intervention phase 
show an immediacy of effect that is not rapid. Comparison of the average of the last 3 
data points of the intervention phase (7.6) with the average of the first 3 data points 
of the follow-up (8.7) show a worsening of symptoms during the follow-up.  
 
 
Fig 10. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
 
4.5.5 Shame2 Visual Analysis (P5) 
The shame2 graph (Figure 11) shows that the baseline average of the SSGS-shame2 
subscale intensity across the 16 sessions is 18.9 and the range is 17.2 to 22. The 
intervention-phase average intensity across 8 sessions is 18.7 with a range of 13 to 
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21. In the follow-up phase the average level of the shame2 across the 3 data points is 
18 and the range is 17 to 19. The baseline has a trend pattern performing away from 
the therapeutic direction with the average intensity level of 19.4 based on the last 3 
phase data points. However the intervention phase has a decreasing trend pattern 
towards the direction of improvement and the average level of intensity across the 
last 3 data points is 17.5. The average level of the follow-up phase across the 3 
sessions is 18 with a downward trend towards the direction of improvement. 
 
4.5.6 Guilt2 Visual Analysis (P5) 
When the subscale SSGS measure is utilised, (Figure 11), the results indicated by 
guilt2 show that in respect of the baseline average of the intensity across the 16 
sessions is 21 and the range is 19 to 22.8. The intervention-phase average across 8 
sessions is 21 with a range of 16 to 22.6. In the follow-up phase the average level of 
the guilt2 across the 3 data points is 21 and the range is 20 to 23. The baseline has 
an increasing trend pattern with an average intensity level of 21.1 based on the last 3 
phase data points. However the direction of performance of the intervention trends 
towards the therapeutic direction. The average level of the intervention phase across 
the last 3 data points is 19.8. 
 
4.5.7 Anxiety3 Visual Analysis (P5) 
Visual analysis of the STAI-1-state (anxiety3) graph in Figure 11 shows that the 
baseline average of the anxiety3 across the 16 sessions is 69 and the range is 55 to 
78.6. The intervention-phase average intensity across 8 sessions is 70 with a range 
of 65 to 73. In the follow-up phase the average level across the 3 data points is 71 
and the range is 71 to 71. The baseline trends upward and the average intensity 
level, across the last 3 data points is 70.5. Similarly, the direction of the intervention 
trend pattern is also upwards with an average level of 71 across the last 3 data points 
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in the phase. The immediacy of effect is not demonstrated between baseline and 
intervention. There is no trend pattern in the follow-up phase. 
 
 
Fig 11. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
 
 
4.5.8 Tau-U Effect Size (P5) 
Tau-U results for P5 are shown in Table 20 below. The results show there was no 
need to control for the baseline trend. The Tau-U effect size showed evidence of an 
intervention effect for shame1 (p< .001) and guilt1 (p= .003). The other five measures 
did not show evidence of a difference between the baseline and intervention phases. 
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Table 20    
 
Tau-U Results Summary (P5) 
Measures Baseline Tau-U 
Intervention 
vs Baseline 
Tau-U 
z SDtau p value + 85%CI 
Vividness1 0.3015 -0.1569 -0.7085 0.2214 p=0.4786(-0.476<>0.162) 
Shame1 0.0662 -0.7598 -3.4318 0.2214 p=0.0006(-1.079<>-0.441) 
Guilt1 0.0735 -0.6569 -2.9668 0.2214 p=0.0030(-0.976<>-0.338) 
Anxiety1 0.4191 0.2745 1.2399 0.2214 p=0.2150(-0.044<>0.593) 
Shame2 0.3250 -0.0114 -0.0493 0.2303 p=0.9606(-0.343<>0.320) 
Guilt2 0.5500 0.1420 0.6168 0.2303 p=0.5373(-0.190<>0.474) 
Anxiety3 0.6000 0.1989 0.8636 0.2303 p=0.3878(-0.133<>0.530) 
1 = Subjective Measures Emotions Rating Scales (SMERS), 2 = State Shame Guilt Scale (SSGS), 
3 = State Trait Anxiety Inventory (STAI-1) 
 
4.6 Participant P6 - Results 
As is shown in Table 21 below, all the SMERS subscale results, which are 
distinguished by “1” show improvement. However when the same variables were 
assessed using different measures (SSGS and STAI-1) there was no demonstrable 
improvement. 
 
Table 21 
 
Median Median Median Median Median Median
Vividness¹ 9.00 5.40 -3.60 5.40 6.00 0.60
Shame¹ 10.00 5.60 -4.40 5.60 5.00 -0.60
Guilt¹ 9.30 5.60 -3.70 5.60 5.00 -0.60
Anxiety¹ 8.60 7.00 -1.60 7.00 6.00 -1.00
Shame² 22.00 22.74 0.74 22.74 21.00 -1.74
Guilt² 19.20 20.50 1.30 20.50 18.00 -2.50
Anxiety³ 65.00 67.47 2.47 67.47 59.00 -8.47
¹Rated using Subjective Measure Emotions Rating Scale (SMERS)
²Rated using State Shame Guilt Scale (SSGS)
³Rated using State Trait Anxiety Inventory (state subscale) (STAI) 
Variable
Time-series pretest, intervention and follow-up phases median scores (Participant P6)
Baseline 
Phase-A
Intervention 
Phase-B
diff of Score 
of the ...
Intervention 
Phase-B
Follow-up 
Phase-C
diff of Score of the 
...
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4.6.1 Imagery Vividness1 Visual Analysis (P6) 
The graphed data analysis for the vividness baseline phase, (Figures 12 and 13), 
shows an average level of intensity of 8.8 across the 10 sessions. The level of the 
intensity per session ranges from 6.6 to 10. However, across the 9-session 
intervention-phase the average level of vividness intensity is 6 and the range is 3 to 
10. Wherein the follow-up phase, the average level across the 3 sessions is 4.7 and 
the range is from 1 to 7. A decreasing trend across the baseline phase has the last 
three data points averaging 8.6 compared to a curvilinear trend pattern in the 
intervention-phase showing the average of the last 3 data points of 7.3. The change 
in level between the average of the last three data points in the baseline phase (8.6) 
and the first three data points in the intervention (6.3), demonstrate the immediacy of 
effect. The follow-up phase also has a decreasing trend in the direction of 
improvement with the last 3 data points averaging 4.7. Furthermore, the symptoms 
performed as well or better at follow-up based on the change in level between the 
average of the last three data points in the intervention-phase (6.3) and the first three 
data points of the follow-up-phase (4.7).  
 
4.6.2 Shame1 Visual Analysis (P6) 
The average level of shame1 intensity across the 10 sessions at baseline phase is 
9.6 of which the range of the levels is 7 to10. Whereas the intervention phase 
average level of the intensity and the range of the level of intensity are reduced to 
5.8, and 1 to 9.7 respectively. Furthermore, observations of the follow-up phase show 
the average level of shame1 across the 3 data points is reduced to 5 including its 
range of the intensity level to 1 to 9. Although the baseline has a downward trend 
pattern towards improvement, however it has a 9 intensity level averaged across the 
last 3 phase data points. Whereas in the intervention, the intensity level averaged 
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across the last 3 phase data points is reduced to 5.5, and the performance of the 
trend pattern is also reducing towards therapeutic direction. In addition, there is also 
a downward trend towards therapeutic direction in the follow-up phase. Since the 
follow-up phase only has three data points the average of the last three data points is 
the same as the average across all its data points (5). While a treatment effect is 
observed between baseline and intervention, the immediacy of effect is not dramatic. 
Furthermore, although the follow-up phase improves overtime to a final shame1 
severity level of 1, there is dramatic deterioration to 9 at the commencement of the 
phase. In addition, when the improvement performance of the last 3 data points in the 
intervention phase is compared with the first three data points of the follow-up, there 
is no immediacy of the effect. 
 
4.6.3 Guilt1 Visual Analysis (P6) 
The baseline average level of guilt1 intensity across the 10 sessions is 9.5 and the 
range is 8.5 to 10. Whereas the intervention-phase average intensity is reduced to 
5.5, the range of the level of intensity is also reduced to 2 to 8.7. The follow-up phase 
show the average level of guilt1 across the 3 data points is reduced to 4.7 including 
its range of the intensity level to 1 to 8. The baseline has a horizontal trend pattern 
with a 9.5 intensity level averaged across the last 3 phase data points. However, the 
intervention phase has a trend pattern in the direction of improvement with a 4.7 
intensity level averaged across the last 3 data points. In addition, the average level of 
the follow-up guilt1 intensity is reduced to 4.7 across the 3 sessions with a downward 
trend towards the therapeutic direction. Whilst a treatment effect is observed between 
baseline and intervention, the immediacy of effect is nonetheless not apparent. The 
follow-up phase also changed to the lowest possible improvement score of one at the 
end of the study, however the presence of the immediacy of effect between the 
intervention and follow-up is not demonstrated. 
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4.6.4 Anxiety1 Visual Analysis (P6) 
The average level of anxiety1 intensity across the 10 sessions at baseline phase is 
8.8 of which the range of the levels is 7.6 to10 (see Figure 12).  The intervention has 
reduced average intensity level of 7.5 and only the lower range is reduced to 5.2 and 
the upper range remains unchanged (10).  Furthermore, the follow-up phase shows 
the average level across all its data points is down to 6.3 and its range is 3 to 10. The 
9.4 intensity level averaged across the last 3 baseline data points has no trend 
pattern. Although a curvilinear trend pattern with an 8.5 average score across the last 
3 intervention data points is observed, however the follow-up phase has a downward 
trend towards therapeutic direction. However the average of the intensity remains 
unchanged across the last three data points (6.3). Although a treatment effect is 
observed between baseline and intervention, the immediacy of effect is not clearly 
demonstrated. 
Fig 12. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
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4.6.5 Shame2 Visual Analysis (P6) 
The shame2 graph (Figure 13) shows that the baseline average of the SSGS-shame2 
subscale intensity across the 7 sessions is 22 and the range is 19 to 25. The 
intervention-phase average intensity across 8 sessions is 22 with the range of 15 to 
25. In the follow-up phase the average level of the shame2 across the 3 data points is 
17 and the range is 6 to 25. The baseline has a trend pattern performing away from 
the therapeutic direction with the average intensity level of 22 based on the last 3 
phase data points. Similarly, the intervention phase has a trend pattern opposite the 
direction of improvement and the average level of intensity across the last 3 data 
points is 24. The average level of the follow-up phase across the 3 sessions is 
reduced to 17 with a downward trend towards the direction of improvement. 
 
4.6.6 Guilt2 Visual Analysis (P6) 
When the subscale SSGS measure is utilised, (Figure 13), the results indicated by 
guilt2 show that in respect of the baseline average of the intensity across the 7 
sessions is 19 and the range is 17 to 20. The intervention-phase average intensity 
across 8 sessions is 20 with the range of 13 to 23. In the follow-up phase the average 
level of the guilt2 across the 3 data points is 16 and the range is 7 to 22. The baseline 
has a symptom improvement performing trend pattern with an average intensity level 
of 18 based on the last 3 phase data points. On the contrary the direction of 
performance of the intervention trend pattern opposes the therapeutic direction. The 
average level of intensity across the last 3 data points is 21. The average level of the 
follow-up phase across the 3 sessions is reduced to 16 with the trend pattern 
performing in favour of therapeutic direction. 
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4.6.7 Anxiety3 Visual Analysis (P6) 
Visual analysis of the STAI-1-state anxiety (anxiety3) graph in Figure 13 shows that 
the baseline average of the anxiety3 across the 9 sessions is 65 and the range is 59 
to 71. The intervention-phase average intensity across 8 sessions is 51 with the 
range of 54 to 73. In the follow-up phase the average level of the anxiety3 across the 
3 data points is 57 and the range is 45 to 66. The baseline trends upward and the 
average intensity level across the last 3 data points, is 65. Similarly, the direction of 
the intervention trend pattern is also upwards and it performed worse on the average 
intensity level, across the last 3 data points (71) compared to the baseline (65). As a 
result, no treatment effect is observed between baseline and intervention. However 
an improvement is observed in the average level of the follow-up phase across the 3 
sessions (57) and the trend pattern performing towards improvement. 
 
 
Fig 13. 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circle examines the Immediacy of effect between baseline and intervention phases 
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4.6.8 Tau-U Effect Size (P6) 
The results show there was no need to control for baseline trend (Table 24 below). 
The effect size analysis indicates evidence of an intervention effect for vividness1 (p= 
.003), shame1 (p= .0003) and guilt1 (p= .0001). There was no evidence of an 
intervention effect for anxiety1, shame2, guilt2 and anxiety3. 
  
Table 24     
 
Tau-U results summary (Participant P6) 
Measures Baseline Tau-U 
Intervention 
vs Baseline 
Tau-U 
z SDtau p value + 85%CI 
Vividness1 -0.3333 -0.7500 -2.9672 0.2528 p=0.0030(-1.114<>-0.386) 
Shame1 -0.2444 -0.9250 -3.6596 0.2528 p=0.0003(-1.289<>-0.561) 
Guilt1 -0.0222 -0.9833 -3.8903 0.2528 p=0.0001(-1.347<>-0.619) 
Anxiety1 0.0222 -0.3583 -1.4177 0.2528 p=0.1563(-0.722<>0.006) 
Shame2 0.2381 -0.0390 -0.1359 0.2868 p=0.8919(-0.452<>0.374) 
Guilt2 -0.5238 0.1688 0.5887 0.2868 p=0.5561(-0.244<>0.582) 
Anxiety3 0.1667 0.0505 0.1899 0.2659 p=0.8498(-0.332<>0.433) 
1 = Subjective Measures Emotions Rating Scales (SMERS), 2 = State Shame Guilt Scale (SSGS),  
3 = State Trait Anxiety Inventory (STAI-1) 
 
4.7 Multiple Baseline Across all 5 Participants Analyses 
Figures 14 to 20 (Appendices 35a, 36a, 37a, 38a, 39a, 40a) present graphs for each 
symptom, (vividness1, shame1, guilt1, anxiety1, shame2, guilt2 and anxiety3), across all 
5 participants, with introduction of the treatment at a different points in time for each 
participant. 
 
4.7.1 Multiple baseline Vividness1 
Figure 14, (Appendix 35a), presents mixed results demonstrating inter-subject 
replication of a covariation between change in level and/or variability and introduction 
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of imagery rescripting (treatment). For instance a covariation between change in level 
and treatment manipulation across the 5 participants is demonstrated at two different 
points in time (P4 and P6). Similarly a change in variability and introduction of 
treatment is demonstrated at two different points in time (P1 and P3). However the 
baseline level and variability at P5, which remained constant on treatment, failed to 
replicate across the 5 participants. 
 
4.7.2 Multiple baseline Shame1 
The results of Shame1 in Figure 15 (Appendix 36a), demonstrate inter-subject 
replication of a covariation between change in both level, and variability and 
introduction of the treatment within five different series, where in the level the 
demonstration is at four different points in time (level: P3, P4, P5 and P6) and an 
increase in variability is replicated at three points in time (variability: P3, P4 and P6). 
However the baseline level and variability at P1 failed to replicate across the 5 
participants. 
 
4.7.3 Multiple baseline Shame2 
Results in Figure 16  (Appendix 37a) of Shame2 demonstrate inter-subject replication 
of a covariation between change in level, and introduction of the treatment within five 
different series, where in the level the demonstration is at four different points in time 
(level: P3, P4, P5 and P6). 
 
4.7.4 Multiple baseline Guilt1 
The results of Guilt1 in Figure 17 (Appendix 38a) are exactly the same as the results 
of Shame1 in the paragraph above. 
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4.7.5 Multiple baseline Guilt2 
Results of Guilt2 in Figure 18 (Appendix 39a), show an inter-subject replication of a 
covariation between change in both level, and variability and introduction of the 
treatment within five different series, where in the level the demonstration is at three 
different points in time (level: P3, P5 and P6) and in variability the demonstration of 
replication is also at four points in time (variability: P1, P3, P4 and P5). 
 
4.7.6 Multiple baseline Anxiety1 
A reduction in baseline Anxiety1 level and variability (Figure 19 Appendix 40), is 
observed at five different points in time (level: P1, P3, P4, P5 and P6). However an 
increase in variability is observed at three different points in time (P3, P4 and P6) 
when treatment is introduced in a staggered fashion across the 5 participants. 
 
4.7.7 Multiple baseline Anxiety3 
Results in Figure 20  (Appendix 41a) for Anxiety3 demonstrate inter-subject 
replication of a covariation between change in level, and introduction of the 
treatment, where in the level the demonstration of observed improvement is at four 
different points in time (level: P3, P4, P5 and P6). However, the variability was 
greater at three different points (P1, P4 and P6).  
 
4.8 Tau-U Weighted Average Across all 5 Participants 
Tau-U summaries for all the measures across all the 5 participants are provided in 
Appendices 35b, 36b, 37b, 38b, 39b, 40b, and 41b). The weighted average reported 
in all the measures is based on all the five participants and set at 95% confidence 
interval (CI). The analyses demonstrate a significant difference between the 
intervention and baseline phases for vividness1 p= 0.0350 (-0.4512<>-0.0164); 
shame1 p=< .0001 (-0.694<>-0.262); guilt1 p= 0.0002 (-0.626<>-0.194) and anxiety1 
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p= 0.0398 (-0.4426<>-0.0106). However, there was no evidence of a significant 
difference observed between the intervention and baseline phases for SSGS shame2 
p= 0.2263 (-0.3768<>0.0892), guilt2 p= 0.859(-0.2119<>0.2541) or STAI-1 anxiety3 
p= 0.7219 (-0.1861<>0.2687). 
 
4.9 Neurocognitive Impairment (EDS and SSRT Outcomes) 
The initial baseline data for cognitive inflexibility/set-shifting deficit as measured by 
Extradimensional Shift errors (EDS) and for motor inhibitory control impairment as 
measured by the stop signal reaction time (SSRT) were collected and are presented 
in Table 39 below. Each patient’s performance results were compared against the 
mean of the healthy control group prior published data obtained from the 
Chamberlain et al (2006) study. The results were then compared against the mean of 
the OCD clinical group (Chamberlain et al 2006), in order to examine the hypothesis 
that the patients individual initial baseline scores on the Extradimensional Set-Shift) 
and the Stop-Signal Reaction Time are impaired compared to the responses reported 
for the non-OCD Healthy Control Group. 
 
Eye balling the performance score for each patient shows that all the patients except 
patient P3 has an individual score greater than the mean of the healthy control group 
(see Table 39 below). The individual results for patients P1, P2 and P6 (EDS: 26) 
shows not a lot of difference compared to the mean OCD control group (EDS: 25.9). 
The results for patient P5 (EDS: 29) was slightly higher than the mean OCD group 
(EDS: 25.9). Results for Patient P4 (EDS: 19) are much lower than the man OCD 
group (EDS: 25.9). P3 EDS errors score is less than both the means of the healthy 
control and OCD control groups, P3 (EDS: 3) < healthy norm (16.3) and OCD control 
group (EDS: 25.9).  
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The individual Stop-Signal Reaction Time score patient P1, P4, P5 and P6 are 
greater the healthy control group. Whereas the results of patient P2 (SSRT: 167.075) 
is slightly less than the healthy control group mean (SSRT: 167.8), whilst P3 (SSRT: 
106.5) is much less than the mean of the health control group (SSRT: 167.8). 
Similarly the SSRT results for patients P4, P5 and P6 are almost the same or slightly 
more than the mean OCD control group. Patient P1 (SSRT: 251.3) score is notably 
larger than the mean OCD control group (SSRT: 211.6). 
 
Table 39  
 
Neurocognitive Initial Baselines with Comparison Group Norms 
 
 
EDS errors: Number of errors commissioned during the extradimensional task 
SSRT: The length of time in milliseconds to control a motor response when the response is no 
longer required – as the measurement motor inhibitory control 
Normative Data: The comparison OCD and Healthy Group Norms are from the Chamberlain 
et al (2006) study 
  
Norms: N=20  Mean(SD) Norms: N=20  Mean(SD)
P1 P2 P3 P4 P5 P6 OCD Group Healthy Group
EDS errors 26 26 2 19 29 26 25.9 (18.1) 16.3 (13.1)
SSRT 251.3 167.075 106.5 216.95 216.125 210.45 211.6 (57.9) 167.8 (48.6)
Study Participants 
Initial Baseline (BL1)
 Comparison Norms Data
Neurocognitive 
Impairments
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4.10 Reliable and Clinically Significant Analysis 
The test-retest reliability data provided in Table 40 below was used to help analyse 
the results of the YBOCS, MADRS, EDS errors and the SSRT in order to establish 
whether an observed change was both a reliable change and clinically significant 
based on standard norms (Jacobson & Truax, 1991). 
 
Table 40 
Test-retest Coefficients for Neurocognitive and Clinical Measures 
 
 
 
The YBOCS raw data before and after treatment is provided in Table 41 below. 
Patients P2 data was excluded for the YBOCS analysis because the patient withdrew 
after the initial baseline. Patients P1 and P3 withdrew at the end of three weeks 
follow-up. Baseline data was collected twice and indicated as BL1 and BL2.  The two 
baselines were used to assess baseline stability for each patient. Changes in YBOCS 
at post treatment were assessed using BL2, whilst the changes at post follow-ups 
were assessed from post treatment scores (imagery rescripting). 
r Mean Interval; N=Sample
(Sample type) (SD) (Data Source)
EDS Errors 0.70 (elderly healthy) 21.8(16.85) 4weeks; N = 162                          (Lowe & Rabbitt 1998)
16.3                           
(Chamberlain et al 2006)
SSRT 0.71 (adults healthy) 139.91(24.98)  Same day variable times; N = 129    (Congdon et al 2012) ≤200ms
YBOCS 0.97 (adults OCD) 26.6(4.10) 7 days; N = 23                                  (Kim et al 1992) ≤16
MADRS 0.9 (adults depression) 24.95(7.05) 24hrs; N = 20                                 (Mundt et al 2006) remission≤10
MADRS:  Measures severity of depression
EDS:  Evaluates cognitive flexibility performance
SSRT:   Evaluates motor inhibition performance
YBOCS:   Measures severity of OCD symptoms
Norms for Clinical/Healthy 
PopulationMeasures
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Table 41   
 
YBOCS Raw Data for all Participants 
 
 
Assessment of baseline performances of the YBOCS show that two patients, (P1 and 
P5), each had a stable baseline. There is an increase in the YBOCS score at BL2 for 
patients P3 and P4 and both patients show a reliable change between BL1 and BL2, 
however patient P4 reliable change of 33.33% was clinically significant deterioration 
(see Table 42 below). Patient P6 showed a slight decrease in the YBOCS score at 
BL2 but the observed baseline improvement is not a reliable change. 
 
 
  
Post-test 
Scores
Initial 
Baseline 
(BL1)
End of 
Baseline (BL2)
Imagery 
Rescripting
3weeks 
F/U (FU1)
6weeks 
F/U (FU2)
9weeks 
F/U (FU3)
P1 34 34 37 30 ◊ ◊
P3 22 24 23 18 ◊ ◊ 
P4 24 32 27 26 28 29
P5 29 29 30 23 26 18
P6 29 28 16 25 16 12
F/U-test ScoresAll Five 
Patients
Pretest Scores
YBOCS:   Measures severity of OCD symptoms
BL1: Initial Baseline;  BL2:  End of Baseline;   ImRs:  Imagery Rescripting
FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;     FU3:  9 weeks follow-up
◊  Missing data;   ∆• Not applicable
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Table 42  
 
YBOCS Baselines Reliable Change & Clinical Significance 
 
 
The comparisons at End of Baseline (BL2) and post imagery rescripting (ImRs) show 
reliable change in the YBOCS results for three patients (P1, P4 and P6) out of the 
five patients. The reliable change in, Patient P1 is a deterioration but not clinically 
significant. The YBOCS improvements demonstrated in, Patient P4 and P6 shows 
clinically significant change at -42.86% in, patient P6 (see Table 43 below). 
 
  
Reliable Change 
Index (RCI< -1.65)
Clinical Significance
(X2  – X1)            
Sdiff.
change ≥ 25% 
P1 0# 0%∆•
P3 1.99ѣⁿ 9.01%∆•ⁿ
P4 7.97ѣⁿ 33.33%†ⁿ
P5 0# 0%∆•
P6 -1.00# -3.45%∆•
All Five Patients
BL1 to BL2
BL1: Initial Baseline;  BL2:  End of Baseline; #Not a reliable change;  ⁿDeteriotated
ѣReliable change; †Clinically significant; ◊  Missing data;   ∆• Not applicable
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Table 43  
 
YBOCS End of Baseline to Imagery Rescripting Reliable Change & Clinical 
Significance 
 
 
The observed gains in the reliable change at post treatment (ImRs) for patients P4 
were maintained at the follow-up period (FU1), but subsequently failed to maintain at 
follow-ups FU2 and FU3 as shown in Table 44. Patient P6 shows clinically significant 
deterioration (56.25%) at follow-up period (FU1) and then clinically significant 
improvement of -25% at follow-up, FU3.  
 
  
Reliable Change 
Index (RCI< -1.65) Clinical Significance
(X2  – X1)                  
Sdiff.
change ≥ 25% 
P1 2.99ѣⁿ 8.82%∆•ⁿ
P3 -1# -3.45%∆•
P4 -4.98ѣ -15.63%∆•
P5 1# 3.45%∆•
P6 -11.957ѣ -42.86%†
BL2:  End of Baseline;   ImRs:  Imagery Rescripting (Intervention)
∆• Not applicable;  #Not a reliable change;  ⁿDeteriotated;  ѣReliable Change;  †Change is 
clinically significant;  
BL2 to ImRs
All Five 
Patients
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Table 44  
 
YBOCS Imagery Rescripting to Follow-ups Reliable Change & Clinical Significance 
 
 
The depression (MADRS) raw data for five patients is shown in Table 45, and the 
data for patient P2 is not included following withdrawal from the study after the initial 
baseline.  
 
Table 45    
MADRS Raw Data for all Participants 
 
Reliable Change 
Index (RCI< -1.65) Clinical Significance
Reliable Change 
Index (RCI< -1.65) Clinical Significance
Reliable Change 
Index (RCI< -1.65) Clinical Significance
(X2  – X1)               
Sdiff.
change ≥ 25% (X2  – X1)              Sdiff.
change ≥ 25% (X2  – X1)              Sdiff.
change ≥ 25% 
-6.97ѣ -18.92%∆• ◊ ◊ ◊ ◊
-4.98ѣ -21.74%∆• ◊ ◊ ◊ ◊
-1# -3.45%∆• 1# 3.45%∆• 1.99ѣⁿ 7.41%∆•ⁿ
-6.97ѣ -23.33%∆• -3.98ѣ -13.33%∆• -11.95ѣ -40%†
8.96ѣⁿ 56.25%†ⁿ 0.00# 0%∆• -11.95ѣ -25%†
ImRs:  Imagery Rescripting (Intervention);   FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;   FU3:  9 weeks follow-up.
ImRs to FU2 ImRs to FU3ImRs to FU1
Post-test 
Scores
Initial 
Baseline 
(BL1)
End of 
Baseline (BL2)
Imagery 
Rescripting
3weeks 
F/U (FU1)
6weeks 
F/U (FU2)
9weeks 
F/U (FU3)
P1 26 28 30 29 ◊ ◊
P3 12 19 23 4 ◊ ◊ 
P4 15 32 21 31 23 22
P5 33 32 22 16 16 26
P6 24 21 4 27 11 4
BL1: Initial Baseline;  BL2:  End of Baseline;   ImRs:  Imagery Rescripting
FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;     FU3:  9 weeks follow-up;  ◊  Missing data
MADRS:  Measures severity of depression
All Five 
Patients
Pretest Scores F/U-test Scores
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MADRS baseline performance for each patient shows a relatively stable baseline for 
patients P1, P5 and P6 and a clinically significant deterioration from BL1 to BL2 for 
both patients P3 and P4 (see Table 46 below). 
 
Table 46   
 
MADRS Baselines Reliable Change & Clinical Significance 
 
 
Table 47 below shows that three patients (P4, P5 and P6) demonstrated clinically 
significant improvement in depression from end baseline (BL2) to post treatment, 
imagery rescripting treatment phase. Patients P1 and P3 continued to deteriorate 
between phase BL2 and the treatment phase, however they were not a reliable 
change. 
 
  
Reliable Change 
Index (RCI< -1.65) Clinical Significance
(X2  – X1)                  
Sdiff.
change ≥ 25%  
(Lauge et al 1998) 
P1 0.63# ∆•
P3 2.22ѣⁿ 58.33%†ⁿ
P4 5.39ѣⁿ 113.33%†ⁿ
P5 -0.32# ∆•
P6 -0.95# ∆•
All Five Patients
BL1 to BL2
BL1: Initial Baseline;  BL2:  End of Baseline; ⁿ Deteriotated   ;  #Not a reliable change
ѣReliable Change;  ∆•Not applicable ; † Clinically significant change; ◊  Missing data
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Table 47  
 
MADRS End of Baseline to Imagery Rescripting Reliable Change & Clinical 
Significance 
 
 
The results at follow-up in Table 48 below show that only patient P5 carried through 
the improvement gained achieving a further clinically significant gain at follow-up 
phases FU1 and FU2. Patients P4 and P6 both show clinically significant 
deterioration at FU1 with P6 further deteriorating at clinically significant level to FU2. 
Patient P3 improvement achieved clinically significant level, all at end of FU1.  
 
 
  
Reliable Change 
Index (RCI< -1.65)
Clinical 
Significance
(X2  – X1)            
Sdiff.
change ≥ 25%  
(Lauge et al 1998) 
P1 0.63# #
P3 1.27# #
P4 -3.49ѣ -34.37%†
P5 -3.17ѣ -31.25%†
P6 -5.39ѣ -42.5%†
BL2: End of Baseline; ImRs: Imagery Rescripting (Intervention); # Not a reliable change;   
ⁿ  Deteriotated; ѣReliable Change; †Change is clinically significant;  ◊Missing data;   ∆•Not applicable.
BL2 to ImRs
All Five 
Patients
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Table 48  
 
MADRS Imagery Rescripting to Follow-ups Reliable Change & Clinical Significance 
 
 
 
Table 49 provides raw data for set-shifting deficit measurements (EDS). Based on 
the EDS baseline raw data it is obvious without further calculation that P1, P3, P4 
and P6 could not make any further improvement because their pre ImRs (i.e. end of 
baseline scores) were close to zero.  
 
  
Reliable Change Index 
(RCI< -1.65) Clinical Significance
Reliable Change Index 
(RCI< -1.65) Clinical Significance
Reliable Change Index 
(RCI< -1.65) Clinical Significance
(X 2  – X1)                  
Sdiff.
change ≥ 25%  
(Lauge et al 1998) 
(X 2  – X1)                    
Sdiff.
change ≥ 25%  
(Lauge et al 1998) 
(X 2  – X1)                   
Sdiff.
change ≥ 25%  
(Lauge et al 1998) 
-0.32# # ◊ ◊ ◊ ◊
-6.03ѣ -82.61%† ◊ ◊ ◊ ◊
3.17ѣⁿ 47.62%†ⁿ 0.63# ∆• 0.32# #
-1.9ѣ -27.27%† -1.9ѣ -27.27%† 1.27# #
7.29ѣⁿ 575%†ⁿ 2.22ѣⁿ 175%†ⁿ 0.00# #
ImRs to FU1 ImRs to FU2 ImRs to FU3
BL2:  End of Baseline;   ImRs:  Imagery Rescripting (Intervention);   FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;   FU3:  9 weeks follow-up
# Not a reliable change;   ⁿ Deteriotated;    ѣ Reliable Change;  † Change is clinically significant;   ◊ Missing data;   ∆• Not applicable.
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Table 49  
 
EDS Errors Raw Data for All Participants 
 
 
 
The analysis of baseline stabilities in shown in Table 50 revealed that most 
improvement was made for most participants between initial baseline (BL1) and end 
of baseline (BL2). It is worth noting that, in the context of no intervention at all, P1, P4 
and P6 all improved dramatically with two of the participants yielding a reliable 
change score of P1 (RCI: -1.69) and P6 (RCI: -1.76) (see Table 50). Participant P5, 
however, is the only one who did not show EDS improvement between BL1 and BL2.  
 
  
Post-test 
Scores
Initial 
Baseline 
(BL1)
End of 
Baseline (BL2)
Imagery 
Rescriptin
g
3weeks 
F/U (FU1)
6weeks 
F/U (FU2)
9weeks 
F/U (FU3)
P1 26 4 7 4 ◊ ◊
P3 2 1 1 1 ◊ ◊ 
P4 19 1 2 2 1 2
P5 29 28 19 17 27 11
P6 26 3 0 1 1 2
BL1: Initial Baseline;  BL2:  End of Baseline;   ImRs:  Imagery Rescripting
FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;     FU3:  9 weeks follow-up
All Five 
Patients
Pretest Scores F/U-test Scores
EDS:  Evaluates set-shifting deficit. EDs errors scores can be influenced by practice effect
◊  Missing data;   ∆• Not applicable
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Table 50   
 
EDS Errors Baselines Reliable Change & Clinical Significance 
 
 
 
  
Reliable Change 
Index (RCI< -1.65)
Practice Effects 
Adjusted RCIPE  Clinical Significance
(X2 – X1)                
Sdiff.
((X2 – X1) – (M2 – M1))    
SD
change ≥ 2SD from 
the mean of healthy 
norm: 16.3
P1 -1.69ѣ   ѣ † 
P3 -0.08∆• ∆• ∆•
P4 -1.38# # ∆•
P5 -0.08# # #
P6 -1.76ѣ   ѣ † 
† Change is clinically significant;   ◊ Missing data;   ∆• Not applicable
All Five 
Patients
# Not a reliable change;   ⁿ Deteriotated;    ѣ Reliable Change
EDS:  Evaluates set-shifting deficit.
BL1 to BL2
BL1: Initial Baseline;  BL2:  End of Baseline
RCIPE   is calculated where a reliable change is confirmed.
 141 
Table 51 below shows that there is a change observed between BL2 and ImRs in 
patients P5, but it is not a reliable change.  
 
Table 51   
 
EDS Errors End of Baseline to Imagery Rescripting Reliable Change & Clinical 
Significance 
 
 
Furthermore, P5 shows no reliable changes are achieved between imagery 
rescripting and each of the follow-up phases. 
 
 
  
Reliable Change 
Index (RCI< -1.65)
Practice Effects 
Adjusted RCIPE  
Clinical 
Significance
(X2  – X1)              
Sdiff.
((X2 – X1) – (M2 – M1))    
SD
change ≥ 2SD from 
the mean of healthy 
norm: 16.3
P1 0.23# ∆• ∆•
P3 0∆• ∆• ∆•
P4 0.08# ∆• ∆•
P5 -0.69# ∆• #
P6 -0.23# ∆• #
◊ Missing data;   ∆• Not applicable;  #Not a reliable change;  ⁿDeteriotated  
All Five 
Patients
BL2 to ImRs
BL2:  End of Baseline;   ImRs:  Imagery Rescripting (Intervention) .
ѣReliable Change;  †Change is clinically significant    
RCIPE   is calculated where a reliable change is confirmed.
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Table 52  
  
EDS Errors Imagery Rescripting to Follow-ups Reliable Change & Clinical 
Significance 
 
 
 
The raw data for the motor inhibitory impairment changes following intervention is 
provided in Table 53 below.  
 
Table 53    
 
SSRT Raw Data for All Participants 
 
 
 
Reliable Change 
Index (RCI< -1.65)
Practice Effects 
Adjusted RCIPE  
Clinical 
Significance
Reliable Change 
Index (RCI< -1.65)
Practice Effects 
Adjusted RCIPE  
Clinical 
Significance
Reliable Change 
Index (RCI< -1.65)
Practice Effects 
Adjusted RCIPE  
Clinical 
Significance
(X2  – X1)              
Sdiff.
((X2 – X1) – (M2 – M1))    
SD
change ≥ 2SD from 
the mean of healthy 
norm: 16.3
(X2  – X1)             
Sdiff.
((X2 – X1) – (M2 – M1))    
SD
change ≥ 2SD from 
the mean of healthy 
norm: 16.3
(X2  – X1)             
Sdiff.
((X2 – X1) – (M2 – M1))    
SD
change ≥ 2SD from 
the mean of healthy 
norm: 16.3
P1 -0.23# ∆• ∆• ◊ ◊ ◊ ◊ ◊ ◊
P3 0∆• ∆• ∆• ◊ ◊ ◊ ◊ ◊ ◊
P4 0# ∆• ∆• -0.08# # # 0# # #
P5 -0.15# ∆• # 0.61# ∆• # -0.61# ∆• #
P6 0.08# ∆• # 0.08# ∆• # 0.70# ∆• #
ImRs:   Imagery Rescripting (Intervention);   FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;   FU3:  9 weeks follow-up;   ◊ Missing data;   ∆• Not applicable.
ImRs to FU1
All Five 
Patients
ImRs to FU2 ImRs to FU3
#Not a reliable change;  ⁿDeteriotated;  ѣReliable Change;  †Change is clinically significant;  RCIPE is calculated where a reliable change is confirmed
Post-test 
Scores
Initial 
Baseline 
(BL1)
End of 
Baseline (BL2)
Imagery 
Rescriptin
g
3weeks 
F/U (FU1)
6weeks 
F/U (FU2)
9weeks 
F/U (FU3)
P1 251.3 545.325 393.275 275.95 ◊ ◊
P3 106.5 107.9 126.675 103.125 ◊ ◊ 
P4 216.95 146.75 161.175 266.575 150.65 141.325
P5 216.125 196.925 184.275 251.2 168.35 194.725
P6 210.45 205.25 173.125 163.475 101.675 156.125
FU3:  9 weeks follow-up; ◊Missing data;   ∆• Not applicable
F/U-test ScoresPretest Scores
All Five 
Patients
SSRT:   Evaluates motor inhibition performance;  BL1: Initial Baseline;  BL2:  End of Baseline   
ImRs:  Imagery Rescripting;  FU1:  3 weeks follow-up;  FU2:  6 weeks follow-up;  
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Table 54 below shows the performances of SSRT for each of the five participants 
between the initial (BL1) and end of the baseline (BL2). The results demonstrate an 
improvement prior to the intervention (ImRs), in two participants (P4 and P5) of which 
only P4 pre-intervention results yield a reliable change, RCI: -3.69. Conversely, 
Participant P1 demonstrated a dramatic deterioration, (RCI: 15.46), at the end of 
baseline (BL2). Participants P3 and P6 SSRT performance between the two 
baselines seems stable with P3 demonstrating an RCI: 0.07 and P6 (RCI: -0.27). 
 
Table 54   
 
SSRT Baselines Reliable Change & Clinical Significance 
 
 
 
Table 55 below shows SSRT results after the intervention (ImRs). The analyses 
reveal reliable changes in performance score for P1 (RCI: -7.99) and P6 (RCI: -1.69). 
The observed changes in P3 and P5 at post intervention failed to show reliable 
improvement  
 
  
Reliable Change Index 
(RCI< -1.65) Clinical Significance
(X 2  – X1)                        
Sdiff.
Change ≥ 2SD from the 
mean of healthy norm: 
167.8
P1 15.46ѣⁿ †ⁿ 
P3 0.07∆• #ⁿ∆•
P4 -3.69ѣ † 
P5 -1.01# #
P6 -0.27# #
BL1: Initial Baseline;  BL2:  End of Baseline
# Not a reliable change;   ѣ Reliable Change
† Change is clinically significant;   ⁿ Deteriotated
All Five 
Patients
BL1 to BL2
◊  Missing data;   ∆• Not applicable
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Table 55   
 
SSRT End of Baseline to Imagery Rescripting Reliable Change & Clinical 
Significance 
 
 
The results in Table 56 shows that patient P1 was able to maintain observed 
improvements at the first follow-up (FU1) (RCI: -6.17) before withdrawing from the 
study. Whereas P6 observed improvements at follows-ups did not show reliable 
change until at FU2 (RCI: -3.76). Patient P5 had a clinically significant deterioration 
(RCI = 3.52) in follow-up phase FU1 and the small improvement gained beyond FU1 
did not meet a reliable change level. Similarly, a large deterioration between ImRs 
and FU1 is also observed in P4 (RCI: 5.54). 
 
  
Reliable Change 
Index (RCI< -1.65) Clinical Significance
(X2  – X1)             
Sdiff.
Change ≥ 2SD from the 
mean of healthy norm: 
167.8
P1 -7.99ѣ  ∆•
P3 0.99# #ⁿ∆•
P4 0.76# #ⁿ∆•
P5 -0.66# ∆•
P6 -1.69ѣ  ∆•
BL2 to ImRs
All Five 
Patients
BL2: End of Baseline; ImRs: Imagery Rescripting
# Not a reliable change;   ѣ Reliable Change
† Change is clinically significant;   ⁿ Deteriotated
◊  Missing data;   ∆• Not applicable
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Table 56   
 
SSRT Imagery Rescripting to Follow-ups Reliable Change & Clinical Significance 
 
 
 
 
  
Reliable 
Change Index 
(RCI< -1.65) Clinical Significance
Reliable 
Change Index 
(RCI< -1.65) Clinical Significance
Reliable 
Change Index 
(RCI< -1.65) Clinical Significance
(X 2  – X1)         
Sdiff.
Change ≥ 2SD from the 
mean of the healthy 
norm: 167.8
(X 2  – X1)        
Sdiff.
Change ≥ 2SD from the 
mean of the healthy 
norm: 167.8
(X2  – X1)                
Sdiff.
Change ≥ 2SD from the 
mean of the healthy 
norm: 167.8
P1 -6.17ѣ  ∆• ◊ ◊ ◊ ◊
P3 -1.24# #∆• ◊ ◊ ◊ ◊
P4 5.54ⁿ ⁿ -0.55# #∆• -1.04# #∆•
P5 3.52ⁿ ⁿ -0.84# # 0.55# #
P6 -0.51# #∆• -3.76ѣ † -0.89# #∆•
All Five 
Patients
ImRs to FU1 ImRs to FU2 ImRs to FU3
ImRs:   Imagery Rescripting (Intervention);   FU1:  3 weeks follow-up;   FU2:  6 weeks follow-up;   FU3:  9 weeks follow-up
# Not a reliable change;   ⁿ Deteriotated;    ѣ Reliable Change;  † Change is clinically significant;   ◊ Missing data;   ∆• Not applicable.
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Chapter. 5 Discussion 
5.1 Introduction 
5.1.1. Study rationale 
The current study examined the therapeutic utility of imagery rescripting in people 
with OCD who experience intrusive images. The rationale for using imagery 
rescripting was based upon reports of its efficacy in ameliorating both intrusive 
images and associated distress in disorders such as post-traumatic stress disorder 
(PTSD) (Arntz, Tiesema, & Kindt 2007), social anxiety (Lee, & Kwon 2013; Wild, 
Hackmann, & Clark 2008), shame and guilt (Grunert et al 2003; 2007), depression 
(Brewin et al 2009) and as a potential treatment for use in obsessive compulsive 
disorder (OCD) (Veale et al 2015) and body dysmorphic disorder (BDD) (Wilson, 
Veale & Freeston 2015). 
 
Given the focus was on the individual participants, a series of six single cases were 
recruited, with one dropping out prematurely following the initial baseline testing. 
Single case multi-baseline experimental design (SCED) was utilised to investigate 
the following research hypotheses: 
1. Patients receiving one session of imagery rescripting with 7 days’ home 
practice will report reduced vividness in the intrusive imagery, between pre- 
and post-intervention. 
2. Improvements in key clinical symptoms (shame, guilt, and OCD) will coincide 
with changes in imagery vividness. 
3. The initial baseline scores of the individual patients’ performance on the set-
shifting (Extradimensional Set-Shift) and the motor inhibitory control (Stop-
 147 
Signal Reaction Time) tasks of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB) are impaired compared to the responses 
reported for the non-OCD Healthy Control Group as published in the 
Chamberlain et al (2006) study. 
4. Improvements in neurocognitive performance will be demonstrated after one 
session of imagery rescripting with 7 days’ home practice, which will align with 
the clinical changes observed. 
5. Improvements will be maintained over a period of 3 weeks, 6 weeks and 9 
weeks follow-up. 
 
5.1.2. Chapter Structure 
This chapter discusses the major findings, situating them within the wider literature 
and contextual knowledge. A broad overview of the major findings is provided first 
before critical evaluation of the findings is considered. The section on critical 
evaluation of the key findings focuses on factors likely to influence the results to 
either concur or depart from the current literature. Factors considered in the critique 
include, first, the theoretical bases for similarities and differences with PTSD and 
OCD as one of the possible explanations for the findings. A second consideration is 
the impact of the delivery of the intervention on the findings with a particular focus on 
the mode of treatment delivery and the monitoring of the patients’ adherence to the 
home-based treatment. A critical evaluation of the methodology follows next, 
reflecting on the impact of the time series design on the outcome of the intervention. 
The strength and limitations of the study followed by applied implications of the study 
are then discussed before a section on personal reflections. A conclusion section 
finalises the discussion. 
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5.2. Overview of Findings 
The study demonstrated a clinically meaningful reduction in imagery vividness, 
shame, guilt and OCD that coincided with the introduction of imagery rescripting, in 
only one of the patients (P6) out of the six recruited. The study findings also showed 
that, prior to the commencement of imagery rescripting, the majority of the patients 
performed worse on the initial CANTAB neurocognitive assessment of the 
impairment of set shifting and motor inhibitory control. Furthermore, the 
neurocognitive impairments showed improvement during the re-testing of the 
measures in the second baseline phase.  
 
5.3. Critical Evaluation of the Findings 
The results of only one patient (P6’s) demonstrated change across all the key clinical 
symptoms consistent with hypotheses 1, 2 and 5 of the study. Although the other 
patients (P1, P3, P4 and P5) demonstrated improvement on one or two of the 
hypothesised indices, none of these patients showed a consistent profile of change in 
the indices that would have provided sufficient evidence to support the hypotheses. 
The wider conceptual literature on ameliorating distressing intrusive images suggests 
that imagery rescripting (ImRs) is an effective treatment for intrusive imagery, which 
can be visual, auditory, or physiological in nature (Smucker & Dancu 1999). In the 
case of PTSD, the images are often associated with a past traumatic experience 
(Arntz et al 2007; Grunert et al 2007; Holmes et al 2007; Smucker & Dancu 1999). 
ImRs instils a non-dysfunctional emotional processing of the trauma, by helping the 
patient change the distressing intrusive mental images into a much-preferred 
outcome (Arntz et al 2007; Hackmann 2011; Holmes et al 2007). Moreover the 
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negative emotions such as shame and guilt among others, arising as a consequence 
of the negative intrusive image, become less prominent in the preferred newly 
rescripted image (Smucker & Dancu 1999). Given that patient P6’s OCD is comorbid 
with PTSD and that she experienced intrusive images driven by memories of past 
traumatic events, it is not surprising, based on the conceptual literature on 
ameliorating distressing intrusive imagery, that the patient’s results were consistent 
with the study hypothesis 1, 2 and 5. Moreover, the results of P6 are consistent 
specifically with published results demonstrating improvement in intrusive images 
and the associated distress in patients diagnosed with PTSD following treatment with 
ImRs (Arntz et al. 2007; Grunert et al 2007; Hackmann 2011; Holmes et al 2007; Wild 
et al 2007). Similarly, the results are consistent with Veale et al., (2015), 
demonstrating OCD symptom improvement following imagery rescripting. The 
common denominator in both the OCD patients in Veale et al (2015) and patient P6 
diagnosed with OCD is that the intrusive images were linked to trauma memories.  In 
summary, PTSD and/or the intrusive images linked to memories of a traumatic 
experience may have influenced and explains the key findings observed in the 
patient P6. 
 
Whilst PTSD and OCD share similar symptom profiles, for example, distressing 
intrusive images, and ritualised behaviours (Fontenelle, Domingues, Souza, 
Mendlowicz, de Menezes, et al 2007; Huppert, Moser, Gershuny, Riggs, Spokas, et 
al 2005), the distressing intrusive images in OCD are less strongly attached to ideas 
of past adverse experiences (Day et al 2004; Hackmann et al 2000; Lipton et al 2010; 
Speckens et al 2007). Furthermore OCD differs from PTSD in that people with OCD 
experience an urge, which is usually distressing and drives ritualistic behaviours 
(Rachman 2007). Although the intrusive images experienced in the other patients 
(P1, P3, P4 and P5) are not influenced by ideas of past adverse events as is in 
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PTSD, it has been argued that this type of intrusive imagery in OCD can also be 
ameliorated using ImRs (Holmes et al 2007). However, patients (P1, P3, P4 and P5) 
failed to demonstrate a consistent profile of change in all the symptom indices 
following ImRs. It could be that these patients were attempting to rescript an urge that 
was possibly mistakenly viewed as a physiological arousal /sensation that was 
capable of being rescripted. Evidence indicates that OCD urges tend to be treated 
effectively with exposure and response prevention (ERP) (de Silva, Menzies & 
Shafran 2003; Foa & Kozak 1996; Rachman & Hodgson 1980; Stanley & Averill 
1998) and evidence based does not exist on the use of ImRs for OCD urges. 
Therefore, this possibly explains the absence of a clinically significant improvement 
across all the key symptoms in the patients (P1, P3, P4 and P5) following ImRs.  
 
Another difference between OCD and PTSD that possibly explains the study results 
is the number of images experienced in OCD. OCD patients tend to experience more 
intrusive images, for example at least ten intrusive images per week, compared to 
one image experienced in PTSD (Lipton et al 2010; Speckens et al 2007). Therefore, 
the intrusive images need to continue to be worked on during imagery rescripting 
sessions until new scripts are attained for each of the intrusive images. If necessary 
the patient is aided by the therapist to rescript the sequence (Arntz 2012; Hackmann 
2011). On this basis, it is plausible that the one session of therapist-administered 
ImRs was not sufficient to address all the intrusive images experienced by OCD 
patients. This potentially explains why improvement was not seen in the other 
patients (P1, P3, P4 and P5) across all the symptoms. 
 
The therapist’s previous treatment relationship with P6 could also have influenced the 
differences in the results observed between P6 and the other participants. For 
instance it is argued that developing and maintaining a strong therapeutic relationship 
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(Cloitre, Stovall-McClough, Miranda & Chemtob 2004) and the patient’s ability to 
work collaboratively with the therapist (Cronin, Brand & Mattanah 2014) influence 
better treatment outcome (Martin, Garske, & Davis 2000; Paivio & Patterson 1999). 
Given that the therapist had not previously treated all the other participants except for 
P6, there would have been no pre-existing therapeutic alliance between these 
patients and the therapist, at commencement of the one session therapist 
administered ImRs. Moreover, more therapy sessions may be required in order to 
develop and maintain therapy alliance, given the view that stronger therapy alliance 
tends to become evident over several therapy sessions (Falkenstrom, Granstrom & 
Holmqvist 2013). On this basis the single session was insufficient to nurture a strong 
therapy alliance/relationship that could be transferred into home practice. 
Consequently this could have had a bearing on the results demonstrated in the 
patients (P1, P3, P4 and P5). In contrast participant P6 had already established a 
previous strong therapy relationship with the therapist. Therefore the therapist effect 
in this case may have had an influence on the results observed in P6 being different 
from the other patients.  
 
A further explanation for the difference in outcomes between patients is variability in 
their competence to self-administer ImRs and also the monitoring of treatment 
adherence during home-based ImRs. Patients can experience uncertainty and fear 
when receiving the ImRs treatment for the first time (Napel-Schutz, Abma, Bamelis & 
Arntz 2011). In fact, during the collection of follow-up data, some of the patients 
reported that they found it harder and distressing to self-administer imagery 
rescripting at home. Such experiences are likely to compound the already known 
problem of non-adherence to self-directed homework practice observed in OCD 
patients (Carmin, Wiegartz & Wu 2005; Smucker & Dancu 1999). Supporting this 
argument is P1 who reported that she withdrew from the study after the first follow-up 
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session because she found it too distressing to focus on the intrusive image. She 
struggled to modify the intrusive images without the guidance of the therapist and she 
felt that she did not have confidence in applying imagery rescripting. One therefore 
can only speculate that the absence of monitoring competence in using ImRs, 
including whether the patients were actually using ImRs at home, makes it harder to 
rule out the possibility that these factors impacted on the observed results. 
 
It is important to note that the intervention seemed to have an immediate effect, 
especially on shame in at least three of the five participants. However, the single 
case design only indicates some evidence towards potential effectiveness but not 
definite evidence. The time series design utilised is not robust enough to control 
potential artefacts that could account for the observed improvement, aside from the 
intervention. Therefore, in order to test these results in the future so as to be able to 
conclude that the observed changes in the dependent variables are attributable only 
to the effects of imagery rescripting, a control group will need to be considered  
(Kazdin 2011; Poling & Grossett 1986; Smith 2012). 
 
Turning attention to the findings relating to the neurocognitive tests, all but one 
patient, P3, demonstrated results that were consistent with hypothesis 3, showing a 
worse performance on the initial CANTAB neurocognitive assessments compared to 
the healthy controls. These results are also consistent with current knowledge 
suggesting cognitive inflexibility (set-shifting and inhibitory control impairments) 
characterises OCD (Chamberlain et al. 2006). However, contra to the hypothesis, 
patient P3 performed better than the healthy comparison sample from the literature. 
Although intelligent Quotient (IQ) can impact on the results (Leeson, Robbins, 
Matheson, Hutton, Ron et al 2009), drawing conclusions about the potential for IQ to 
explain the difference between the study sample and the healthy comparison is 
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limited because IQ was not measured in the current study. Consequently, the study 
could not be certain if the deficits relative to the comparison sample are due to OCD 
or IQ. 
 
Neurocognitive measures were taken twice during baseline to assess the effect of 
learning before any intervention was applied. Repeated assessment of the CANTAB 
tasks ordinarily results in improved performance scores at re-test. This improvement 
with practice might erroneously be attributed to the effect of the intervention (Basso, 
Bornstein & Lang 1999; Lowe & Rabbitt 1998), which is why these measures were 
repeated during baseline. The results found that all but patient P5 made very 
substantial improvements in EDS performance in the absence of the treatment. 
These changes were expected because observed improvement over two 
administrations is a result of task learning (Barch, Braver, Carter, Poldrack, & 
Robbins (2009). As noted, P5 did not make any obvious change however. Practice 
effects do depend on intact memory processing. Pitel, Beaunieux, Witkowski, Vabret, 
Guillery-Girard et al (2007) found that episodic memory, a key component concerned 
with the storage, encoding and retrieval which are essential ingredients for learning, 
is affected by chronic alcoholism. P5 had a history of extensive and sustained alcohol 
misuse, as well as a history of organic brain disorder (minor stroke). Both potentially 
could contribute to poor memory and overall poor EDS performance. 
 
The neurocognitive performance results of all the patients, except P5, were at the 
ceiling by the end of the second baseline; therefore it was not possible to establish an 
association between imagery rescripting and neurocognitive performance change. 
There was no capacity for the imagery rescripting to produce further benefit in 
performance. The results on the SSRT showed there was evidence of a modest 
practice effect comparing end baseline to the initial baseline in all but one patient 
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(P1), who showed dramatic worsening at the baseline. The study also found that 
there were very modest and inconsistent changes from end baseline to imagery 
rescripting with some patients showing modest improvements and others worsening.  
On balance, there was no conclusive evidence to suggest imagery rescripting had 
significantly changed motor inhibitory control ability as measured by the SSRT. With 
sustained follow up and repetition of the test there was also some modest 
improvement in reaction time, which could be explained as the effect of practice on 
reaction time, as discussed previously. 
 
5.4. Study Strengths and Limitations   
5.4.1. Study Strengths 
One of the study’s major strength is its use of single case experimental design to help 
understand the individual differences treatment response. For instance the single 
case design allows for an in depth focus on each participant by collecting data on 
several measures at multiple time-points. The study’s design is also an advantage in 
that it can be used in a clinical setting using a small sample size, without losing 
experimental validity and credibility and is cost effective compared to using group 
design based studies. Another strength to note is in the methodology of the study 
where good level of experimental control was enhanced by having the data collection 
done by someone independent of the therapist. Also, a strength is that this is the only 
study to look at ImRs in OCD and focussing on shame. The study has only provided 
the only evidence on single session ImRs for OCD. 
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5.4.2. Limitations 
This study used single case experimental design (SCED). Part of the aim was to 
investigate neurocognitive problems in OCD. However, the SCED relies on repeated 
measures and a minimum of five repeated data points is considered the gold 
standard   (Kratochwill et al 2010, 2013). In the current study, it was not meaningful 
to take repeated neurocognitive / neuropsychological assessment tasks with this 
frequency. It is stated by others that the; 
 “...tests of frontal or `executive` function `work` only when they are novel 
because performance on them can abruptly improve as soon as an individual 
discovers an optimal strategy, but will improve less or not at all if no strategy is 
found and may even deteriorate if a sub-optimal strategy is attempted”  (Lowe & 
Rabbitt 1998:918-919). 
 
Even if one were to try and control for the practice effect by, for example, introducing 
different levels of the test in order to maintain the novelty effect, the varied levels of 
the test would also require repeating at least five times in line with how SCED studies 
should be carried out. Therefore, in this current study the use of single case 
experimental design limited the degree to which it was meaningful to use the 
Extradimensional Shift Task and the Stop Signal Reaction Time task to investigate 
the impact of imagery rescripting on set-shifting deficit and motor inhibitory control as 
well as the improvements over time.  
 
Having different instruments measuring the same key study constructs (shame, guilt 
and anxiety) has its limitations in that the analysis and reporting of the findings 
creates confusion in the reporting of the results. For instance, the State Shame and 
Guilt Scale (SSGS) and the State Trait Anxiety Inventory (STAI-1), which measured 
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the same constructs as the SMERS instrument showed no evidence of significant 
improvement. In retrospect, these measures might not have been the most effective 
in assessing improvement following intervention. The SSGS and the STAI-1 are trait 
measures that assess global shame, guilt, and anxiety. In contrast, the SMERS scale 
evaluates changes in vividness of the intrusive images, and state shame, guilt and 
anxiety, that were directly associated with the intrusive images. So, for the purposes 
of the current study, it might be argued that the SMERS are the critical ones in 
relation to assessing the effectiveness of ImRs in relation to the actual images. Given 
the study was not focusing on global shame, guilt and anxiety that were not a direct 
result of an intrusive image, on reflection it might not have been necessary to include 
SSGS and STAI-1 in the study. 
 
Two patients reported that they did not feel that the single session of therapist 
administered imagery rescripting adequately prepared them to rescript intrusive 
images whilst at home, consequently they felt that they did not use imagery 
rescripting appropriately. The patients’ feedback, coupled with the view that OCD 
patients experience several intrusive images per week and each intrusive image 
requires rescripting, suggests that the single session of therapist administered ImRs 
is a limitation in this current study. Although the study considered possible risks 
associated with the study, including risks associated with the experimental 
intervention, there was no proactive routine monitoring of adverse reactions during 
the entire course of the study treatment. 
 
5.5. Study Implications and Recommendations 
It is imperative to note that the recommendations presented below are tentative, 
given that this is a single study of ImRs using a small sample that requires 
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replication. The study recommends that caution is exercised when considering the 
use of single session ImRs in OCD, since OCD patients experience more intrusive 
images than, for instance, PTSD patients (Lipton et al., 2010; Speckens et al., 2007). 
Therefore, the single session approach should only be considered if it is established 
that the intrusive images presented can be adequately addressed in the single 
session. Furthermore, using ImRs for the first time can cause distress; consequently, 
patients may become reluctant to undertake home-based ImRs. More sessions of 
ImRs are likely to facilitate a stronger therapy alliance, which will in turn likely 
promote patient active engagement in treatment and confidence in using it. It is 
therefore necessary as part of clinical practice to elicit patients’ view of the presence 
of a therapeutic relationship when contemplating ImRs in OCD. Interval evaluation of 
patients’ competence and confidence in self-administration of ImRs, including 
treatment adherence, should also be factored in the overall treatment process. For 
instance  questionnaires, treatment practice diaries and/or telephone follow-up calls 
can be used to assist in this endeavour. In addition, given the distress associated 
with ImRs, monitoring of adverse reactions in psychological treatment trials should be 
a routine practice as is done in drug trials. The design will need to be modified so as 
to accommodate increasing the number of therapy sessions in order to improve the 
intervention, for instance using the changing criterion design. According to Morley, 
Linton, & Vlaeyen (2015), when using a changing criterion design, the treatment 
should be administered in sequence and the imagery vividness response should be 
measured at the end of each set of the predetermined imagery rescripting sessions. 
If the desired changes are not achieved, the imagery rescripting sessions are then 
increased to the next predetermined level where, again, changes in imagery 
vividness are evaluated, until all the sessions are completed. 
 
 158 
The implication of utilising a single case experimental design (SCED) is that it does 
not provide a robust platform to be able to control potential artefacts that could 
account for the observed improvement, aside from the intervention. A control group 
should be factored as a result. Furthermore, SCED should not be used to investigate 
neurocognitive-based variables, given repeated use of the same neurocognitive 
measures during the course of a study results in a learning effect, and therefore 
introduces potential bias in the interpretation of the results (Basso, Bornstein & Lang 
1999; Lowe & Rabbitt 1998). Where it is necessary to utilise SCED then the 
neurocognitive tests should be varied to control the learning effect. 
 
5.6. Dissemination of the results  
The aim of undertaking the Doctorate study was to build up skills and knowledge in 
carrying out research and contributing to knowledge concerning obsessive-
compulsive disorders, the management and treatments of OCD and related spectrum 
disorders. Working in specialist service for treatment resistant OCD, at both local and 
national levels, demands being on the forefront and driving research in this field and 
disseminating research findings. Consequently an abstract for this piece of work is 
currently being prepared for submission for oral presentation/poster presentation at 
the future British Association for Behavioural and Cognitive Psychotherapy  (BABCP) 
2017 Conference, and the International College of Obsessive Compulsive Spectrum 
Disorders (ICOCS) specialist interest group meeting. 
 
5.7. Personal Reflection (The Research Log) 
I started my Doctorate research in January 2010 with the view to develop research 
skills. Throughout the study I monitored my research skills and knowledge 
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development progress using a research log. The log focused on the research cycle, 
thus, from the identification of a research topic, literature search, selection of a 
methodology, recruitment strategy, writing a research proposal, application for ethical 
and R&D approval, interview skills, data collection, results analysis, thesis writing, 
and publication. My interest in research came about following clinical experience 
where I noticed that some of the patients were not responding to treatment despite 
the treatment administered competently. Following discussion with various clinical 
colleagues it became apparent that a number of assumptions about the underpinning 
drivers for poor treatment response were being expressed. In order to understand 
more about these assumptions I sought assistance from our local hospital library with 
searching for only a couple of publications that had been suggested by a community 
of clinical practitioners with interest in obsessive compulsive and related spectrum 
disorders. One of the papers was on neuroscience with a focus on impairment in 
executive function in OCD. The other paper proposed comorbid disorders in OCD as 
possible complicating factors in the treatment of OCD. The views expressed in the 
neuroscience papers were consistent with some of my clinical practice experiences 
of OCD patients and in particular the rigidity in the thinking and behavioural 
responses. I became more interested in understanding how the rigidity and negative 
emotions impact on treatment and how these factors might be improved. I had no 
prior knowledge on neuroscience, so I self-taught through reading various books and 
journals, and consulting academic and clinical experts on neuroscience and its 
application in OCD. I became a member of various forums networks interested in the 
neuroscience of OCD for instance I joined the International College of Obsessive 
Compulsive Spectrum Disorders (ICOCS)/the communities of practice for networking, 
where my research idea/topic refined. Through these networks and academic 
supervisions my research idea gradually became much clearer. 
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I attended lectures and held discussions with fellow students to help improve my 
literature search. I spent some time learning about keyword searching and subject 
searching to improve my search rigor. Evaluating what I found was a bit daunting in 
the beginning. All the material appeared interesting and important but had to learn 
quickly about keeping relevant material for literature review purpose. I used single 
case experimental design as my research design. Initially, it was difficult to influence 
my department at work to appreciate the utility of this design because the clinical 
scientists in the department use RCT. Although I found my department’s position very 
frustrating indeed however I appreciated that their lack of understanding of the design 
and my rational for utilizing the design over the RCT was not clearly articulated I read 
a lot about the design, attended workshops as well as discussing more about the 
design with my academic supervision. My second discussion with the department 
focused in helping the department appreciate the experimental capability of the 
design including the advantages of using the design over an RCT and in particular in 
the case of the aims and objectives of my study. I must also add that because of my 
naivety in terms of using this design, I did not appreciate the huge data that this 
design generated per variable examined because of the repeated measurements of 
each variable. I was able to negotiate for an extra half a day study leave per week 
from work in order to better accommodate the demands of the study when it came to 
analyze the data. 
  
Lectures on research ethics helped a great deal to be aware of the ethical issues 
surrounding autonomy and choice particularly when recruiting patients. I ensured the 
patients did not feel undue pressure to participate by giving them ample time to read 
about the study and to consult friends and family including healthcare professionals 
e.g. their GP for further advice. I ensured I was available to answer questions when 
they needed. I found out that my ability to be flexible and innovative thinking in 
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helping problem solve the participants challenges associated with attending the clinic 
for the study largely helped the recruiting. I was able to recruit the number of 
participants planned. The application process of NHS Research Ethical approval – 
was very bureaucratic and cumbersome nonetheless I appreciated the rigor of the 
process because of the need to ensure patient’s safety and rights were at the 
forefront of everything else. The NHS ethics Committee comprised of a mixture of 
health care professionals, an expert in the field of study, patients and lay people. I 
found that by the time of attending the ethics committee my ability to articulate my 
ideas and rationale for the approach considered in the study had improved a grate 
deal. Consequently, I did not find the robust examination from the ethics committee 
about my work daunting. However, on reflection, I spoke with a fast tone of voice and 
at times I was asked by the chair of the committee to clarify for the benefit of other 
members of the committee some of the scientific/”Jargon” terms that I used. After the 
committee, I started practicing with my work colleagues, friends and family to control 
the speed and rate of the tone of my voice and to use terms that are understood by 
the audience. 
  
I had not used some of the data collection instruments particularly those that are 
used to examine executive function. I enrolled for training and learning the CANTAB 
a battery of executive function assessment tasks. I joined another community of 
practice/OCD club at the Behavioural and Neuroscience Unit in Cambridge, where 
the CANTB is most used. Patients’ engagement in data collection and ensuring that 
the data was brought back to the study centre at the predetermined points during the 
course of the study as collaboratively agreed with each participant helped maximise 
data returns.  In the study I used visual analysis, Reliable Change and Clinically 
Significance tests to analyze the results. I knew little of these analyses, and struggled 
with the analysis.  I then spent more time reading and evaluating papers that utilised 
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these analyses. I attended workshops and received additional supervision time 
including coaching from one of my academic supervisors, Dr Laura Simonds.  
  
The thesis writing was the most challenging aspect of the whole research cycle, this 
was so because of the family and personal problems that just befall me at the very 
wrong time; this coupled with high workload, meant I had to work harder to keep the 
concentration and focus going. I requested endless extensions as a result. Without 
the dedicated support, guidance and encouragement from my academic supervisors I 
don’t think I would have got this far.  
 
  
 163 
Chapter. 6 Conclusion 
  
6.1 Summary of the Findings and Contribution to Current 
Knowledge 
This study was influenced by clinical experience where observations noted that 
symptoms of Obsessive–Compulsive Disorder (OCD) sometimes do not improve 
despite being competently treated with known effective pharmacological and/or 
cognitive behavioural therapy with exposure and response prevention interventions. 
The study proposed to examine the therapeutic utility of imagery rescripting in 
treating OCD intrusive images, given reported efficacy in ameliorating both intrusive 
images and the intensity of the associated distressing emotions in disorders such as 
post-traumatic stress disorder (PTSD) (Arntz, Tiesema, & Kindt 2007), social anxiety 
(Lee, & Kwon 2013; Wild, Hackmann, & Clark 2008), shame and guilt (Grunert et al 
2003; 2007); depression (Brewin et al 2009) and its promising potential therapeutic 
utility in OCD and body dysmorphic disorder (BDD) (Veale et al  2015; Wilson, Veale 
& Freeston 2015). 
 
In summary the main conclusions regarding the hypotheses are that only one patient 
supplied evidence consistent with imagery rescripting having therapeutic potential for 
OCD images. The study demonstrated replication failure of this result across the 
other participants. It has been argued that, amongst other factors, this might be due 
to the ImRs protocol being more effective for intrusive cognitions related to trauma. 
Furthermore, there was also no conclusive evidence to suggest imagery rescripting 
had significantly changed set-shifting and motor inhibitory impairments. However, it 
has been argued that this latter result might be due to difficulty in the valid application 
of multiple neurocognitive assessments. It is concluded that further investigation is 
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required, taking into account of the study limitations and implications outlined above, 
before it is possible to make definitive conclusions about the potential effectiveness 
of ImRs for intrusive images.  
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APPENDIX 1   SCREENING PRETEST PROTOCOL 
 
STEP 1. Offer opportunity to go through the PIS and answer any questions 
STEP 2. Go through the Informed Consent Form (ICF) and ask participant to 
sign and date the consent 
STEP 3. Allocate Patient Identifying unique code 
STEP 4. Screen for: 
i. Aggression/harm, sexual and religious obsessions (YBOCS Checklist) 
ii. OCD symptoms severity with a score ≥ 17 (YBOCS) 
iii. Depression (MADRS) 
iv. Presence of excludable disorders & conditions (M.I.N.I) 
 
STEP 5. Collect Demographic Data (Demographic Data Form) 
STEP 6. Assess imageries (Intrusive Imagery Interview Questionnaires) 
 
Participant has 15 minutes break 
 
STEP 7. Participant completes self-assessment questionnaires 
i. Vividness of the imageries (SMERS-vividness) 
ii. Shame state (SMERS-shame & SSGS) 
iii. Guilt state (SMERS-guilt & SSGS) 
iv. Anxiety state (SMERS-anxiety & STA-I state) 
v. Depression (MADRS) 
vi. Presence of the study excluded disorders & conditions (M.I.N.I) 
 
STEP 8. Neurocognitive Assessment Tests 
i. Warm up exercise (CANTAB - MOT task) 
ii. Measure of Response inhibition (CANTAB – SST task) 
iii. Training exercise before IED set shift test (CANTAB – BLC task) 
iv. Rule acquisition & reversal/attentional set shifting (CANTAB – IED 
task) 
 
 
STEP 9. Patient Randomization 
i. Follow the Procedure for the Random Assignment to the Pre-test Data 
Collection Period (Appendix 26) 
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STEP 10. Patient is given self-assessment questionnaires to collect daily pre-test 
data for the duration allocated through randomization. 
 
STEP 11. Study Recruitment Adherence Protocol Flowchart: 
 
 
 
 
  
 NHS REC Ref: 13/EE/0101 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment	
An	 invite	 letter	 &	 Participant	
Information	Sheet	(PIS)	are	given	out	
to	patients	 that	have	been	 identified	
through	case	notes	or	during	routine	
psychiatric	clinic	to	have	harm,	sex	or	
religious	obsessions.	
WEEK3-4:	Visit	3	(1	week	follow-up)	
	
Post-test	Interviews	
- IED	and	SST	tests		
- YBOCS,	SSGS,	STA-I,	MADRS	
- Repeated	Subjective	Measures	of	
Emotion	(SMERS)	
Data	Analysis:	
- Visual	Graphed	Data	Analysis	
- Tau-U	Effect	Size	Calculation	
- Clinical	 Significance	 and	
Reliable	Change	Calculations	
WEEK2-3:	Visit	2	(in	7,	10,	14days	of	Visit	1)	
	
Pre-Test	score	Interviews	
- IED	and	SST	tests		
- YBOCS,	SSGS,	STA-I,	MADRS	
- Repeated	 Subjective	 Measures	 of	
Emotion	(SMERS)	
The	Treatment	
- Intervention	per	Treatment	Protocol		
	
Follow-up	Tel	call	
Participants	 are	 given	
up	 to	 48hrs	 to	 make	 a	
decision	before	a	tel-call	
is	made	by	the	CI.	
Responders	
Non-Responders	
Establish	 interest:	 2nd	 follow	 up	
Tel	call	5	days	post	the	invitation	
WEEK1:	Visit	1:	
Eligibility	&	Pre-test	Interview	
- Signing	 consent	 form;	 demographic	 data	 collection;	 the	 MINI,		
Imagery	Interview;	Cognitive	Inflexibility	(IED	&	SST)		
	
- Eligibility	 of:	 OCD	 severity	 ≥	 17	 (YBOCs);	 State	 Shame	 (SSGS);	
Depression	(MADRS)	
	
- 6	participants	randomised	to	7days,	10days,	14days	treatment	start	
date	
	
- Repeated	pre-tests	done	daily	at	home	for	 	7days,	10days,	14days	
according	to	the	participant’s	randomised	group	
Non-Responders	&	
Decliners	
No	further	action	
Interested	
Invite	 to	 the	 first	 visit	 for	 eligibility	
assessment.	
Declined	
Unsuitable		
Excluded	
Screening	
Adults	aged	18-65years	
under	 the	 care	 of	 the	
OCD	Clinic	or	the	CMHT	
will	 be	 screened	 for	
harm,	 sex	 or	 religious	
obsessions	 either	 by:	
(1).	 psychiatrists	 in	
person	 using	 YBOC	
checklist;	
(2).	 Chief	 Investigator	
using	care	notes.	
WEEK5-6:	Visit	4	(3	weeks	follow-up)	
	
Post-test	Interviews	
- IED	and	SST	tests	
- YBOCS,	SSGS,	STA-I,	MADRS	
- Repeated	Subjective	Measures	of	
Emotion	(SMERS)	
WEEK11-12:	Visit	6	(9	weeks	follow-up)	
	
Post-test	Interviews	
- IED	and	SST	tests	
- YBOCS,	SSGS,	STA-I,		MADRS	
- Repeated	 Subjective	 Measures	 of	
Emotion	(SMERS)	
	
***Study	Ends***	
WEEK8-9:	Visit	5	(6	weeks	follow-up)	
	
Post-test	Interviews	
- IED	and	SST	tests	
- YBOCS,	SSGS,	STA-I,		MADRS	
- Repeated	Subjective	Measures	of	
Emotion	(SMERS)	
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APPENDIX 2   PARTICIPANT INVITATION LETTER 
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APPENDIX 3   PARTICIPANT INFORMATION SHEET V2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Why have I been invited to take part in the study? 
You have been chosen because we are looking for individuals who have a diagnosis 
of OCD. We are approaching you because you were referred to the OCD Specialist 
Clinic. 
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Do I have to take part? 
No, you do not have to take part. It is entirely your decision whether you wish to 
participate or not. The care you receive will not be affected if you decide not to 
participate. To help you decide we will describe the study and go through this 
information sheet with you. We will give you time to make your own decision.  
 
What will happen to me if I take part? 
If you agree to participate this is what will happen: 
1. You will be invited to attend the first of six visits at the OCD Outpatient Clinic, 
QEII Hospital. At the first meeting, your suitability to take part in the study will 
be assessed. At this meeting, we will ask you about the obsessional images 
you have and we will measure your OCD symptoms, shame, cognitive 
inflexibility, anxiety, depression and other emotions. We will use a 
combination of questionnaire interviews and computer based assessment 
tasks. We expect the interview to take up to 2 hours. We will also explain the 
study and answer your questions. If you decide you want to take part, we will 
ask you to read and sign a consent form. At the end of this meeting, you will 
be randomly allocated to one of the three groups. You will then be given a 
questionnaire to take home and complete 5 times daily. Depending on the 
group you are allocated, you will complete the questionnaire daily for 7 days, 
10 days or 14 days. The questionnaire takes no more than 5 minutes to 
complete. 
 
2. You will then attend the clinic for a second visit for the Imagery Rescripting 
treatment. You will be asked to complete the questionnaires that you did in 
the first visit. Then you will be given 90 minute Imagery Rescripting treatment 
session. This visit including treatment is expected to take up to 2.5hours. 
 
3. At home we will ask you to complete a questionnaire 5 times daily for 7 days. 
This should take 5 minutes each time. You will then be asked to attend the 
clinic, for your third visit, seven days (one week) after the second visit.  During 
the meeting you will be asked to hand in all the questionnaires you had 
completed at home. Then you will complete the questionnaires that you did in 
the first visit. We expect this visit to take no more than 90 minutes to 
complete. 
 205 
 
4. We will then invite you attend the clinic for your fourth visit. This visit will take 
place three weeks after the second visit. We will again ask you to complete 
the questionnaires that you did in the first visit. The meeting will take no more 
than 90 minutes to complete. 
 
5. Your fifth visit to the clinic where you will complete the same questionnaires 
that you did in previous visits will take place six weeks after the second visit. 
 
6. You will then be invited to attend your sixth visit to the clinic to complete the 
same questionnaires you had completed in previous visits. This will be your 
final visit to the clinic and the visit will take place nine weeks since attending 
your second visit. The meeting will take no more than 90 minutes to complete. 
The entire study is expected to last for 12 weeks. 
 
What will Imagery Rescripting procedure involve? 
The treatment program lasts 90 minutes and involves you focussing images that you 
find distressing. Each image will be treated in turn following the procedure below.  
1. Patient’s description of the images and their impact. 
2. Education about the nature and meaning of the images 
3. Description of the treatment process 
4. Imaginary exposure of image for 3mins, with eyes closed describing in present tense the 
experience.  
5. Imagery rescripting for 3mins is undertaken with eyes remaining closed. The participant 
spends the time altering the disturbing aspects of the image in a way they would like it to 
be. The therapist writes down the description. 
6. The Altered Image is then held in the participant’s mind for 3mins so as to achieve a more 
satisfying outcome. 
 
(Note: Phase 2 is repeated 3 times. Where a participant has several intrusive images 
they will be asked to apply imagery rescripting to each of the images) 
7. Cognitive Restructuring - In this final phase of the treatment, the therapist uses various 
cognitive therapy techniques to help the patient enhance the alternative ways of making 
sense of the images. 
 
What will I have to do? 
If you would like to take part please contact me, (Chief Investigator), on +44 (0)1707 
224409 or by email on D.Mpavaenda@surrey.ac.uk or 
davis.mpavaenda@hpft.nhs.uk. I will also contact you within 48 hours of receiving 
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this information sheet to establish your decision and assist you with arranging your 
first appointment where you indicate interest to participate.  
 
What are the possible disadvantages or risks of taking part? 
To our knowledge, there are no known unacceptable risks associated with imagery 
rescripting. However, you may experience raised level of distress during the 
treatment. This effect is to be expected and is usually short lived. If you do not wish 
to continue for any reason, remember that you can withdraw from the study at any 
time. Also during the 12-week treatment study you will not be able to change 
medication or commence other forms of intervention; otherwise you will need to be 
withdrawn from the study.  
 
What are the possible benefits of taking part? 
You are unlikely to benefit directly from this study as we are trying to understand how 
things work.  However, it is hoped that this research will contribute to the 
development of a larger research project that will examine the benefits of Imagery 
rescripting in OCD.  
 
What happens when the research study stops? 
Imagery rescripting will not be offered at the end of this study. Also those who are on 
medication will continue to receive their medication and reviewed regularly by their 
consultant psychiatrist. Additionally, all participants will be offered a full course of 
group CBT for OCD if you wish. When data from the research is collected, it will be 
analysed and written up for publication in a journal. The results may also be 
presented at research meetings, or in talks at academic institutions. All data will be 
anonymised before analysed. The results will always be presented in such a way that 
data from individual volunteers cannot be identified. You will also receive a summary 
of the research findings if you would like one. 
 
What if there is a problem? 
Any complaint or concern about any aspect of the way you have been dealt with 
during the course of the study will be addressed by contacting Dr Ann Gallagher and 
to Patient Advice and Liaison Service (PALS) using the details provided below. 
 
Dr Ann Gallagher (Reader in Nursing Ethics) 
Director, International Centre for Nursing Ethics & Editor, Nursing Ethics 
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School of Health and Social Care 
Faculty of Health and Medical Sciences 
University of Surrey, Guildford, Surrey, GU2 7TE 
T: +44 (0)1483 689462. 
Email: A.Gallagher@surrey.ac.uk 
  
PALS and Complaints Department 
HPFT NHS Foundation Trust 
99 Waverley Road 
St Albans, Herts, AL3 5BR 
Tel: +44 (0)1727 804629 
 
Are there compensation arrangements if something goes wrong? 
In the unlikely event of anything untoward happening, the University of Surrey 
arranged Public Liability Insurance cover for negligent and non-negligent harm to 
volunteer research participants. The contact person is Mrs Nicky Routh (Insurance 
Officer), Tel: +44 (0)1483 689008 and email: n.routh@surrey.ac.uk. 
 
Will my taking part in the study be kept confidential? 
All research data will be anonymised and your name will not appear in any reports or 
publications. Data will be kept securely and will be handled in compliance with 
relevant UK statutory and Data protection laws (Data Protection Act 1998). You will 
be assigned a code number and only members of the research team and the clinical 
team responsible for your care will have access to the data. Confidentiality will be 
maintained in accord with the guidelines in professional codes, that is, information 
would not be shared without consent unless it is considered that you or someone 
else is at risk of significant harm. 
 
Research data will be stored for 10 years after the end of the study, using subject 
codes to ensure anonymity. All inquiries concerning access to data held should be 
addressed to me as the chief investigator. 
 
Who is organising and funding the research? 
This study is being organised and sponsored by the University of Surrey. The contact 
person is: 
 
 208 
Ms Alison Cummings 
University of Surrey 
University Ethics Committee 
Registry, Senate House, Floor 5 
University of Surrey, Guildford 
Surrey, GU2 7XH 
       
+44 (0)1483 689035 
Email: a.cummings@surrey.ac.uk. 
 
Who has reviewed the project? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. The 
study has also been reviewed and received a favourable opinion from 
Cambridgeshire Region NHS Research Ethics Committee and also by the University 
of Surrey Ethics Committee. 
 
Thank you for considering taking part in this study. If you require any further 
information, we will be pleased to help you in any way we can. 
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APPENDIX 4   INFORMED CONSENT FORM 
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APPENDIX 5   DEMOGRAPHIC DATA SHEET V2 
  NHS REC Ref: 13/EE/0101
Date	of	Visit:
18	-	35 46	-	55
36	-	45 56	-	65
Male
Female
Not	stated
S White
M A British
D B Irish
W C Any	other	White	background
P Mixed
N D White	and	Black	Caribbean
E White	and	Black	African
F White	and	Asian
None G Any	other	mixed	background
O	level/GCSE	or	equivalent
A	level	or	equivalent H Indian
Certificate	of	higher	education/HND/HNC J Pakistani
Bachelors	degree	or	equivalent K Bangladeshi
Masters	degree	or	equivalent L Any	other	Asian	background
Doctoral
M Caribbean
N African
1 P Any	other	Black	background
2
3 Students	 R
4 S Any	other	ethnic	group
5
6 Z
7
8
ZZ
Harm Moderate
Religious Severe
Sexual Extreme
Duration	of	OCD: Pre-treatment	Level	of	Functioning:
<1yr Work
1	to	4yrs	11months Social
5	to	9yrs	11months Family
10yrs	and	more Leisure
Not	receiving	benefits	and	Not	
Living:
Ethinicity:
Education	Level:
Alone
With	others
Age	Band:
Asian	or	Asian	British
Demographic		Data	Sheet
Employed
Unemployed	and	Seeking	Work
Receiving	Benefit,	or	Employment	
and	Support	Allowance
Married/Civil	Partner
Divorced/Person	whose	Civil	
Partnership	has	been	dissolved
Widowed/Surviving	Civil	Partner
Separated
Interviewer:
Chief	Investigator:
Type	of	Obsessions:
Gender:
Patient	Identification	Number:
Employment	Status:
Marital	Status:
Not	stated
Chinese
Other	Ethnic	Groups
Symptom	Severity:
Black	or	Black	British
Not	Stated	
Single
Unpaid	voluntary	work
Retired
Not	disclosed
Homemaker	
 211 
 
APPENDIX 6   M.I.N.I. QUESTIONNAIRE – DSM-IV 
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APPENDIX 7   YBOCS CHECKLIST 
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APPENDIX 8   YBOCS SCALE 
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APPENDIX 9   INTRUSIVE IMAGERY INTERVIEW SCHEDULE 
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APPENDIX 10   STATE SHAME GUILT SCALE (SSGS) 
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APPENDIX 11   MONTGOMERY-ASBERG DEPRESSION RATING 
SCALE 
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APPENDIX 12   STAI-1 (STATE ANXIETY) QUESTIONNAIRE 
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APPENDIX 13   SMERS QUESTIONNAIRE 
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APPENDIX 14   RISK ASSESSMENT 
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APPENDIX 15   ZURICH MUNICIPAL INDEMNITY CERTIFICATE 
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APPENDIX 16   ESSENTIAL GOOD CLINICAL PRACTICE 
CERTIFICATE 
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APPENDIX 17   PRINCIPAL INVESTIGATOR - CV 
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APPENDIX 18   TREATMENT PROTOCOL 
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APPENDIX 19   APPLICATION FOR RESEARCH SPONSORSHIP 
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APPENDIX 20   RESEARCH SPONSORSHIP CONFIRMATION 
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APPENDIX 21   NRES ETHICS REVIEW BOOKING CONFIRMATION 
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APPENDIX 22   NRES PROVISIONAL ETHICAL OPINION 
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APPENDIX 23   NRES CONFIRMATION OF ETHICAL OPINION 
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APPENDIX 24   UNIVERSITY OF SURREY CONFIRMATION OF                            
ETHICAL OPINION 
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APPENDIX 25   NHS R&D 
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APPENDIX 26    RANDOMISATION PROCEDURE 
 
Random Number Tables  
Reproduced from Million Random Digits, used with permission of the Rand Corporation, 
Copyright, 1955, The Free Press. The publication is available for free on the Internet at 
http://www.rand.org/publications/classics/randomdigits.  
All of the sampling plans presented in this handbook are based on the assumption that the 
packages constituting the sample are chosen at random from the inspection lot. Randomness 
in this instance means that every package in the lot has an equal chance of being selected as 
part of the sample. It does not matter what other packages have already been chosen, what 
the package net contents are, or where the package is located in the lot.  
To obtain a random sample, two steps are necessary. First it is necessary to identify each 
package in the lot of packages with a specific number whether on the shelf, in the warehouse, 
or coming off the packaging line. Then it is necessary to obtain a series of random numbers. 
These random numbers indicate exactly which packages in the lot shall be taken for the 
sample.  
The Random Number Table  
The random number tables in Appendix B are composed of the digits from 0 through 9, with 
approximately equal frequency of occurrence. This appendix consists of 8 pages. On each 
page digits are printed in blocks of five columns and blocks of five rows. The printing of the 
table in blocks is intended only to make it easier to locate specific columns and rows.  
Random Starting Place  
Starting Page. The Random Digit pages numbered B-2 through B-8. You can use the day of 
the week to determine the starting page or use the first page for the first lot you test in a 
location, the second page for the second lot and so on moving to the following page for each 
new lot.  
Starting Column and Row. You may choose a starting page in the random number table and 
with eyes closed, drop a pencil anywhere on the page to indicate a starting place in the table.  
For example, assume that testing takes place on the 3rd day of the week. Start with Table 3 
of Appendix B. Assume you dropped your pencil on the page and it has indicated a starting 
place at column 22, row 45. That number is 1.  
If 1-digit random numbers are needed, record them, going down the column to the bottom of 
the page and then to the top of the next column, and so on. Ignore duplicates and record zero 
(0) as ten (10). Following on from the last example, these numbers are 3, 2, 9, 8, etc. If two-
digit random numbers are needed, rule off the pages, and further pages if necessary, in 
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columns of two digits each. If there is a single column left on the page, ignore this column, 
and rule the next page in columns of two. Again, ignore duplicate numbers and record 00 as 
100. For example, using the same starting place as in the last example (Table 3, column 22, 
row 45), the recorded two-digit recorded numbers would be 11, 34, 26, 95, etc. When three-
digit numbers are needed, rule the page in columns of three. Record 000 as 1000. Starting on 
Table 3, column 22, row 45, the recorded numbers would be 119, 346, 269, 959, etc.  
 
 
Random Assignment for the Current Study to Varying Baseline Length Groups 
 
 
Table 6 - Random Digits (see Appendix 27) 
The random table was obtained from: http://www.rand.org/publications/classics/randomdigits 
 
1. The random number table used was chosen out of seven tables, by matching the 
table number to the number of participants in the study (n = 6). Table 6 was used. 
2. The 500 numbers in the table are spread across 10 columns. 
3. Each number is made up of 5 digits. 
 
Random Starting Place 
The random starting place in Table 6 is determined by the following equation: 
 
Starting Place = Date day of the first screening appointment + Calendar week number 
Number of participants for screening on the date 
 
The equation answer rounded up to the nearest 10 is the starting point for selecting the first 
random number to be used, going down along the columns. 
 
Random Assignment of Participant to Baseline Data Period 
• The pretest data collection periods are: 7 days, 10 days, and 14 days. 
• The pretest data have pre-determined odd and even combination numbers as follows: 
The first odd or even number in the combination is drawn from the last digit of the 
selected 5 digit random number; 
The second odd or even number in the combination is drawn from the last digit of the 
total aggregate of the 5 digits of the selected random number above. 
 
Example: 
1. The selected 5 digit random number is 21644 and it is an Even number 
2. The total aggregate of this random number is 17 and it is an Odd number 
3. The combination of these two numbers is 21644/17 = Even/Odd 
4. The participant is then assigned to the Pretest Data Collection period that matches 
this combination. 
 
Varying Baseline Length Groups 
7 Days 10 Days 14 Days 
Odd/Even Odd/Odd or Even/Even Even/Odd 
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APPENDIX 27    RANDOM DIGITS 
 
TABLE 6  
96195   07059   13266   31389   87612   88004   31843   83469   22793   14312 
22408   94958   19095   58035   43831   32354   83946   57964   70404   32017 
53896   23508   16227   56929   74329   12264   26047   66844   47383   42202 
22565   02475   00258   79018   70090   37914   27755   00872   71553   56684 
49438   20772   60846   69732   07612   70474   46483   21053   95475   53448 
 
65620   34684   00210   04863   01373   19978   61682   69315   46766   83768 
20246   26941   41298   04763   19769   25865   95937   03545   93561   73871 
09433   09167   35166   32731   73299   41137   37328   28301   61629   05040 
95552   73456   16578   88140   80059   50296   07656   01396   83099   09718 
76053   05150   69125   69442   16509   03495   26427   58780   27576   31342 
 
34822   35843   78468   82380   52313   71070   71273   10768   86101   51474 
07753   04073   58520   80022   28185   16432   86909   82347   10548   83929 
04204   94434   62798   81902   29977   57258   87826   35003   46449   76636 
96770   19440   29700   42093   64369   69176   29732   37389   34054   28680 
65989   62843   10917   34458   81936   84775   39415   10622   36102   16753 
 
06644   94784   66995   61812   54215   01336   75887   57685   66114   76984 
88950   46077   34651   12038   87914   20785   39705   73898   12318   78334 
21482   95422   02002   33671   46764   50527   46276   77570   68457   62199 
55137   61039   02006   69913   11291   87215   89991   26003   55271   08153 
98441   81529   59607   65225   49051   28328   85535   37003   87211   10204  
 
57168   30458   23892   07825   53447   53511   09315   42552   43135   57892 
71886   65334   38013   09379   83976   42441   14086   33197   82671   05037 
40418   59504   52383   07232   14179   59693   37668   26689   93865   78925 
28833   76661   47277   92935   63193   94862   60560   72484   29755   40894 
37883   62124   62199   49542   55083   20575   44636   92282   52105   77664 
 
44882   33592   66234   13821   86342   00135   87938   57995   34157   99858 
19082   13873   07184   21566   95320   28968   31911   06288   77271   76171 
45316   29283   89318   55806   89338   79231   91545   55477   19552   03471 
22788   55433   31188   74882   44858   69655   08096   70982   61300   23792 
08293   86193   05026   21255   63082   92946   28748   25423   45282   57821 
 
29223   70541   67115   84584   10100   33854   26466   77796   70698   99393 
22681   80110   31595   09246   39147   11158   43298   36220   88841   11271 
74580   90354   43744   22178   38084   60027   24201   71686   59767   33274 
69093   71364   08107   96952   50005   30297   97417   89575   04676   35616 
40456   91234   58090   65342   95002   28447   21700   43137   13746   85959  
 
 261 
72927   67349   83962   58912   59734   76323   02913   46306   53956   38936 
61869   33093   81129   06481   89281   83629   81960   63704   56329   10357 
40048   16520   07638   10797   22270   57350   72214   36410   95526   87614 
68773   97669   28656   89938   12917   25630   08068   19445   76250   24727 
09774   30751   49740   11385   91468   28900   76804   52460   52320   70493 
 
46139   36689   82587   13586   35061   76128   38568   62300   43439   53434 
26566   95323   32993   89988   12152   01862   93113   33875   31730   62941 
06765   57141   48617   18282   13086   76064   83334   70192   15972   80429 
35384   90380   12317   89702   33091   68835   62960   38010   52710   87604 
49333   78482   36199   11355   86044   88760   03724   22927   91716   92332 
 
45595   14044   56806   99126   85584   87750   78149   22723   48245   78126 
79819   15054   76174   12206   06886   06814   43285   20008   75345   19779 
11971   62234   74857   46401   20817   57591   41189   49604   29604   30660 
11452   89318   53084   21993   62471   74101   61217   76536   58393   63718 
38746   81271   96260   98137   60275   22647   33103   50090   29395   10016 
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APPENDIX 28   TAU-U CALCULATOR 
 
 
Figure 3 is a pictorial description of the Vannest et al. (2011) web-based Tau-U 
calculator, which is followed by a set of instructions on how to input the raw data onto 
the calculator. 
 
Tau-U Calculator                    
 
 
 
          
 
Results 
 
 
 
 Id Label S PAIRS TAU TAUb VARs SD SDtau Z P 
Value 
CI 
85% 
CI 
90% 
trend: 
 - - - - - - - - - - - - -  
phase:  
 - - - - - - - - - - - - -  
corrected baseline: 
 - - - - - - - - - - - - -  
combined: 
 - - - - - - - - - - - - -  
 
Weighted Average 
 
Label Tau Var-Tau Z P-Value CI 85% CI 90% CI 95% 
- - - - - - - - 
 
Figure 3. Tau-U Calculator and Instructions (Source: Vannest et al. 2011). 
 
	contrast 	 correct	baseline	
BL-1 	 Int-1 	 BL-2 	 Int-2 	 BL-3 	 Int-3 	 BL-4 	 Int-4 	 BL-5 	 Int-5 	
chart 	 clear	all	
	 combine	 to	weighted	 remove	 clear	all	 download	all	
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i. Data are input in up to ten algorithm columns at the top part of the calculator, 
each headed by a label box (e.g. BL-1) and an adjacent                                                                                                                                                                                                                                                                                                                                                         
selection check box. 
ii. Input data from just one phase in each algorithm column, and label each 
phase above, e.g. BL-1, Int-1, FU-1, etc. 
iii. Select only two phases for a first contrast. Select by checking beside a label. 
In each contrast the baseline phase (BL) is to the left, and treatment phase 
(Int) to the right. 
iv. When the “Contrast” button is clicked, the results for that contrast will be 
provided directly below. Where the baseline requires correcting, the “correct 
baseline” button should be checked prior to the Contrast. In that case the 
results will reflect control of confounding baseline trend. 
v. Steps III and IV should be repeated until all phase contrasts for all the 
participants are completed. 
vi. To combine contrasts for a single design, use the check boxes to the left of 
their results (left of “id”), near the middle of the page. Select as many contrast 
results as desired. Then click “Combine” button below. Combined Tau-U 
effect sizes are weighted averages, where weights are the inverse of their 
variances. The combined SDTau is the square root of the sum of Tau 
variances involved. 
vii. The final “to weighted average” button permits any combination of individual 
contrasts or combined contrasts, by first checking them above. The 
combination algorithms are the same as in step VI.  
 
Since the current study used multiple baseline design, in addition to calculating the 
Tau-U effect size for each baseline-intervention phase contrast, the overall effect size 
for the variable of interest is also calculated by averaging the Tau-U effect size 
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scores across the participants and is presented as weighted average in the Tau 
column (Fig. 3; Vannest et al. 2011). The calculated Tau-U effect size scores range 
from 0% to 100%, where higher scores represent a greater intervention effect, and an 
ineffective/less effective intervention shows a lower score (Rakap 2015).  
 
 
 
APPENDIX 29    PARTICIPANT P1 RAW DATA 
 
 
 
 
Table 6              Table 7
  
              
 
 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 10 10
2 9 10 10 9.3
3 9.6 10 10 10
4 9.7 10 10 10
5 10 10 10 10
6 9 9.5 10 9.5
7 9.8 9.2 9.8 9.2
8 8.8 8.6 9.2 8.2
9 6.6 5.8 7 6.6
10 4.6 4.8 6.4 4.4
11 6.8 6.4 6.6 6.8
12 10 10 10 10
13 9.8 9.4 9.8 9.6
14 8.4 7.4 8.6 8.4
15 6.2 5.8 6.8 6.8
16 10 7 9 9
17 10 10 10 10
18 10 9 10 7
19 9.7 9.3 9 9
20 8 9.4 7.6
21 9.8 9.2 9.4 9.2
22 9.8 9.2 9.2 8.8
23 9.4 9 9 8
24 9 7.8 7.5 9.3
25 9.2 7.6 8.2 9.2
26 9 7 7 8
27 7 10 10 7
28
29
Participant	P1	SMERS	Scales
Days
Vividness¹ Shame¹ Guilt¹ Anxiety¹
BL Int F/U BL Int F/U BL Int F/U
1 18 25 66
2 19 21 69
3 21 25 76
4 18 23 73
5 14 21 68
6 17 25 71
7 17 24 70
8 14 23 68
9 9.2 15 61
10 6.8 13 59
11 9.8 16 63
12 20 25 79
13 18 24 78
14 17 22 73
15 13 18 68
16 16 24 74
17
18
19 17 23 75
20 14 21 68
21 17 25 77
22 13 19 71
23 9.8 15 67
24 15 22 80
25 15 23 73
26 13 21 70
27 25 25 67
28
29
Participant	P1	SSGS	and	STAI	Scales
Days
SSGS	Shame² SSGS	Guilt² STAI	Anxiety²
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APPENDIX 30   PARTICIPANT P3 RAW DATA 
 
 
 
 
 
 
 
 
Table 10              Table 11 
   
 
 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 7 6 8 7
2 4.5 4 5 6
3
4
5 5.3 5 5.5 6.3
6 7 7 7 7
7 7 6.3 6 6.3
8 6.7 5 5.3 5.7
9 8 6 7 7
10 	
11 	
12 4 4 4 5 	
13 4.7 5 4.7 4.7 	
14 7 6 7 8
15 7 7 8 4
16 7 1 1 1
17
18 6.5 4 4.5 5.5
19
20
21 6 5 6 4
22 5.5 5 5 5.8
23 6 4.3 5.3 6
24 7 5 7 7
25 5 5 7 6
26
27
28
29
Participant	P3	SMERS	Scales
Days
Vividness¹ Shame¹ Guilt¹ Anxiety¹
BL Int F/U BL Int F/U BL Int F/U
1 6 9 37
2 6.3 7.7 41
3
4
5 10 13 56
6 12 15 56
7 9.3 12 47
8 9.3 12 50
9 12 15 59
10
11
12 9 13 50
13 8.7 12 52
14 12 15 56
15
16
17
18 7.5 9.5 43
19
20
21 9 10 45
22 7.8 9.5 48
23 7 10 49
24 7 12 53
25 7 10 42
26
27
28
29
Participant	P3	SSGS	and	STAI	Scales
Days
SSGS	Shame² SSGS	Guilt² STAI	Anxiety²
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APPENDIX 31   PARTICIPANT P4 RAW DATA 
  
 
 
 
 
Table 14              Table 15 
   
    
 
 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 10 10
2 10 9.5 9 10
3 7.2 8.6 8.6 8.8
4 7.4 8.4 8.4 8.6
5 7.6 9 9 8.6
6 5 5.8 6 6.2
7 10 10 10 10
8 10 10 10 10
9 9 8.8 8.8 9
10 6.4 6.8 7.2 7.4
11 9.8 9.4 9.8 9.8
12 10 9.9 10 10
13 10 10 10 10
14 10 10 10 9
15 5 4 4 4
16 10 10 10 9
17 10 10 10 9.8
18 8.6 9 9.8 8
19 8.2 8.8 9.4 7.8
20 7.6 8.6 9 7.6
21 7.8 8.8 9 8
22 9.2 10 10 9.6
23 8 9 9 8
24 8 9 9 9
25 9 10 10 10
26 8 9 9 8
27
28
29
Participant	P4	SMERS	Scales
Days
Vividness¹ Shame¹ Guilt¹ Anxiety¹
BL Int F/U BL Int F/U BL Int F/U
1 18 25 48
2 70
3 18 24 63
4 63
5 22 25 71
6 16 19 60
7 25 25 79
8 25 25 79
9 23 24 74
10 18 19 62
11 22 24 73
12 24 25 77
13 25 25 78
14
15
16 17 25 64
17 23 25 77
18 24 25 77
19 23 25 72
20 23 25 72
21 24 25 75
22 24 24 76
23 19 25 66
24 18 25 68
25 23 25 73
26 20 24 71
27
28
29
Participant	P4	SSGS	and	STAI	Scales
Days
SSGS	Shame² SSGS	Guilt² STAI	Anxiety²
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APPENDIX 32   PARTICIPANT P5 RAW DATA 
 
 
 
 
 
 
 
 
Table 18              Table 19 
   
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 10 10
2 8.7 10 9.3 7.3
3 7.8 10 9.6 7.4
4 7.8 9.6 9.6 6.6
5 8 9.6 9.6 6
6 8 8.6 7.4 5.4
7 9.2 9.8 8.8 5.6
8 9.4 9.6 9 7
9 9.2 9.8 9 6.8
10 10 10 9.8 7.4
11 10 10 10 7.8
12 9.8 10 10 8
13 9.8 9.6 9.4 8.4
14 9.6 10 9.8 8
15 9 9 9 9
16 9 10 9 8
17 10 10 10 9
18 10 9 8 7
19 9 8 6 8
20 9 9 8.2 7.2
21 9 9.4 9.2 8
22 9.2 9.2 9 8.2
23 9.2 9.4 9 8.4
24 9.4 9.6 9.2 8.4
25 9.4 9.8 9.2 8.4
26 8 9 8 6
27 9 9 8 8
28 9 9 9 10
29 8 8 8 8
Participant	P5	SMERS	Scales
Days
Vividness¹ Shame¹ Guilt¹ Anxiety¹
BL Int F/U BL Int F/U BL Int F/U
1 22 19 55
2 18 19 66
3 18 20 70
4 17 20 65
5 17 19 64
6 17 20 68
7 18 21 69
8 18 21 70
9 18 21 70
10 19 22 72
11 21 23 73
12 20 23 79
13 20 22 72
14 19 21 70
15 19 20 70
16 20 22 71
17
18
19 19 21 69
20 19 21 69
21 19 22 70
22 21 23 72
23 20 22 70
24 20 22 72
25 20 22 73
26 13 16 65
27 19 20 71
28 18 23 71
29 17 20 71
Participant	P5	SSGS	and	STAI	Scales
Days
SSGS	Shame² SSGS	Guilt² STAI	Anxiety²
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APPENDIX 33   PARTICIPANT P6 RAW DATA 
 
 
 
 
 
 
 
Table 22            Table 23 
  
        
 270 
APPENDIX 34   MBD ACROSS PARTICIPANT SMERS VIVIDNESS1 RAW 
DATA      
 
 
Table 25       
 
 
 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 7 10 10
2 10 10 4.5 9 8.7
3 9 7 10 7.8
4 9 7 10 7.8
5 8 8 5.3 10 8
6 9 5 7 9 8
7 7 10 7 10 9.2
8 9 10 6.7 9 9.4
9 7 9 8 7 9.2
10 10 6 5 10
11 3 10 7 10
12 8.7 10 4 10 9.8
13 7.4 10 4.7 10 9.8
14 4.2 10 7 8 9.6
15 4.2 5 7 6 9
16 4.4 10 7 10 9
17 5.4 10 10 10
18 6.4 9 6.5 10 10
19 10 8 9.7 9
20 7 8 9
21 6 8 6 9.8 9
22 1 9 5.5 9.8 9
23 8 6 9.4 9
24 8 7 9 9
25 9 5 9.2 9
26 8 9 8
27 7 9
28 9
29 8
SMERS*Vividness¹
P5
Days
P6 P4 P3 P1
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APPENDIX 34A MBD ACROSS PARTICIPANTS SMERS VIVIDNESS1  
GRAPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
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APPENDIX 34B MBD TAU-U SMERS VIVIDNESS1 WEIGHTED AVERAGE  
 
 
 
 
 
 
Table 26  Tau-U Weighted Average SMERS Vividness1  
 
 
 
 
 
 
 
 
 
 
 
 
  
Participant Baseline Tau-U
Intervention 
vs Baseline 
Tau-U
z SDtau p value + 85%CI
P6 -0.3333 -0.7500 0.2528 p=0.003 (-1.114<>-0.386)
P4 0.1758 -0.1964 0.2315 p=0.3961 (-0.53<>0.137)
P3 0.0909 -0.1169 0.2868 p=0.6836 (-0.53<>0.296)
P1 -0.0735 0.0392 0.2425 p=0.8715 (-0.31<>0.388)
P5 0.3015 -0.1569 0.2214 p=0.4786 (-0.476<>0.162)
Weighted average -0.2338 -2.1079 p=0.0350 (-0.4512<>-0.0164) 95%CI 
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APPENDIX 35   MBD ACROSS PARTICIPANTS SMERS SHAME1 RAW DATA 
 
Table 27      
    
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 6 10 10
2 10 10 4 10 10
3 10 9 10 10
4 10 8 10 9.6
5 10 9 5 10 9.6
6 10 6 7 10 8.6
7 9 10 6.3 9 9.8
8 10 10 5 9 9.6
9 7 9 6 6 9.8
10 10 7 5 10
11 1 9 6 10
12 9.7 10 4 10 10
13 8.2 10 5 9 9.6
14 5.6 10 6 7 10
15 5.2 4 7 6 9
16 6.2 10 1 7 10
17 7 10 10 10
18 5.6 9 4 9 9
19 4 9 9.3 8
20 9 9 8 9
21 5 9 5 9.2 9
22 1 10 5 9.2 9
23 9 4.3 9 9
24 9 5 7.8 10
25 10 5 7.6 10
26 9 7 9
27 10 9
28 9
29 8
Days
P6 P4 P3 P1 P5
SMERS	Shame¹
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APPENDIX 35A MBD ACROSS PARTICIPANTS SMERS SHAME1 GRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases  
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APPENDIX 35B MBD TAU-U SMERS SHAME1 WEIGHTED AVERAGE 
 
 
 
 
 
Table 28    Tau-U Weighted Average SMERS Shame1 
 
 
Participant
Baseline	
Tau-U
Intervention	vs	
Baseline	Tau-U
z SD	Tau-U p	value	+	85%CI
P6 -0.2444 -0.925 0.2528 p=0.0003	(-1.289<>-0.561)
P4 0.1648 -0.0417 0.2315 p=0.8571	(-0.375<>0.292)
P3 0.1273 -0.5584 0.2868 p=0.0515	(-0.971<>-0.145)
P1 -0.3824 -0.1412 0.2343 p=0.5468	(-0.479<>0.196)
P5 0.0662 -0.7598 0.2214 p=0.0006	(-1.079<>-0.441)
Weighted	average -0.478 -4.3369 p=0.0000	(-0.694<>-0.262)	95%CI	
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APPENDIX 36   MBD ACROSS PARTICIPANTS SSGS SHAME2 RAW DATA 
 
 
Table 29  
    
 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 19 18 6 18 22
2 6.3 19 18
3 23 18 21 18
4 20 18 17
5 25 22 10 14 17
6 24 16 12 17 17
7 21 25 9.3 17 18
8 22 25 9.3 14 18
9 23 12 9.2 18
10 18 6.8 19
11 22 9.8 21
12 22 24 9 20 20
13 21 25 8.7 18 20
14 15 12 17 19
15 19 13 19
16 24 17 16 20
17 24 23
18 24 24 7.5
19 25 23 17 19
20 25 23 14 19
21 21 24 9 17 19
22 6 24 7.8 13 21
23 19 7 9.8 20
24 18 7 15 20
25 23 7 15 20
26 20 13 13
27 25 19
28 18
29 17
SSGS	Shame²
Days
P6 P4 P3 P1 P5
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Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
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Table 30  Tau-U Weighted Average SSGS Shame2 
 
Participant
Baseline	
Tau-U
Intervention	vs	
baseline	Tau-U
z SD	Tau-u p	value	+	85%CI
P6 0.2381 -0.013 0.2868 p=0.9639	(-0.426<>0.4)
P4 0.3636 -0.0331 0.2517 p=0.8955	(-0.396<>0.329)
P3 0.2889 -0.55 0.3073 p=0.0735	(-0.993<>-0.107)
P1 -0.3167 -0.1806 0.2453 p=0.4617	(-0.534<>0.173)
P5 0.325 -0.0114 0.2303 p=0.9606	(-0.343<>0.32)
Weighted	average -0.1438 -1.2099 p=0.2263	(-0.3768<>0.0892)	95%CI
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APPENDIX 37    MBD ACROSS PARTICIPANTS SMERS GUILT1 RAW DATA 
 
 
Table 31       
   
 
 
 
 
 
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 8 10 10
2 10 9 5 10 9.3
3 9.2 8.6 10 9.6
4 9.2 8.4 10 9.6
5 9.2 9 5.5 10 9.6
6 9.2 6 7 10 7.4
7 9.4 10 6 9.8 8.8
8 8.5 10 5.3 9.2 9
9 10 8.8 7 7 9
10 10 7.2 6.4 9.8
11 2 9.8 6.6 10
12 8.7 10 4 10 10
13 7.6 10 4.7 9.8 9.4
14 4.6 10 7 8.6 9.8
15 4.8 4 8 6.8 9
16 5.8 10 1 9 9
17 6.2 10 10 10
18 5.6 9.8 4.5 10 8
19 4 9.4 9 6
20 8 9 9.4 8.2
21 5 9 6 9.4 9.2
22 1 10 5 9.2 9
23 9 5.3 9 9
24 9 7 7.5 9.2
25 10 7 8.2 9.2
26 9 7 8
27 10 8
28 9
29 8
SMERS	Guilt¹
Days
P6 P4 P3 P1 P5
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APPENDIX 37A MBD ACROSS PARTICIPANTS GUILT1 GRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
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APPENDIX 37B MBD TAU-U SMERS GUILT1 WEIGHTED AVERAGE 
 
 
 
 
 
 
 
 
 
 
Table 32    Tau-U Weighted Average SMERS Guilt1 
 
 
 
  
Participant
Baseline	
Tau-U
Intervention	vs	
Baseline	Tau-U
z SD	Tau-U p	value	+	85%CI
P6 -0.0222 -0.9833 0.2528 p=0.0001(-1.347<>-0.619)
P4 0.2088 0.0536 0.2315 p=0.817(-0.28<>0.387)
P3 0.0182 -0.2857 0.2868 p=0.3191(-0.699<>0.127)
P1 -0.3603 -0.1882 0.2343 p=0.4218(-0.526<>0.149)
P5 0.0735 -0.6569 0.2214 p=0.003(-0.976<>-0.338)
Weighted	average -0.41 -3.7206 p=0.0002	(-0.626<>-0.194)	95%CI	
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APPENDIX 38   MBD ACROSS PARTICIPANTS SSGS GUILT2 RAW DATA 
 
 
 
Table 33       
 
 
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 20 25 9 25 19
2 7.7 21 19
3 20 24 25 20
4 18 23 20
5 19 25 13 21 19
6 19 19 15 25 20
7 17 25 12 24 21
8 19 25 12 23 21
9 24 15 15 21
10 19 13 22
11 24 16 23
12 21 25 13 25 23
13 18 25 12 24 22
14 13 15 22 21
15 18 18 20
16 23 25 24 22
17 21 25
18 20 25 9.5
19 23 25 23 21
20 22 25 21 21
21 18 25 10 25 22
22 7 24 9.5 19 23
23 25 10 15 22
24 25 12 22 22
25 25 10 23 22
26 24 21 16
27 25 20
28 23
29 20
SSGS	Guilt²
P5
Days
P6 P4 P3 P1
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APPENDIX 38A MBD ACROSS PARTICIPANTS SSGS GUILT2 GRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
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APPENDIX 38B – MBD TAU-U SSGS GUILT2 WEIGHTED AVERAGE 
 
 
 
 
 
 
Table 34   Tau-U Weighted Average SSGS Guilt2 
 
 
 
 
 
 
 
 
 
  
Participant
Baseline	
Tau-U
Intervention	vs	
Baseline	Tau-U
z
SD	Tau-
U
p	value	+	85%CI
P6 -0.5238 0.16880 0.2868 p=0.5561	(-0.2440<>0.5820)
P4 0.1273 0.31400 0.2517 p=0.2122	(-0.0480<>0.6770)
P3 0.3778 -0.51670 0.3073 p=0.0927	(-0.9590<>-0.0740)
P1 -0.1833 -0.09030 0.2453 p=0.7129	(-0.4440<>0.2630)
P5 0.5500 0.14200 0.2303 p=0.5373	(-0.1900<>0.4740)
Weighted	average 0.0211 0.1776 	 p=0.859(-0.2119<>0.2541)	95%CI	
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APPENDIX 39   MBD ACROSS PARTICIPANTS SMERS ANXIETY1 RAW 
DATA 
 
 
 
 
 
Table 35       
 
 
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 10 10 7 10 10
2 8.5 10 6 9.3 7.3
3 8.6 8.8 10 7.4
4 8.6 8.6 10 6.6
5 8.4 8.6 6.3 10 6
6 8.2 6.2 7 9.5 5.4
7 7.6 10 6.3 9.2 5.6
8 9.2 10 5.7 8.2 7
9 9 9 7 6.6 6.8
10 10 7.4 	 4.4 7.4
11 7 9.8 	 6.8 7.8
12 9.3 10 5 	 10 8
13 8.6 10 4.7 	 9.6 8.4
14 6 9 8 8.4 8
15 6 4 4 6.8 9
16 5.2 9 1 9 8
17 6.2 9.8 10 9
18 9.2 8 5.5 7 7
19 10 7.8 9 8
20 10 7.6 7.6 7.2
21 6 8 4 9.2 8
22 3 9.6 5.8 8.8 8.2
23 8 6 8 8.4
24 9 7 9.3 8.4
25 10 6 9.2 8.4
26 8 8 6
27 7 8
28 10
29 8
SMERS	Anxiety¹
Days
P6 P4 P3 P1 P5
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APPENDIX 39A MBD ACROSS PARTICIPANTS SMERS ANXIETY1 GRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
10"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21" 22" 23" 24" 25" 26" 27" 28" 29"
An
xie
ty¹
"Se
ve
rit
y"
Data"Collec=on"Sessions"Over"12"weeks"
P1#$#Anxiety¹#
BL# F/U#INT#
0.0#
1.0#
2.0#
3.0#
4.0#
5.0#
6.0#
7.0#
8.0#
9.0#
10.0#
0# 1# 2# 3# 4# 5# 6# 7# 8# 9# 10# 11# 12# 13# 14# 15# 16# 17# 18# 19# 20# 21# 22# 23# 24# 25# 26# 27# 28# 29#
An
xie
ty¹
#Se
ve
rit
y#
Data#Collec>on#Sessions#Over#12#weeks#
P3#$#Anxiety¹#
BL# F/U#INT#
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
10"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21" 22" 23" 24" 25" 26" 27" 28" 29"
An
xie
ty¹
"Se
ve
rit
y"
Data"Collec=on"Sessions"Over"12"weeks"
P4#$#Anxiety¹#BL#
F/U#
INT#
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
10"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21" 22" 23" 24" 25" 26" 27" 28" 29"
An
xie
ty¹
"Se
ve
rit
y"
Data"Collec=on"Sessions"Over"12"weeks"
P5#$#Anxiety¹#
BL#
F/U#
INT#
0"
1"
2"
3"
4"
5"
6"
7"
8"
9"
10"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" 11" 12" 13" 14" 15" 16" 17" 18" 19" 20" 21" 22" 23" 24" 25" 26" 27" 28" 29"
An
xie
ty¹
"Se
ve
rit
y"
Data"Collec=on"Sessions"Over"12"weeks"
P6#$#Anxiety¹#
BL# F/U#INT#
 287 
 
APPENDIX 39B  MBD TAU-U SMERS ANXIETY1 WEIGHTED AVERAGE 
 
 
 
 
 
 
Table 36   Tau-U Weighted Average SMERS Anxiety1 
 
 
 
 
 
 
 
 
  
Participant
Baseline	
Tau-U
Intervention	vs	
Baseline	Tau-U
z SD	Tau-U p	value	+	85%CI
P6 0.0222 -0.3583 0.2528 p=0.1563	(-0.722<>0.006)
P4 0.022 -0.4107 0.2315 p=0.0760	(-0.744<>-0.077)
P3 -0.2909 -0.3506 0.2868 p=0.2215	(-0.764<>0.062)
P1 -0.25 -0.3471 0.2343 p=0.1386	(-0.684<>-0.010)
P5 0.4191 0.2745 0.2214 p=0.9823	(-0.324<>0.314)
Weighted	average -0.2266 -2.0561 p=0.0398	(-0.4426<>-0.0106)	95%CI	
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APPENDIX 40   MBD ACROSS PARTICIPANTS STAI-1 ANXIETY3 RAW DATA 
 
 
 
Table 37 
 
  
BL Int F/U BL Int F/U BL Int F/U BL Int F/U BL Int F/U
1 65 48 37 66 55
2 62 70 41 69 66
3 60 63 76 70
4 60 63 73 65
5 69 71 56 68 64
6 70 60 56 71 68
7 59 79 47 70 69
8 71 79 50 68 70
9 67 74 59 61 70
10 62 59 72
11 73 63 73
12 66 77 50 79 79
13 61 78 52 78 72
14 54 56 73 70
15 66 68 70
16 73 64 74 71
17 72 77
18 69 77 43
19 72 72 75 69
20 66 72 68 69
21 59 75 45 77 70
22 45 76 48 71 72
23 66 49 67 70
24 68 53 80 72
25 73 42 73 73
26 71 70 65
27 67 71
28 71
29 71
STAI	Anxiety	3
Days
P6 P4 P3 P1 P5
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APPENDIX 40A MBD ACROSS PARTICIPANTS STAI-1 ANXIETY3 GRAPHS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dotted red lines          delineate variability within a phase 
Blue lines          phase trendlines 
Vertical dotted black line           indicates phase change: baseline to intervention to follow-up 
The circles examines the Immediacy of effect between baseline and intervention phases 
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APPENDIX 40B MBD TAU-U STAI-1 ANXIETY3 WEIGHTED AVERAGE 
 
 
 
 
 
 
Table 38  Tau-U Weighted Average STAI-1 Anxiety3 
 
 
 
 
  
Participant
Baseline	
Tau-U
Intervention	vs	
baseline	Tau-U
z SD	Tau-U p	value	+	85%CI
P6 0.1667 0.0505 0.2659 P=0.8494	(-0.332<>0.433)
P4 0.4231 0.0979 0.2414 P=0.6851	(-0.25<>0.446)
P3 0.4000 -0.4000 0.3073 P=0.1931	(-0.843<>0.043)
P1 0.0917 0.1597 0.2453 P=0.5150	(-0.194<>0.513)
P5 0.6000 0.1989 0.2303 P=0.3878	(-0.133<>0.53)
Weighted	average 0.0413 0.3559 	 p0.7219	(-0.1861<>0.2687)	95%CI
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APPENDIX 41   NRES END OF STUDY DECLARATION 
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Chapter. 7 Overview of the Integration of Knowledge and Practice 
 
7.1 Introduction  
This chapter consolidates the knowledge and research skills gained through the 
doctorate programme in clinical practice. The program was concerned with how 
knowledge and research is applied in clinical settings, taking into account 
underpinning NHS/organization policy drivers that impact on clinical practice. The 
taught modules to address some of these issues included the role of policy, politics 
and power, communities of practice, advanced research methods, and service 
evaluation and leadership in the organization. The discussion will take each taught 
module in turn and evaluate the knowledge gained and its impact in clinical practice 
and the healthcare organization. 
 
7.2 Policy Politics and Power  
In this module I learnt about how policies are developed and the various drivers that 
influence the development of a policy for instance the need to prevent harm to 
patients and what tools one can use to evaluate intended and unintended 
consequences of the policy. The essay I wrote reviewing and analyzing an NHS 
Policy consequently helped to put into clinical practice reviewing on organizational 
policy on delivery of psychological intervention. Using policy analysis tools, (Buse, 
Mays, & Walt 2005), I was able to elicit the wider organization politics, therapy teams 
cultural way of doing things, and the economic/resource factors that drove the 
resistance to change and how the current policy at the time maintained the 
resistance. I was able to highlight to my clinical colleagues how the policy and the 
factors possibly impacted on what the policy had intended to achieve. 
 294 
  
The taught module also explored how to influence change of policy by identifying key 
players who have a vested interest in one’s agenda. The key players had to have the 
power to influence change at an organizational level, key players who were valued by 
clinical staff so they could help influence the clinical staff adopting and ownership of 
the proposed new policy. In order to do this, I needed evidence to support the 
agenda. The knowledge gained from modules on communities of practice and 
advanced research methods were incorporated as part of the wider strategy I used to 
influence change of policy within the department. 
 
7.3 Communities of Practice  
This module helped me have a better understanding and appreciation of the 
importance of networking and engaging the right group of people or forums to help 
support your clinical agenda. I liaised with forums from other NHS organizations 
whose clinical practice was not driven by the same policy as the one I endeavored to 
change but others were not willing to. Exchanging of ideas with these forums helped 
me put my ideas forward in a more robust and coherent way, particularly linking the 
benefits of changes and how they translated into the key agenda the old policy tried 
to address. 
 
7.4 Advanced Research Methods  
This module explored various research methodologies that one could use for 
example qualitative, quantitative or mixed methods. In the module I learnt also about 
literature search and reviewing of the literature including the stages of the research 
process. I applied what I learnt by undertaking a research study examining an 
experimental treatment for the management of OCD. It is hoped that with further 
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supporting evidence if the experimental treatment demonstrates ameliorative 
qualities in OCD it could be administered for patients on the waiting list as well as an 
add on treatment to the overall treatment strategy for OCD.  
 
7.5 Service Evaluation  
Although I have not had the opportunity to evaluate the service I have used the policy 
analysis tools to evaluate the policy and clinical practices discussed above. The 
leadership module helped to identify ways of motivating staff through facilitative 
leadership style. 
 
7.6 Conclusion  
The Doctorate clinical practice programme has helped develop not only research 
skills but how to work in an organization, promoting innovative ways of working and 
use of leadership styles conducive to staff engagement and managing resistance to 
change.  
 
 
Reference:  
Buse K., Mays N., & Walt, G. (2005). Making Health Policy: Understanding Public 
Health. Open University Press, London.  
 
